US20060167010A1 - Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds - Google Patents
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds Download PDFInfo
- Publication number
- US20060167010A1 US20060167010A1 US11/335,198 US33519806A US2006167010A1 US 20060167010 A1 US20060167010 A1 US 20060167010A1 US 33519806 A US33519806 A US 33519806A US 2006167010 A1 US2006167010 A1 US 2006167010A1
- Authority
- US
- United States
- Prior art keywords
- infection
- phenylahistin
- substituted
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 192
- GWMHBVLPNWHWGW-CNYBTUBUSA-N (3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione Chemical compound N1C=NC(\C=C/2C(N[C@@H](CC=3C=CC=CC=3)C(=O)N\2)=O)=C1C(C)(C=C)C GWMHBVLPNWHWGW-CNYBTUBUSA-N 0.000 title description 204
- 230000000259 anti-tumor effect Effects 0.000 title description 46
- 238000000034 method Methods 0.000 claims abstract description 81
- -1 amino, substituted amino, nitro, substituted nitro, phenyl Chemical group 0.000 claims abstract description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 23
- 125000003118 aryl group Chemical group 0.000 claims abstract description 16
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 15
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 15
- 125000005843 halogen group Chemical group 0.000 claims abstract description 15
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 15
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims abstract description 7
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 claims abstract description 7
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 42
- 206010017533 Fungal infection Diseases 0.000 claims description 29
- 208000031888 Mycoses Diseases 0.000 claims description 29
- 241000222122 Candida albicans Species 0.000 claims description 25
- 206010061418 Zygomycosis Diseases 0.000 claims description 24
- 201000007524 mucormycosis Diseases 0.000 claims description 23
- 206010007134 Candida infections Diseases 0.000 claims description 16
- 201000003984 candidiasis Diseases 0.000 claims description 16
- 201000002909 Aspergillosis Diseases 0.000 claims description 10
- 208000036641 Aspergillus infections Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 206010005098 Blastomycosis Diseases 0.000 claims description 8
- 230000002685 pulmonary effect Effects 0.000 claims description 8
- 241000223205 Coccidioides immitis Species 0.000 claims description 7
- 201000007336 Cryptococcosis Diseases 0.000 claims description 7
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 7
- 208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 claims description 6
- 206010033767 Paracoccidioides infections Diseases 0.000 claims description 6
- 201000000301 Paracoccidioidomycosis Diseases 0.000 claims description 6
- 201000003486 coccidioidomycosis Diseases 0.000 claims description 6
- 210000001635 urinary tract Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 91
- 201000011510 cancer Diseases 0.000 abstract description 24
- 239000000126 substance Substances 0.000 abstract description 24
- 150000003839 salts Chemical class 0.000 abstract description 21
- 239000002246 antineoplastic agent Substances 0.000 abstract description 18
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 17
- 229940002612 prodrug Drugs 0.000 abstract description 16
- 239000000651 prodrug Substances 0.000 abstract description 16
- 150000002148 esters Chemical class 0.000 abstract description 14
- 239000001257 hydrogen Substances 0.000 abstract description 13
- 210000004027 cell Anatomy 0.000 description 140
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 124
- 102000029749 Microtubule Human genes 0.000 description 62
- 108091022875 Microtubule Proteins 0.000 description 62
- 229960001338 colchicine Drugs 0.000 description 62
- 230000000694 effects Effects 0.000 description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 50
- 230000002401 inhibitory effect Effects 0.000 description 45
- 102000004243 Tubulin Human genes 0.000 description 43
- 108090000704 Tubulin Proteins 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 229940121375 antifungal agent Drugs 0.000 description 41
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 36
- 210000004688 microtubule Anatomy 0.000 description 34
- 230000027455 binding Effects 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 30
- 238000011282 treatment Methods 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 230000000843 anti-fungal effect Effects 0.000 description 28
- 239000001963 growth medium Substances 0.000 description 26
- 229930012538 Paclitaxel Natural products 0.000 description 25
- 229960001592 paclitaxel Drugs 0.000 description 25
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 239000000843 powder Substances 0.000 description 24
- 241000122818 Aspergillus ustus Species 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 238000006116 polymerization reaction Methods 0.000 description 20
- GWMHBVLPNWHWGW-DFSFMLJYSA-N (3r,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione Chemical compound N1C=NC(\C=C/2C(N[C@H](CC=3C=CC=CC=3)C(=O)N\2)=O)=C1C(C)(C=C)C GWMHBVLPNWHWGW-DFSFMLJYSA-N 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- 239000003429 antifungal agent Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 241000233866 Fungi Species 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 229960005190 phenylalanine Drugs 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 17
- 230000022131 cell cycle Effects 0.000 description 17
- 238000007920 subcutaneous administration Methods 0.000 description 17
- 229940063683 taxotere Drugs 0.000 description 17
- 230000004614 tumor growth Effects 0.000 description 17
- 230000004071 biological effect Effects 0.000 description 16
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 14
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 244000053095 fungal pathogen Species 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 12
- 125000002883 imidazolyl group Chemical group 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000002538 fungal effect Effects 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 229920001817 Agar Polymers 0.000 description 10
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 10
- 108010036949 Cyclosporine Proteins 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 0 [1*]C.[2*]C(C1=CC=CC=C1)C1C(=C)N([4*])c(c([5*])C2=C([8*])N([6*])C([7*])=N2)C(=C)N1[3*] Chemical compound [1*]C.[2*]C(C1=CC=CC=C1)C1C(=C)N([4*])c(c([5*])C2=C([8*])N([6*])C([7*])=N2)C(=C)N1[3*] 0.000 description 10
- 239000008272 agar Substances 0.000 description 10
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 10
- 229960003942 amphotericin b Drugs 0.000 description 10
- 230000001946 anti-microtubular Effects 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- 230000000394 mitotic effect Effects 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 238000013414 tumor xenograft model Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229930105110 Cyclosporin A Natural products 0.000 description 9
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 229960001265 ciclosporin Drugs 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000011278 mitosis Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 8
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 8
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 8
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 8
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 8
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 239000012829 chemotherapy agent Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 8
- 229960002867 griseofulvin Drugs 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 7
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 7
- 241000228212 Aspergillus Species 0.000 description 7
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 230000001028 anti-proliverative effect Effects 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000004296 chiral HPLC Methods 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229960004130 itraconazole Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 7
- 229960001156 mitoxantrone Drugs 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 230000006369 cell cycle progression Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000011987 methylation Effects 0.000 description 6
- 238000007069 methylation reaction Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 238000011255 standard chemotherapy Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 102100029855 Caspase-3 Human genes 0.000 description 5
- 230000004668 G2/M phase Effects 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 241000223229 Trichophyton rubrum Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000005917 in vivo anti-tumor Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000013587 production medium Substances 0.000 description 5
- 208000023958 prostate neoplasm Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 150000003852 triazoles Chemical class 0.000 description 5
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 4
- KMWCSNCNHSEXIF-UHFFFAOYSA-N 5-methyl-1h-imidazole-4-carbaldehyde Chemical compound CC=1N=CNC=1C=O KMWCSNCNHSEXIF-UHFFFAOYSA-N 0.000 description 4
- 241001225321 Aspergillus fumigatus Species 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 206010041736 Sporotrichosis Diseases 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000003080 antimitotic agent Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 4
- 229960004884 fluconazole Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- UZOJHXFWJFSFAI-VIFPVBQESA-N (3s)-3-benzylpiperazine-2,5-dione Chemical compound N1C(=O)CNC(=O)[C@@H]1CC1=CC=CC=C1 UZOJHXFWJFSFAI-VIFPVBQESA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UZOJHXFWJFSFAI-UHFFFAOYSA-N 3-benzylpiperazine-2,5-dione Chemical compound N1C(=O)CNC(=O)C1CC1=CC=CC=C1 UZOJHXFWJFSFAI-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000335423 Blastomyces Species 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 206010009192 Circulatory collapse Diseases 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108091077621 MAPRE family Proteins 0.000 description 3
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- XNRPVPHNDQHWLJ-UHFFFAOYSA-N Tryprostatin A Natural products N1C(=O)C2CCCN2C(=O)C1CC1=C(CC=C(C)C)NC2=CC(OC)=CC=C21 XNRPVPHNDQHWLJ-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 3
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 229960004413 flucytosine Drugs 0.000 description 3
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 3
- 230000000855 fungicidal effect Effects 0.000 description 3
- 230000001408 fungistatic effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005918 in vitro anti-tumor Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229960004125 ketoconazole Drugs 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 230000029115 microtubule polymerization Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- XNRPVPHNDQHWLJ-PMACEKPBSA-N tryprostatin A Chemical compound N1C(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=C(CC=C(C)C)NC2=CC(OC)=CC=C21 XNRPVPHNDQHWLJ-PMACEKPBSA-N 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- YGKOYVNJPRSSRX-UHFFFAOYSA-M (4-dodecylphenyl)methyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC1=CC=C(C[N+](C)(C)C)C=C1 YGKOYVNJPRSSRX-UHFFFAOYSA-M 0.000 description 2
- ABFQGXBZQWZNKI-UHFFFAOYSA-N 1,1-dimethoxyethanol Chemical compound COC(C)(O)OC ABFQGXBZQWZNKI-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 2
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 2
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001480036 Epidermophyton floccosum Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001480037 Microsporum Species 0.000 description 2
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XJTXBUKLGQCZHC-UHFFFAOYSA-N Steganacin Natural products C1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC3C(=O)OCC3C(OC(C)=O)C2=CC2=C1OCO2 XJTXBUKLGQCZHC-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000002827 antifungal susceptibility testing Methods 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000004814 combretastatins Chemical class 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000018842 conidium formation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000012926 crystallographic analysis Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- UZOJHXFWJFSFAI-SECBINFHSA-N cyclic glycylphenylalanine Natural products N1C(=O)CNC(=O)[C@H]1CC1=CC=CC=C1 UZOJHXFWJFSFAI-SECBINFHSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- WEIYXEFMCIRZHC-MWGWWEMPSA-N fumitremorgin B Chemical compound O=C1[C@@H]2CCCN2C(=O)[C@]2(O)[C@@H](O)C(C3=CC=C(C=C3N3CC=C(C)C)OC)=C3[C@H](C=C(C)C)N21 WEIYXEFMCIRZHC-MWGWWEMPSA-N 0.000 description 2
- BOFFNKYESMKUPP-UHFFFAOYSA-N fumitremorgin B Natural products COc1ccc2c3C(O)C4(O)N(C(C=C(C)C)c3n(C(=C(C)C)C)c2c1)C(=O)C5CCCN5C4=O BOFFNKYESMKUPP-UHFFFAOYSA-N 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000012606 in vitro cell culture Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000025090 microtubule depolymerization Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 2
- 229960003255 natamycin Drugs 0.000 description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 229960001237 podophyllotoxin Drugs 0.000 description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012449 sabouraud dextrose agar Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- XJTXBUKLGQCZHC-GCKMJXCFSA-N steganacin Chemical compound C1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H]3C(=O)OC[C@H]3[C@H](OC(C)=O)C2=CC2=C1OCO2 XJTXBUKLGQCZHC-GCKMJXCFSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 201000002327 urinary tract obstruction Diseases 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- WWJFFVUVFNBJTN-UIBIZFFUSA-N (2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid Chemical class C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O)C(O)=O)[C@H](O)c1ccc(O)cn1 WWJFFVUVFNBJTN-UIBIZFFUSA-N 0.000 description 1
- HLXXMJDWTBXTOR-STQMWFEESA-N (3s,6s)-3-benzyl-6-(1h-imidazol-5-ylmethyl)piperazine-2,5-dione Chemical compound C([C@@H]1NC([C@@H](NC1=O)CC=1NC=NC=1)=O)C1=CC=CC=C1 HLXXMJDWTBXTOR-STQMWFEESA-N 0.000 description 1
- RSGRSUVVCYUKLM-RDQDRAATSA-N (3z,6s)-3-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]-6-propan-2-ylpiperazine-2,5-dione Chemical compound N1C(=O)[C@H](C(C)C)NC(=O)\C1=C\C1=C(C(C)(C)C=C)NC=N1 RSGRSUVVCYUKLM-RDQDRAATSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- AMLDZYCRKRBTAA-UHFFFAOYSA-N 10,29-diphenyl-12,15,18,21,24,27-hexaoxapentacyclo[26.8.0.02,11.03,8.031,36]hexatriaconta-1(28),2(11),3,5,7,9,29,31,33,35-decaene Chemical compound O1CCOCCOCCOCCOCCOC2=C(C=3C=CC=CC=3)C=C3C=CC=CC3=C2C(C2=CC=CC=C2C=2)=C1C=2C1=CC=CC=C1 AMLDZYCRKRBTAA-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 238000001026 1H--1H correlation spectroscopy Methods 0.000 description 1
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 1
- RJWLLQWLBMJCFD-UHFFFAOYSA-N 4-methylpiperazin-1-amine Chemical compound CN1CCN(N)CC1 RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001480523 Basidiobolus ranarum Species 0.000 description 1
- 241000751139 Beauveria bassiana Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000123650 Botrytis cinerea Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 244000197813 Camelina sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241001480517 Conidiobolus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 241000235555 Cunninghamella Species 0.000 description 1
- LUEYTMPPCOCKBX-UHFFFAOYSA-N Curacin A Natural products C=CCC(OC)CCC(C)=CC=CCCC=CC1CSC(C2C(C2)C)=N1 LUEYTMPPCOCKBX-UHFFFAOYSA-N 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N Curacin A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000592938 Helminthosporium solani Species 0.000 description 1
- XMAUFHMAAVTODF-STQMWFEESA-N His-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 XMAUFHMAAVTODF-STQMWFEESA-N 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical class COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 229940119336 Microtubule stabilizer Drugs 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229930184499 Nikkomycin Natural products 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- NCXMLFZGDNKEPB-UHFFFAOYSA-N Pimaricin Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCC(C)OC(=O)C=CC2OC2CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 NCXMLFZGDNKEPB-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930182764 Polyoxin Natural products 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000293824 Rhinosporidium seeberi Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000593344 Rhizopus microsporus Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000223598 Scedosporium boydii Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000591119 Trichophyton sp. Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229930183739 Tryprostatin Natural products 0.000 description 1
- 241001238303 Turdus fuscater Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical class [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000000416 anti-micotic effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- RSGRSUVVCYUKLM-UHFFFAOYSA-N aurantiamine Natural products N1C(=O)C(C(C)C)NC(=O)C1=CC1=C(C(C)(C)C=C)NC=N1 RSGRSUVVCYUKLM-UHFFFAOYSA-N 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 125000005841 biaryl group Chemical group 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960004348 candicidin Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000033366 cell cycle process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- CWJSHJJYOPWUGX-UHFFFAOYSA-N chlorpropham Chemical compound CC(C)OC(=O)NC1=CC=CC(Cl)=C1 CWJSHJJYOPWUGX-UHFFFAOYSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960005527 combretastatin A-4 phosphate Drugs 0.000 description 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000012225 czapek media Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000000490 effect on mitosis Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 201000005889 eumycotic mycetoma Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- KRYDBLGWCUNDCJ-ZDUSSCGKSA-N methyl 2-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]acetate Chemical compound COC(=O)CNC(=O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 KRYDBLGWCUNDCJ-ZDUSSCGKSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 230000012169 negative regulation of microtubule polymerization Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- RBLGNOOTVOIAPR-UHFFFAOYSA-N pyridine;trifluoromethylsulfonyl trifluoromethanesulfonate Chemical compound C1=CC=NC=C1.FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F RBLGNOOTVOIAPR-UHFFFAOYSA-N 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003512 tremorgenic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the present invention relates to the fields of chemistry and medicine. More specifically, the present invention relates to compounds and procedures useful in the treatment of cancer, or in the treatment of fungal infections.
- tryprostatins A and B which are diketopiperazines consisting of proline and isoprenylated tryptophan residues
- five other structurally-related diketopiperazines inhibited cell cycle progression in the M phase, see Cui, C. et al., J. Antibiotics (1996), 49, 527-33; Cui, C. et al. J. Antibiotics (1996), 49, 534-40, and that these compounds also affect the microtubule assembly, see Usui, T. et al. Biochem J. (1998) 333, 543-48; Kondon, M. et al. J. Antibiotics (1998) 51, 801-04.
- CLC-site colchicine binding-site
- Microtubules are thought to be involved in several essential cell functions, such as axonal transport, cell motility and determination of cell morphology. Therefore, inhibitors of microtubule function may have broad biological activity, and be applicable to medicinal and agrochemical purposes. It is also possible that colchicine (CLC)-site ligands such as CLC, steganacin, see Kupchan, S. M. et al., J. Am. Chem. Soc. (1973) 95, 1335-36, podophyllotoxin, see Sackett, D. L., Pharmacol. Ther. (1993) 59, 163-228, and combretastatins, see Pettit, G. R. et al., J. Med. Chem. (1995) 38, 166-67, may prove to be valuable as eukaryotic cell cycle inhibitors and, thus, may be useful as chemotherapeutic agents.
- CLC colchicine
- steganacin see Kupchan, S. M
- diketopiperazine-type metabolites have been isolated from various fungi as mycotoxins, see Horak R. M. et al., J.C.S. Chem. Comm. (1981) 1265-67; Ali M. et al., Toxicology Letters, (1989) 48, 235-41, or as secondary metabolites, see Smedsgaard J. et al., J. Microbiol. Meth. (1996) 25, 5-17, little is known about the specific structure of the diketopiperazine-type metabolites and their antitumor activity, particularly in vivo.
- X 1 and X 2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
- the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
- the invention comprises, in substantially purified form, the compound herein named alternatively “( ⁇ )-phenylahistin,” “( ⁇ )-NSCL-96F037,” or “( ⁇ )-PLH,” which is a diketopiperazine composed of L-phenylalanine and isoprenylated dehydrohistidine.
- This compound has the following stereo-specific chemical structure:
- the invention also comprises a method of treating cancer comprising administering an effective tumor-growth-inhibiting amount of the compound, and any pharmaceutically acceptable salt or pro-drug ester of generic structure (I), and preferably, phenylahistin, and more preferably, ( ⁇ )-phenylahistin, and pharmaceutically acceptable salt and pro-drug esters thereof.
- R 3 and R 4 are hydrogen, and each are involved in hydrogen bonds, and/or the dashed bond is a double bond.
- inventions relate to methods of treating and/or preventing at least one fungal infection in a mammal afflicted with at least one fungal infection.
- the methods can include, for example, administering an antifungally effective amount of a compound sufficient for such treating or preventing.
- the compound can have, for example, the following structure:
- R 1 , R 2 , R 5 , R 7 , and R 8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,
- R 3 , R 4 , and R 6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 12 alkyl, unsaturated C 1 -C 12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
- X 1 and X 2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
- the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
- the fungal infection can be for example, an Aspergillosis infection, a blastomycosis infection, a Candidiasis infection, a Coccidioidomycosis infection, a Cryptococcosis infection, a Histopolasmosis infection, a Paracoccidioidomycosis, a Sporotrichosis and, a Mucormycosis infection, and the like.
- the Aspergillosis infection can be invasive pulmonary aspergillosis.
- the Mucormycosis infection can be craniofacial mucormycosis, pulmonary mucormycosis and the like.
- the Candidiasis infection can be retrograde candidiasis of the urinary tract, for example.
- compositions for treating or preventing fungal infection can include, for example, an antifungally effective amount of a pharmaceutically acceptable carrier and a compound having the structure:
- R 1 , R 2 , R 5 , R 7 , and R 8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,
- R 3 , R 4 , and R 6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 12 alkyl, unsaturated C 1 -C 12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
- X 1 and X 2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
- the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
- the fungal infection can be an Aspergillosis infection, a blastomycosis infection, a Candidiasis infection, a Coccidioidomycosis infection, a Cryptococcosis infection, a Histopolasmosis infection, a Paracoccidioidomycosis, a Sporotrichosis and, a Mucormycosis infection, and the like.
- the Aspergillosis infection can be invasive pulmonary aspergillosis.
- the Mucormycosis infection can be craniofacial mucormycosis, pulmonary mucormycosis and the like.
- the Candidiasis infection can be retrograde candidiasis of the urinary tract, for example.
- Embodiments also relate to methods and materials for treating or preventing cancers and infection by a pathogenic fungus in a mammalian subject, particularly a human patient, by administering to the subject a phenylahistin or its analog.
- the methods can include administering to the subject a composition comprising an effective antitumor or antifungal amount of a phenylahistin or its analog.
- FIG. 1 illustrates Reaction Scheme 1, which shows the preparation of certain reduced derivatives of ( ⁇ )- and (+)-phenylahistin from the enantiomers of phenylahistin.
- FIG. 3 illustrates Reaction Scheme 3, which shows the preparation of two reduced derivatives of ( ⁇ )-phenylahistin, compounds identified as ( ⁇ )-12 and ( ⁇ )-13, which are respectively, identical to compounds 3 and 5 of FIG. 1 .
- (a) refers to H 2 /10% Pd—C, MeOH, room temperature, reaction time of 2 hours
- (b) refers to H 2 /10% Pd—C, MeOH, room temperature, reaction time of 24 hours.
- FIG. 4 illustrates Reaction Scheme 4, which shows the preparation of two N-methylated derivatives of ( ⁇ )-phenylahistin.
- (a) refers to MeI, NaH, DMF, ⁇ 30° C., reaction time of 2 hours
- (b) refers to MeI, NaH, DMF, room temperature, reaction time of 2 hours
- (c) refers to chiral HPLC separation as described herein.
- FIG. 5 illustrates Reaction Scheme 5, which shows the preparation of two derivatives of ( ⁇ )-phenylahistin, compounds identified as 19 and 20, which is the ( ⁇ )-enantiomer of compound 9 of FIG. 2 .
- (a) refers to MeOH at reflux for 14 hours
- (b) refers to AcO 2 , AcONa, 80° C., reaction time of 14 hours
- (c-e) refers to reaction in a mixture of compound 18, LDA, HMPA, DMF, at ⁇ 60° C. for 30 minutes, followed by cooling to room temperature and placing in a solution of Tf 2 O, pyridine for 10 minutes, followed by overnight reaction in NH 4 OH at room temperature.
- FIG. 6 depicts the effect of t-butyl-phenylahistin in comparison to colchicine and taxol on HuVEC monolayer permeability to FITC-Dextran.
- FIG. 7 depicts the effects of t-butyl-phenylahistin alone and in combination with CPT-11 on estimated tumor growth in the HT-29 human colon tumor xenograft model.
- FIG. 8 depicts the effects of t-butyl-phenylahistin alone and in combination with CPT-11 on the weight of tumors excised at autopsy in individual mice in the HT-29 Human Colon Tumor Xenograft model.
- FIG. 9 depicts the effects of t-butyl-phenylahistin alone and in combination with Taxotere on the estimated tumor growth based on observations made during the in-life portion of the DU-145 Human Prostate Tumor Xenograft Model.
- FIG. 10 depicts the effects of t-butyl-phenylahistin alone and in combination with Taxotere in MCF-7 Human Breast Tumor Xenograft model.
- FIG. 11 depicts effects of t-butyl-phenylahistin alone and in combination with Paclitaxel in the Murine Melanoma B16 F10 Metastatic Tumor Model.
- Objects of this invention include (1) providing a class of new compounds, including pharmaceutically acceptable salts of the class of compounds, that exhibit animal cell-specific proliferation inhibiting, tumor-growth inhibiting activity, anti-fungal activity, and/or cell-cycle inhibiting activity, and (2) providing a class of fungi for producing, and (3) providing a method for producing said class of compounds, as well as a class of pharmaceutically acceptable cell cycle inhibitors, antitumor agents, and anti-fungal agents comprising said compounds and/or their derivatives as active ingredients. It is also an object of this invention to provide a method of treating cancer, particularly human cancer, comprising the step of administering an effective tumor-growth inhibiting amount of a member of a class of new anti-tumor compounds.
- an effective tumor-growth inhibiting amount of a member of a class of new anti-tumor compounds comprising the step of administering an effective tumor-growth inhibiting amount of a member of a class of new anti-tumor compounds.
- the invention provides the compound represented by Formula (I):
- R 1 , R 2 , R 5 , R 7 , and R 8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups, all having, where applicable, up to 24 carbon atoms,
- R 3 , R 4 , and R 6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 12 alkyl, unsaturated C 1 -C 12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, all having, where applicable, up to 12 carbon atoms,
- X 1 and X 2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and the dashed bond represents either a carbon-carbon single bond or a carbon-carbon double bond, of any tertiary conformation, in a particular embodiment of the invention.
- the invention also provides pharmaceutically acceptable salts and pro-drug esters of the compound of Formula (I).
- pro-drug ester especially when referring to a pro-drug ester of the compound of Formula (I), refers to a chemical derivative of the compound that is rapidly transformed in vivo to yield the compound, for example, by hydrolysis in blood.
- pro-drug ester refers to derivatives of the compound of the present invention formed by the addition of any of several ester-forming groups that are hydrolyzed under physiological conditions. Examples of pro-drug ester groups include pivoyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-2-oxo-1,3-dioxolen-4-yl)methyl group.
- pro-drug ester groups can be found in, for example, T. Higuchi and V. Stella, in “Pro-drugs as Novel Delivery Systems”, Vol. 14, A.C.S. Symposium Series, American Chemical Society (1975); and “Bioreversible Carriers in Drug Design: Theory and Application”, edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987) (providing examples of esters useful as prodrugs for compounds containing carboxyl groups).
- pharmaceutically acceptable salt refers to any pharmaceutically acceptable salts of a compound, and preferably refers to an acid addition salt of a compound.
- pharmaceutically acceptable salt are the alkali metal salts (sodium or potassium), the alkaline earth metal salts (calcium or magnesium), or ammonium salts derived from ammonia or from pharmaceutically acceptable organic amines, for example C 1 -C 7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine or tris-(hydroxymethyl)-aminomethane.
- the preferred examples of pharmaceutically acceptable salts are acid addition salts of pharmaceutically acceptable inorganic or organic acids, for example, hydrohalic, sulfuric, phosphoric acid or aliphatic or aromatic carboxylic or sulfonic acid, for example acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, p-toluensulfonic or naphthalenesulfonic acid.
- pharmaceutically acceptable inorganic or organic acids for example, hydrohalic, sulfuric, phosphoric acid or aliphatic or aromatic carboxylic or sulfonic acid, for example acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, p-toluensulfonic or naphthalenesulfonic acid.
- Preferred pharmaceutical compositions of the present invention include pharmaceutically acceptable salts and pro-drug esters of the compound of Formula (I). Accordingly, if the manufacture of pharmaceutical formulations involves intimate mixing of the pharmaceutical excipients and the active ingredient in its salt form, then it is preferred to use pharmaceutical excipients which are non-basic, that is, either acidic or neutral excipients.
- a relatively rigid, planar pseudo three-ring structure is formed.
- R 3 and R 4 are hydrogen, each involved in hydrogen bonds.
- the dashed bond is a double bond.
- halogen atom means any one of the radio-stable atoms of column 17 of the Periodic Table of the Elements, i.e., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
- alkyl means any unbranched or branched, substituted or unsubstituted, saturated hydrocarbon, with C 1 -C 6 unbranched, saturated, unsubstituted hydrocarbons, being preferred, with methyl, ethyl, iosbutyl, and tert-butyl being most preferred.
- substituted, saturated hydrocarbons C 1 -C 6 mono- and di- and per-halogen substituted saturated hydrocarbons and amino-substituted hydrocarbons are preferred, with perfluromethyl, perchloromethyl, perfluoro-tert-butyl, and perchloro-tert-butyl being the most preferred.
- cycloalkyl refers to any non-aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring.
- alkenyl means any unbranched or branched, substituted or unsubstituted, unsaturated hydrocarbon including polyunsaturated hydrocarbons, with C 1 -C 6 unbranched, mono-unsaturated and di-unsaturated, unsubstituted hydrocarbons being preferred, and mono-unsaturated, di-halogen substituted hydrocarbons being most preferred.
- a z-isoprenyl moiety is particularly preferred.
- cycloalkenyl refers to any non-aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring.
- aryl refers to aromatic hydrocarbon rings, preferably having five, six, or seven atoms, and most preferably having six atoms comprising the ring.
- Heteroaryl and “substituted heteroaryl,” refer to aromatic hydrocarbon rings in which at least one heteroatom, e.g., oxygen, sulfur, or nitrogen atom, is in the ring along with at least one carbon atom.
- alkoxy refers to any unbranched, or branched, substituted or unsubstituted, saturated or unsaturated ether, with C 1 -C 6 unbranched, saturated, unsubstituted ethers being preferred, with dimethyl, diethyl, methyl-isobutyl, and methyl-tert-butyl ethers being most preferred.
- cycloalkoxy refers to any non-aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring.
- purified refers to the compound of the invention being free of other, dissimilar compounds with which the compound of the invention is normally associated in its natural state, so that the compound of the invention comprises at least 0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75% of the mass, by weight, of a given sample. In one preferred embodiment, these terms refer to the compound of the invention comprising at least 95% of the mass, by weight, of a given sample.
- anti-tumor and “tumor-growth-inhibiting,” when modifying the term “compound,” and the terms “inhibiting” and “reducing”, when modifying the terms “compound” and/or the term “tumor,” mean that the presence of the subject compound is correlated with at least the slowing of the rate of growth of the tumor. More preferably, the terms “anti-tumor,” “tumor-growth-inhibiting,” “inhibiting,” and “reducing” refer to a correlation between the presence of the subject compound and at least the temporary cessation of tumor growth.
- anti-tumor also refer to, particularly in the most preferred embodiment of the invention, a correlation between the presence of the subject compound and at least the temporary reduction in the mass of the tumor.
- the invention also provides fungi of the genus Aspergillus that are capable of producing the anti-tumor compound of the invention, and specifically, fungi that are capable of producing the anti-tumor compound of the invention wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each a hydrogen atom, and X 1 and X 2 are each separately an oxygen atom.
- the fungi is an Aspergillus ustus capable of producing the antitumor compound of the invention in an amount of not less than 2 mg, preferably not less than 8 mg, per liter of the production medium as measured, by high performance liquid chromatography using the compound represented by Formula (I) as a standard with respect to what is obtained by placing, in 18 mm-diameter, 180 mm-length test tubes, 5 ml of production medium (production medium: glucose 5 g/l, glycerin 20 ml/l, cotton seed lees 20 g/l, yeast extract 2 g/l, sodium chloride 2.5 g/l, calcium carbonate 4 g/l (pH6.5)), and then inoculating each test tube with 50 ⁇ l of a fungus suspension prepared by suspending conidia of the fungal strain in sterilized water, incubating the culture broth for 5 days at 27° C.
- production medium production medium: glucose 5 g/l, glycerin 20 ml/l, cotton seed le
- the invention also provides a method of producing the anti-tumor compound of Formula (I) comprising the steps of incubating in a culture medium a microorganism belonging to the genus Aspergillus that is capable of producing the antitumor compound represented of Formula (I) and collecting the compound from the culture.
- the invention further provides a cell cycle inhibitor and an antitumor agent containing the antitumor substance of Formula (I) as an active ingredient, in combination with a pharmaceutically acceptable carrier or excipient.
- phenylahistin which exhibits the following physical and chemical characteristics:
- phenylahistin has been isolated from Aspergillus ustus NSC-F038 and NSC-F037, two new strains of fungus; this phenylahistin exhibits cytotoxic and cell cycle inhibitory activities. Both of these strains of fungi have been deposited with the National Institute of Bioscience and Human-Technology, Japan, Agency of Industrial Science and Technology, Ministry of International Trade and Industry. These strains exhibit the following mycological characteristics:
- Conidiophore Smooth surface, brown with length of 100-350 ⁇ m, 4-7 ⁇ m diameter
- Vesicles Spherical-flask-shaped, 11-15 ⁇ m diameter, upper 2 ⁇ 3-1 ⁇ 2 forms metulae
- Metulae covering upper half to two-thirds of the vesicles, 5-7 ⁇ 4-7 ⁇ m
- Phialides amplliform, 5-8 ⁇ 3-4 ⁇ m
- Aspergillus ustus NSC-F037 and Aspergullus ustus NSC-F038 were found, in accordance with the text Aspergillus , K. B. Raper and D. I. Fennel, Williams and Wilkins (1965), to belong to subphylum Fungi Imperfecti, order monilliales, genus Aspergillus , species ustus .
- the strains were therefore termed Aspergullus ustus NSC-F037 and Aspergillus ustus NSC-F038. It was concluded that Aspergullus ustus NSC-037 and Aspergillus ustus NSC-038 were both novel fungal strains, and they were respectively assigned the acquisition numbers FERM P-15829 and FERM P-15930.
- the compound of Formula (I), the compound of the invention can be produced by ordinary methods, from a culture medium and via extracting the compound from a culture of either Aspergillus ustus NSC-037 or Aspergillus ustus NSC-038 in the following manner.
- the culture can be either liquid or solid, industrially advantageous culture can be achieved by inoculating a liquid medium with a fungus suspension of the microorganism and incubating the medium under aeration-mixing.
- the culture medium nutrients are not particularly limited, carbon sources, nitrogen sources and other culture medium ingredients ordinarily used to culture microorganisms may be included and are preferred.
- Usable carbon sources include starch, glycerin, glucose, sucrose, galactose, and the like.
- Usable nitrogen sources included peptone, soy bean powder, meat extract, corn-steeped liquor, cotton seed lees, ammonium salt, nitrates, and other organic and inorganic nitrogen compounds.
- inorganic salts and trace nutrients may be added as will be deemed appropriate by those of skill in the art.
- the culture temperature, culture time period, and other culture conditions are preferably chosen as conditions that are appropriate for growth of the selected fungus, and also to maximize production of the compound represented by Formula (1).
- the pH of the culture medium is preferably between approximately 4 and approximately 9, and more preferably between 5 and 8, and the culture temperature is preferably between 15 and 35° C., and more preferably between 23 and 28° C.
- the culture period is preferably between 48 and 192 hours, and more preferably between 72 and 192 hours.
- the culture medium composition, culture medium pH, culture medium temperature, culture period and other culture conditions should naturally be appropriately adjusted according to the type of fungus used, the external conditions, and the like so as to obtain the desired results of producing the compound of the present invention.
- the compound represented by Formula (1) can be collected from such a culture by appropriate use of means ordinarily used for collecting metabolites.
- any means utilizing the difference in affinity for and organic solvent between the compound represented by Formula (1) and other substances contained in the culture means utilizing difference in solubility and means utilizing difference in adsorptive affinity for various resins can be used independently, in appropriate combination, or repeatedly.
- ion-exchange chromatography chromatography using a nonionic adsorptive resin
- gel-filter chromatography chromatography using an adsorbent such as activated carbon, alumina or silica gel
- adsorbent such as activated carbon, alumina or silica gel
- high-speed liquid chromatography various other types of liquid chromatography, crystallization, vacuum concentration, freeze-drying and other such means can be used independently, in appropriate combination, or repeatedly.
- the compound of Formula (I) can be administered by either oral or a non-oral pathways.
- it can be administered in capsule, tablet, granule, spray, syrup, or other such form.
- it can be administered as an aqueous suspension, an oily preparation or the like or as a drip, suppository, salve, ointment or the like, when administered via injection, subcutaneously, intreperitoneally, intravenously, intramuscularly, or the like.
- the compound of the invention may be administered topically, rectally, or vaginally, as deemed appropriate by those of skill in the art for bringing the compound of the invention into optimal contact with a tumor, thus inhibiting the growth of the tumor.
- Local administration at the site of the tumor is also contemplated, either before or after tumor resection, as are controlled release formulations, depot formulations, and infusion pump delivery.
- the cell cycle inhibitor and antitumor agent of the invention may be orally or non-orally administered to a human patient in the amount of about 0.001 mg/kg/day to about 10,000 mg/kg/day of the active ingredient, and more preferably about 0.1 mg/kg/day to about 100 mg/kg/day of the active ingredient at, preferably, one time per day or, less preferably, over two to about ten times per day.
- the compound of the invention may preferably be administered in the stated amounts continuously by, for example, an intravenous drip.
- the preferred daily dose of the active anti-tumor ingredient would be about 0.07 mg/day to about 700 grams/day, and more preferable, 7 mg/day to about 7 grams/day. Nonetheless, as will be understood by those of skill in the art, in certain situations it may be necessary to administer the anti-tumor compound of the invention in amounts that excess, or even far exceed, the above-stated, preferred dosage range to effectively and aggressively treat particularly advanced or lethal tumors.
- the compound of the invention inhibits the progression of the cell cycle when it is dissolved in an organic solvent or hydrous organic solvent and it is directly applied to any of various cultured cell systems.
- organic solvents include, for example, methanol, methylsulfoxide, and the like.
- the formulation can, for example, be a powder, granular or other solid inhibitor, or a liquid inhibitor prepared using an organic solvent or a hydrous organic solvent.
- a preferred concentration of the compound of the invention for use as a cell cycle inhibitor is generally in the range of about 1 to about 100 ⁇ g/ml, the most appropriate use amount varies depending on the type of cultured cell system and the purpose of use, as will be appreciated by persons of ordinary skill in the art. Also, in certain applications it may be necessary or preferred to persons of ordinary skill in the art to use an amount outside the foregoing range.
- certain embodiments provide methods for preventing or treating fungal infections and/or a pathogenic fungus in a subject, involve administering to the subject a composition including a phenylahistin or its analog, for example, administering the phenylahistin or its analog in an amount and manner which provides the intended antifungal effect.
- inventions include the treatment or prevention of infection in a patient by a pathogenic fungus such as those listed above or referred to below.
- Another embodiment relates to the treatment or prevention of infection in a patient by a pathogenic fungus which is resistant to one or more other antifungal agents, especially an agent other than phenylahistin or its analog, including e.g. amphotericin B or analogs or derivatives thereof (including 14(s)-hydroxyamphotericin B methyl ester, the hydrazide of amphotericin B with 1-amino-4-methylpiperazine, and other derivatives) or other polyene macrolide antibiotics, including, e.g., nystatin, candicidin, pimaricin and natamycin; flucytosine; griseofulvin; echinocandins or aureobasidins, including naturally occurring and semi-synthetic analogs; dihydrobenzo[a]napthacenequinones; nucleoside peptide antifungals including the polyoxins and nikkomycins; allylamines such as naftif
- Another embodiment involves the treatment or prevention of infection in a patient by a pathogenic fungus in cases in which the patient is allergic to, otherwise intolerant of, or nonresponsive to one or more other antifungal agents or in whom the use of other antifungal agents is otherwise contra-indicated.
- Those other antifungal agents include, among others, those antifungal agents disclosed above and elsewhere herein.
- a phenylahistin or its analog is administered to the subject in an effective antifungal amount.
- inventions relate to the treatment or prevention of infection by a pathogenic fungus in a patient by administration of a phenylahistin or its analog, in conjunction with the administration of one or more other antifungal agents, including for example, any of the previously mentioned agents or types of agents (e.g. in combination with treatment with amphotericin B, preferably in a lipid or liposome formulation; an azole or triazole such as fluconazole, for example; an aureobasidin; dihydrobenzo[a]napthacenequinone; or an echinocardin) as well as with a different phenylahistin or its analog.
- agents e.g. in combination with treatment with amphotericin B, preferably in a lipid or liposome formulation
- an azole or triazole such as fluconazole, for example; an aureobasidin; dihydrobenzo[a]napthacenequinone; or an echinocardin
- the phenylahistin or its analog may be administered before, after or at the same time the other antifungal agent is administered.
- the combination therapy will permit the use of reduced amounts of one or both antifungal components, relative to the amount used if used alone.
- Still other embodiments relate to administration of a phenylahistin or its analog to a subject for the treatment or prevention of infection by a pathogenic fungus, where the subject is immunosuppressed or immunocompromised, e.g. as the result of genetic disorder, disease such as diabetes or HIV or other infection, chemotherapy or radiation treatment for cancer or other disease, or drug- or otherwise induced immunosuppression in connection with tissue or organ transplantation or the treatment of an autoimmune disorder.
- an immunosuppressive agent e.g., in connection with a tissue or organ transplantation
- a phenylahistin or its analog may be co-administered with the immunosuppressive agent(s) to treat or prevent a pathogenic fungal infection.
- Another aspect of this invention is the treatment or prevention of infection by a pathogenic fungus in a patient infected, or suspected of being infected, with HIV, by administration of an antifungal phenylahistin or its analog, in conjunction with the administration of one or more anti-HIV therapeutics (including e.g. HIV protease inhibitors, reverse transcriptase inhibitors or anti-viral agents).
- an antifungal phenylahistin or its analog in conjunction with the administration of one or more anti-HIV therapeutics (including e.g. HIV protease inhibitors, reverse transcriptase inhibitors or anti-viral agents).
- the phenylahistin or its analog may be administered before, after or at the same time as administration of the anti-HIV agent(s).
- Another aspect of this invention is the treatment or prevention of infection by a pathogenic fungus in a patient by administration of an antifungal phenylahistin or its analog, in conjunction with the administration of one or more other antibiotic compounds, especially one or more antibacterial agents, preferably in an effective amount and regiment to treat or prevent bacterial infection.
- the phenylahistin or its analog may be administered before, after or at the same time as administration of the other agent(s).
- Pathogenic fungal infections which may be treated or prevented by the disclosed methods include, among others, Aspergillosis, including invasive pulmonary aspergillosis; Blastomycosis, including profound or rapidly progressive infections and blastomycosis in the central nervous system; Candidiasis, including retrograde candidiasis of the urinary tract, e.g. in patients with kidney stones, urinary tract obstruction, renal transplantation or poorly controlled diabetes mellitus; Coccidioidomycosis, including chronic disease which does not respond well to other chemotherapy; Cryptococcosis; Histopolasmosis; Mucormycosis, including e.g.
- compositions comprising an antifungal amount of one or more phenylahistin or its analogs may be particularly useful for treating or preventing a pathogenic fungal infection in a mammalian subject where the fungus is resistant to one or more other antifungal therapies, or where the use of one or more other antifungal therapies is contraindicated, e.g., as mentioned above.
- Antifungal pharmaceutical compositions containing at least one antifungal phenylahistin or its analog are also provided for use in practicing the disclosed methods. Those pharmaceutical compositions may be packaged together with an appropriate package insert containing, inter alia, directions and information relating to their antifungal use. Pharmaceutical compositions are also provided which contain one or more phenylahistin or its analog together with a second antifungal agent.
- Certain embodiments disclosed herein relate to methods for treating or preventing a pathogenic fungal infection, including for example Aspergillosis, including invasive pulmonary aspergillosis; Blastomycosis, including profound or rapidly progressive infections and blastomycosis in the central nervous system; Candidiasis, including retrograde candidiasis of the urinary tract, e.g. in patients with kidney stones, urinary tract obstruction, renal transplantaion or poorly controlled diabetes mellitus; Coccidioidomycosis, including chronic disease which does not respond well to other chemotherapy; Cryptococcosis; Histopolasmosis; Mucormycosis, including e.g.
- Aspergillosis including invasive pulmonary aspergillosis
- Blastomycosis including profound or rapidly progressive infections and blastomycosis in the central nervous system
- Candidiasis including retrograde candidiasis of the urinary tract, e.g. in patients with kidney stones, urinary tract obstruction, renal transplant
- the methods may involve administering at least one antifungal phenylahistin or its analog, as described above, to a human subject such that the fungal infection is treated or prevented.
- the phenylahistin or its analog may be administered in conjunction with administration of one or more non-phenylahistin or its analog antifungal agents such as amphotericin B, or an imidazole or triazole agent such as those mentioned previously.
- the pathogenic fungal infection may be topical, e.g., caused by, among other organisms, species of Candida, Trichophyton, Microsporum or Epiderinophyton or micosal, e.g., caused by Candida albicans (e.g. thrush and vaginal candidiasis).
- the infection may be systemic, e.g., caused by Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Coccidiodes, Paracocciciodes, Histoplasma or Blastomyces spp.
- the infection may be also involve eumycotic mycetoma, chromoblastomycosis, cryptococcal meningitis or phycomycosis.
- Further embodiments relate to methods for treating or preventing a pathogenic fungal infection selected from the group consisting of Candida spp. including C. albicans, C. tropicalis, C. kefyr, C. krusei and C. galbrata; Aspergillus spp. including A. fumigatus and A. flavus; Cryptococcus neoibrmans; Blastomyces spp. including Blastomyces dermatilidis; Pneumocvstis carinii; Coccidioides immitis; Basidiobolus ranarum; Conidiobolus spp.; Histoplasma capsulatum; Rhizopus spp. including R. oryzae and R.
- Candida spp. including C. albicans, C. tropicalis, C. kefyr, C. krusei and C. galbrata
- Aspergillus spp. including A. fumigatus and A. flavus
- the method may involve administering a non-immunosuppressive antifungal phenylahistin or its analog to a patient in need thereof such that the fungal infection is treated or prevented without inducing an untoward immunosuppressive effect.
- Further embodiments relate to methods for treating or preventing a pathogenic fungal infection which is resistant to other antifungal therapy, including pathogenic fungal infections which are resistant to one or more antifungal agents mentioned elsewhere herein such as amphotericin B, flucytosine, one of the imidazoles or triazoles (including e.g. fluconazole, ketoconazole, itraconazole and the other previously mentioned examples).
- the methods may involve administering to the patient one or more antifungal phenylahistin or its analog, in an amount and dosing regimen such that a fungal infection resistant to another antifungal therapy in the subject is treated or prevented.
- Further embodiments relate to methods for treating or preventing a pathogenic fungal infection in a patient who is allergic to, intollerant of or not responsive to another antifungal therapy or in whom the use of other antifungal agents is otherwise contra-indicated, including one or more other antifungal agents mentioned elsewhere herein such as amphotericin B, flucytosine, one of the imidazoles or triazoles (including e.g. fluconazole, ketoconazole, itraconazole and the other previously mentioned examples).
- the methods may involve administering to such patient one or more antifungal phenylahistin or its analog, in an amount such that a fungal infection is treated or prevented.
- Certain embodiments relate to packaged phenylahistin or its analogs, preferably packaged nonimmunosuppressive antifungal phenylahistin or its analogs, which term is intended to include at least one phenylahistin or its analog, as described above, packaged with instructions for administering the phenylahistin or its analog(s) as an antifungal agent without causing a untoward immunosuppressive effects within a human subject.
- the non-immunosuppressive antifungal phenylahistin or its analog is a member of one of the preferred subsets of compounds described above.
- the phenylahistin or its analog can be packaged alone with the instructions or can be packaged with another phenylahistin or its analog, raparnycin or another ingredient or additive, e.g., one or more of the ingredients of the pharmaceutical compositions.
- the package can contain one or more containers filled with one or more of the ingredients of the phan-naceutical compositions.
- Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- test tubes In each of 18 mm-diameter, 180 mm-length test tubes, 5 ml of sterilized production medium (production medium: glucose 5 g/l, glycerin 20 ml/l, cotton seed lees 20 g/l, yeast extract 2 g/l, sodium chloride 2.5 g/l, calcium carbonate 4 g/l (pH6.5)) was placed. The number of so-prepared test tubes was 1,700 (total culture medium: 8.5 liter). Each test tube was inoculated with 50 ⁇ l of Aspergillus ustus NSC-F037 fungus suspension prepared by suspending conidia of the strain in sterilized water and the culture broth was incubated for 5 days at 27° C. under reciprocal shaking (260 rpm).
- production medium glucose 5 g/l, glycerin 20 ml/l, cotton seed lees 20 g/l, yeast extract 2 g/l, sodium chloride 2.5 g/l, calcium carbonate 4 g/l (
- the culture broth in each test tube was added with 10 ml. of acetone and was extracted for one (1) day at room temperature. Impurities were then removed by filtration and the filtrate (approximately 20 liters) was vacuum-concentrated to distill off the acetate.
- the ethyl acetate layer was de-watered with sodium sulfate. Vacuum concentration and drying were conducted to obtain a solid which was subjected to silica gel open column chromatography (chloroform-methanol system) to isolate the antitumor activity fraction.
- This fraction was vacuumed-concentrated and dried to a solid, dissolved in a small amount of 70% methanol, subjected to high performance liquid chromatography using a Senshu Pack ODS-5251-SS 20 mm-diameter ⁇ 250 mm (Senshu Science Kabushiki Kaisha) to conduct purification with a mobile phase: methanol/water 7/3 condition and to isolate a fraction exhibiting antitumor activity.
- This fraction was vacuum-concentrated and dried to a solid, subject to high performance liquid chromatography using a Senshu Pack Aquaseal SS5251(60) 20 mm-diameter ⁇ 250 mm (Senshu Science Kabushiki Kaisha) to conduct purification with a mobile phase: chloroform/methanol 95/5 and to isolate the antitumor activity fraction.
- This fraction was vacuum-concentrated to obtain a transparent oily substance. This was suspended in a small amount of benzene and the result was vacuum concentrated and dried to a solid, thereby yielding 25 mg of NSCL-96F037, also herein termed phenylahistin (PLH).
- Aspergillus ustus NSC-F038 was used instead of Aspergillus ustus NSC-F037. It was determined that the ability of Aspergillus ustus NSC-F038 to produce the antitumor substance NSCL-95F037 was approximately four times that of NSC-F037. Specifically, from NSC-F037, approximately 2.9 mg phenylahistin was purified per liter of culture medium, while from NSC-F038, approximately 11.8 mg of phenylahistin was purified per liter of culture medium.
- the production of phenylahistin by A. ustus NSC-F038 was also determined to be related to the conidia formation of the fungus. Therefore, the fungus was cultured on an agar medium containing glucose (0.5%), glycerol (2%), yeast extract (0.2%), Pharmamedia (Traders Protein) (2%), NaCl (0.25%) and agar (1.5%), adjusted to pH 6.5 before sterilization. This medium was suitable for the conidia formation at 28° C. for 8 days. The cultured agar media (200 plates; 4 L) were then extracted with ethyl acetate.
- the extract was initially subject to silica gel column chromatography under an ethyl acetate-acetone stepwise gradient, followed by a second silica gel column and eluted with 2% methanol in chloroform.
- the fractions that exhibited cell cycle inhibitory activity were collected and evaporated, then dissolved in ethyl acetate and left two days at room temperature.
- the fungus A. ustus NSC-F038 was, alternatively, cultured is 20 ml of a culture medium comprising 0.5% glucose, 2% glycerin, 0.2% yeast extract, 2% cotton seed lees, 0.25% sodium chloride 2.5 g/l and 1.5% agar (pH6.5) to form a planar medium in a 9 cm-diameter Petri dish.
- the culture medium was inoculated at 5 points with Aspergillus ustus NSC-F038 and incubated in the dark for 7 days at 26° C. to produce spores.
- the spores were harvested into 5 ml of sterilized water having Tween 20 added to a concentration of 0.05%, thereby obtaining a spore suspension.
- Each of 400 Petri dishes containing 20 ml of the same culture medium was inoculated with 0.1 ml of the spore suspension. Incubation was conducted in the dark at 26° C. for 8 days. The cultures were comminuted with a mixer, 8 liters of ethyl acetate were added, and the mixture left standing 2 days before extraction. The recovered ethyl acetate was then vacuum-concentrated to obtain 15 g of a brown syrup.
- the syrup was dissolved in 20 ml of ethyl acetate, and the solution was subject to a silica gel column (bed volume: 8 cm diameter ⁇ 20 cm length) chromatography under ethyl acetate and eluted with acetone ethyl acetate (1:5).
- the eluate was fractionated in 500 ml lots in the order eluted.
- the active compound was eluted in the fifth to tenth lots. These elutes were then vacuum-concentrated to afford a dark-brown powder in a total amount of approximately 4.65 g.
- the active compound was eluted with methanol in chloroform (1:50) to obtain a brown powder in a total amount of approximately 1.05 g.
- the brown powder was then thoroughly mixed with ethyl acetate and left to stand 2 days to precipitate out approximately 628 mg of a white powder (A) containing the active compound.
- a portion of the white powder (A) was hydrolyzed.
- the so-obtained phenylalanine was analyzed by high performance liquid chromatography using a chiral column. The presence of R-configuration and S-configuration phenylalanine was then confirmed in a standard manner, and it was determined that the white powder (A) was a racemic mixture of the enantiomers of phenylahistin.
- A-549 cells derived from human lung cancer prepared to 10 5 cells/ml in a culture medium obtained by adding 10% bovine fetus serum to EMEM culture medium (Nissui Seiyaku Co., Ltd.) having antitumor effect against A-549 cells derived from human lung cancer was placed.
- Methanol solution of racemic NSCL-96F037 obtained as in Example 1 was added to the wells of the uppermost row, specimens were diluted by the half-log dilution method and added, and the plate was incubated in a carbon dioxide gas incubator at 37° C. for 48 hours.
- Cell strain A431 derived from human lung cancer was used.
- EMEM culture medium containing 10% bovine fetus serum and 1% MEM nonessential amino acid solution (SIGMA M2025) was used to incubate A431 cells at 37° C. in an incubator saturated with 5% carbon dioxide gas and water vapor.
- the refined specimen of racemic phenylahistin obtained in EXAMPLE 1 was added to the cells in the log-growth phase and progression of the cell cycle was analyzed by flow cytometer and microscopic observation. The results, shown in Table 1, indicate that this phenylahistin was useful as a cell cycle inhibitor.
- the human chronic myelogenic leukemia cells exhibited an IC 50 of 13.3 ⁇ g/ml, while the human pudendal epithelial squamous cancer cells exhibited an IC 50 of 2.9 ⁇ g/ml, indicate that (+)-phenylahistin was useful as an antitumor agent.
- Phenylahistin (PLH) had the molecular formula, C 20 H 22 N 4 0 2 , which was determined by HR-FAB-MS (mz found: 350.1741 (M + ), calcd. for C 20 H 22 N 4 O 2 : 350.1743).
- the absorption at 3440 cm ⁇ 1 corresponds to the N—H group
- strong absorptions at 1670 and 1640 indicated the existence of amide groups.
- the 1 H NMR and 1 H- 1 H COSY spectra revealed only the presence of four partial structures: a monosubstituted benzene ring, methylene protons being coupled to a methine proton, which was also coupled to an exchangeable proton, one geminal methyl group and a vinyl group. Since quaternary carbons prevented constructing further partial structures, the PFG-HBMC spectrum were t measured. A partial structure was determined on the basis of the long-range correlations of C-9, C-13, and C-14, which were observed in the spectrum. The carbon chemical shift of C-9 ( ⁇ 164.73) indicated that it was a carbonyl carbon. Therefore, that partial structure was determined to be a phenylalanine residue.
- a second partial structure was determined from the correlations of C-5, C-20, C-21, C-23 and C-24, which showed an isoprenyl group binding to quaternary sp 2 carbon ( ⁇ 136.83).
- the diketopiperazine ring was also constructed from the interpretation of correlations between respectively, C-7 and 11-H, C-10 and 8-H, C-12 and 8-H, and C-12 and 10-H in the PFG-HMBC spectrum.
- the dehydrohistidine moiety was estimated from the remaining three carbons, two nitrogens and three hydrogens, and this structure was supported by correlation signals of C-4, C-s, C-7, and C-12.
- phenylahistin has a chiral center at the C-10 position.
- Chiral HPLC analysis of the phenylalanine was conducted according to methods described in Larsen, T. O et al. Phytochemistry (1992) 31, 1613, under the following conditions: HPLC conditions: column; Crownpak CR(+) ⁇ 4.0 ⁇ 150 mm (Daicel Chemical Industries, Ltd.), mobile phase; H 2 O (pH 2, adjusted with perchloric acid), flow rate; 0.8 ml/min, detector; UV ⁇ 200 nm. Phenylalanine was obtained from the acidic hydrolysate of the amorphous white powder of phenylahistin, see Yamazaki, M.
- a pale yellow crystal having approximately dimension 0.4 ⁇ 0.4 ⁇ 0.8 mm was obtained from the ethyl acetate solution of phenuylahistin. All X-ray measurements were made on a Rigaku AFC7R diffractometer with graphite monochromated CuKa radia and a rotating anode generator. Cell constants and an orientation matrixed for data collection were obtained from a least-squares refinement using the setting angles of 25 carefully centered reflections in the range of 77.59 ⁇ 26 ⁇ 79.03°. These crystal data are summarized in Table 3.
- phenylahistin can be synthesized using the foregoing techniques or others well known organic synthesis techniques.
- Reaction Scheme 2 as shown in FIG. 2 , the synthesis of the phenylahistin derivative designated PLH-Cl, and alternatively designated compound 9, is described.
- This reaction scheme treats H 2 N-Phe-Gly-OMe, a commercially available dipeptide derivative to yield PLH-Cl, a derivative of PLH in which the isoprenyl moiety is replaced with a methyl group. Since partially racemization was occurred (21%), chiral resolution was carried out to obtain optically pure PLH-Cl.
- IC 50 values of ( ⁇ )-phenylahistin (S-configuration) (92.2% e.e.) and (+)-phenylahistin (R-configuration) (97.8% e.e.) were 3.5 ⁇ 10 ⁇ 7 M and 3.8 ⁇ 10 ⁇ 5 M, respectively.
- Judging from the content of ( ⁇ )-phenylahistin in (+)-phenylahistin, (+)-phenylahistin was considered to have relatively low cytotoxicity to P388 cells.
- microtubule protein was prepared from bovine brain by two cycles of assembly and disassembly method. The concentration of microtubule protein used for the assay was 1.5 mg/ml. ***Obtained from SIGMA (code No. C2615)
- P388 cells in the log growth phase were seeded into flasks and cultured for 14 hours, and then various concentrations of phenylahistin were added to each flask. After an 8-hour incubation, the cells were harvested and fixed with 50% MeOH at ⁇ 20° C. overnight. The cells were washed with 30% MeOH and then with 10 mM PBS, and treated with 50 ⁇ g/ml propidium iodide at 4° C. for 2 hours. DNA histograms were obtained using a flow cytometer (Cyto ACE-300:JASCO).
- ( ⁇ )-Phenylahistin ( ⁇ )-PLH) was shown to effect microtubule function, specifically via effecting the proliferation, mitosis, and microtubule structure of A549 cells (human lung carcinoma), and via inhibiting the in vitro polymerization of bovine brain microtubule protein and purified tubulin.
- competitive binding experiments using colchicine (CLC) and vinblastine (VLB), two typical antimitotic agents that bind to individual binding sites on tubulin were used to establish the effect of ( ⁇ )-PLH on the distinct binding sites on tubulin.
- A. Materials. ( ⁇ )-PLH was isolated from the agar-culture medium of A. ustus NSC-F038 (See, Kanoh, K. et al.: Bioorg. Med. Chem. Lett. (1997), 7, 2847-52, as disclosed in Example 1.
- CLC was obtained from Sigma (St. Louis, Mo.) and VLB was from Wako Pure Chemicals (Tokyo, Japan).
- [ 3 H]CLC was purchased from Du Pont/Boston Nuclear (New England, Mass.) and [ 3 H]VLB was from Amersham (Buckinghamshire, UK).
- A549 cell line human lung carcinoma was obtained from American Type Culture Collection (Rockville, Md.).
- A549 cells were cultured in phenol red free EMEM medium from Nissui Pharmaceuticals (Tokyo, Japan), supplemented with MEM non-essential amino acids (Sigma) and 10% fetal bovine serum from JRH Biosciences, (Lenexa, Kans.).
- Alamar BlueTM assay Exponentially growing A549 cells were seeded into 96-well tissue culture plates (2 ⁇ 10 3 cells/100 ⁇ l/well) and cultured for 16 hours. ( ⁇ )-PLH or CLC was then added to each well at various concentrations, and the cells were cultured for an additional 48 hours. Live cells were counted using Alamar BlueTM from BioSource International (Camarillo, Calif.) as described in Ahmed, S. A., J. Immunol. Methods, (1994), 170, 211-24.
- C. Mitotic Index Exponentially growing A549 cells were seeded into 96-well tissue culture plates (2 ⁇ 10 3 cells/100 ⁇ l/well) and cultured for 16 hours. ( ⁇ )-PLH or CLC was then added to each well at various concentrations, and the plates were incubated for an additional 24 hours. The number of cells in mitosis (round cells) and total cells in eight randomly selected fields were counted under a phase-contrast microscope. In a series of preliminary studies, it was confirmed that the round cells in this condition were cells in mitosis by using flow cytometry and Hoechst 33258 staining. The mitotic index represented the percentage of round cells among the total number of cells in the eight selected fields.
- the cells were then fixed with 3.7% formaldehyde for 30 min, permeabilized with 0.2% Triton X-100 for 5 min, and incubated with a mouse monoclonal antibody against ⁇ -tubulin (Calbiochem®, Oncogene Research Products, Cambridge, Mass.), followed by incubation with fluorescein isothiocyanate-conjugated goat anti-mouse IgG from Cosmo Bio Co., (Tokyo, Japan), and the cells were examined under an immunofluorescent microscope.
- Microtubule protein and tubulin preparation were prepared from bovine brain tissue by two cycles of assembly and disassembly according to the method of Tiwari, S. C. et al. Anal. Biochem, (1993), 215, 96-103.
- Tubulin was purified from microtubule protein by phosphocellulose chromatography see Algaier, J. et al. Biochim. Biophys. Acta, (1988), 954, 235-43, and tubulin purity was evaluated by polyacrylamide gel electrophoresis, as in Laemmli, U.K., Nature, (1970), 277, 680-85. Essentially, no microtubule-associated proteins were detected in this preparation. Protein concentrations were determined using the Coomassie® Protein Assay Reagent from Pierce (Rockford, Ill.).
- F Polymerization assay. Polymerization of microtubule protein was monitored by an increase in turbidity at 37° C. in microtubule assembly buffer containing 100 mM MES, 0.5 mM MgCl 2 , 1 mM EGTA and 1 mM GTP. See Johnson, K. A. et al., J. Mol. Biol., (1977), 117, 1-31. Polymerization of purified tubulin was measured using the same method except the microtubule assembly buffer contained 4 M glycerol. See Lee, J. C. et al., Biochemistry, (1975), 14, 5183-87. Microtubule protein and tubulin polymerization was initiated by a temperature shift from 0° C. to 37° C.
- turbidity was measured on a DU-20 thermocontrolled spectrophotometer from Beckman (Fullerton, Calif.) at 360 nm. Drugs were dissolved in dimethyl sulfoxide (DMSO), which was used in all experiments at a final concentration of 2% (v/v).
- DMSO dimethyl sulfoxide
- Microtubule protein (1.5 mg/ml) was polymerized at 37° C. for 20 min in the presence of 100 ⁇ M ( ⁇ )-PLH or vehicle (DMSO). A portion of each sample was diluted 5-fold with 1% glutaraldehyde in the microtubule assembly buffer. Samples were then placed on formvar- and carbon-coated grids, stained with 2% uranyl acetate, and examined using a JEOLJEM-1200 EXII electron microscope JEOL (Tokyo, Japan).
- the concentration of unbound [ 3 H]CLC in the filtrates was determined using a EcoLiteTM(+) liquid scintillator from ICN Pharmaceuticals Inc. (Costa Mesa, Calif.). Specific bound [ 3 H]CLC concentrations were determined by adding an excess ( ⁇ 100) of unlabeled CLC to the reaction mixture.
- bovine brain tubulin (0.2 mg/ml) was incubated in the microtubule assembly buffer with 0.5 ⁇ M [ 3 H]CLC and various concentrations of competitors for 20 min at 37° C.
- [ 3 H]CLC binding was measured as described above.
- DMSO was used as a co-solvent at a concentration that did not affect drug binding to tubulin (final 2% v/v).
- Measurement of [ 3 H]VLB binding was followed by the DEAE-cellulose filter method of Borisy, G. G., Anal. Biochem. (1972) 373-85, and the competition assay was carried out as described for CLC.
- ( ⁇ )-PLH effects microtubule protein polymerization and purified tubulin.
- the effect of ( ⁇ )-PLH on the polymerization of microtubule protein obtained from bovine brain were also examined. Accordingly, the time course of the turbidity change in the presence of various concentrations of ( ⁇ )-PLH and CLC was examined.
- ( ⁇ )-PLH inhibited the in vitro polymerization of microtubule protein in a concentration-dependent manner, 80 ⁇ M of ( ⁇ )-PLH completely inhibited the polymerization of microtubule protein, while (+)—PLH did not affect microtubule assembly at concentrations ranging up to a concentration of 200 ⁇ M.
- VLB see Luduena, R. F.; J. Biol. Chem. (1984) 259:12890-98, or dolastin 10
- dolastin 10 see Li, Y., et al., Chem. Biol. Interact., (1994), 93, 175-83 increases the turbidity in microtubule protein polymerization at concentrations higher than those required for inhibition.
- ( ⁇ )-PLH did not increase the turbidity at concentrations up to 200 ⁇ M.
- ( ⁇ )-PLH inhibited CLC binding to tubulin in a dose-dependent manner, with an estimated K i value for CLC binding of 7.4 ⁇ 10 ⁇ 6 M according to a Dixon plot, assuming that ( ⁇ )-PLH is the competitive inhibitor of CLC binding to tubulin.
- VLB slightly enhanced CLC binding to tubulin, likely an effect of the stabilization of VLB on the CLC binding activity of tubulin. See Lacey, E. et al., Biochem. Pharmacol. (1987) 36:2133-38.
- the binding of [ 3 H]VLG was not inhibited by ( ⁇ )-PLH.
- CLC enhanced and ( ⁇ )-PLH slightly enhanced [3H]VLG binding to tubulin.
- ( ⁇ )-PLH dose-dependently increased the mitotic index in parallel with inhibition of proliferation of A549 cells, indicating that it prevents cell proliferation by arresting the cell cycle in M phase.
- Most antimitotic agents such as CLC and VLB are known to exert anti-microtubule activity, including disruption of the process of mitotic spindle formation, resulting in cell arrest in mitosis.
- ( ⁇ )-PLH also exhibited an anti-microtubule activity, as evident by depolymerization of cytoskeletal microtubule in A549 cells treated with ( ⁇ )-PLH.
- the difference may be due to intracellular transformation of ( ⁇ )-PLH to an inactive form.
- the competitive binding assay using radiolabeled CLC and VLB showed that ( ⁇ )-PLH inhibited the binding of CLC to tubulin, suggesting that ( ⁇ )-PLH is a competitive inhibitor of CLC binding to tubulin and its binding site may be similar or very close to that of CLC.
- tryprostatin A inhibited microtubule polymerization by interacting with MAP2/tau-binding site rather than with CLC binding site, at relatively higher concentrations, see Usui, T., et al., Biochem, J., (1998), 333, 543-48; Kondoh, M., et al., J. Antibiot., (1998), 51, 801-04.
- tryprostatin A and ( ⁇ )-PLH have a similar structural motif, the diketopiperazine ring composed of isoprenylated heterocyclic amino acids, the binding site and effective concentration against microtubule polymerization are different. It is interesting that the two diketopiperazine compounds, which have different constituent amino acids, bind to distinct sites of tubulin molecule and exert a similar biological activity.
- EXAMPLES 13, 14 and 15 phenylahistin was prepared as described above in EXAMPLE 1.
- Agar-cultured medium of Aspergillus ustus NSC-F038 was extracted with ethyl acetate, and the extract was purified by silica gel column chromatography twice.
- PLH was then precipitated in ethyl acetate as a white powder which contained ( ⁇ ) and (+)-PLH.
- Two separate batches of PLH were used, the ( ⁇ )-PLH contents of which has been analyzed by chiral HPLC.
- HCC panel Human Cancer Cell Line Panel
- This HCC panel consists of 38 tumor cell lines including 7 lung cancer, 6 stomach, 6 colon, 5 ovary, 6 central nerve system, 5 breast, 2 kidney and 1 melanoma cell lines. Each tumor cell was seeded in 96-well tissue culture plates and incubated overnight. Various concentrations (5 doses; final 10 ⁇ 4 , 10 ⁇ 5 , 10 ⁇ 6 , 10 ⁇ 7 and 10 ⁇ 8 M) of PLH were added, and the cells were incubated for 48 hours.
- mice were obtained from Japan SLC (Shizuoka, Japan), P388 leukemia cells were obtained from Dainippon Pharmaceuticals Inc. (Osaka, Japan), Lewis Lung Carcinoma from Riken Cell Bank (Tsukuba, Japan), and Colon 26 cells from the National Cancer Center, Japan (Tokyo, Japan).
- HCC panel assay (GI 50 , TGI, and LC 50 for 38 cell lines) are shown in Table 5.
- PLH [( ⁇ )-PLH content: 24.1%] exhibited anti-proliferative activity against 38 cell lines with G1 50 values ranging from 2.3 ⁇ 10 ⁇ 7 M to 4.0 ⁇ 10 ⁇ 5 M.
- the mean graph see Yamori T., Jap. J. Cancer Chemother. (1997) 24, 129-135, of GI 50 was used for analyzing the mode of action of newly found antitumor agents.
- TGI values were relatively high, i.e., even at 100 ⁇ M PLH, and proliferation of 25 of the 38 cell lines was not completely suppressed. PLH did not exhibit intrinsic cytotoxicity under these experimental conditions, and significant LC 50 values were not obtained except for SF-539 cells.
- mice Male CDF1 mice (4 weeks old) were inoculated intraperitoneally with P388 leukemia cells (1 ⁇ 10 6 cells/body) on day 0.
- PLH [( ⁇ )-PLH content; 24%] was suspended in 10% ethanol-saline, and administered daily at a dose of 4.2 mg/kg, 12.5 mg/kg, 42 mg/kg or 125 mg/kg intraperitoneally, as a single injection (0.2 ml/body), from days 1 to 12.
- Each group consisted of six mice.
- PLH antitumor activity of PLH [( ⁇ )-PLH content: 24.1%] in mice inoculated intraperitoneally with murine P388 leukemia is shown in Table 6.
- PLH showed significant antitumor activity with a T/C of 129% and 151% at a daily dosage of 41.5 (the calculated dose of ( ⁇ )-PLH) and 124 (30) mg/kg respectively, for 12 days.
- the increases in body weight seen in the control group were also suppressed by daily administrations of PLH 41.5 and 124 mg/kg.
- diketopiperadine metabolites isolated as micotoxins for example, fumitremorgin B, a diketopiperazine metabolite consisting of proline and isoprenylated tryptophane and identified as cell cycle inhibitors, exert tremorgenic activity when administered to mice.
- fumitremorgin B a diketopiperazine metabolite consisting of proline and isoprenylated tryptophane and identified as cell cycle inhibitors
- PLH did not induce such side effects, even at the highest dose (124 mg/kg/day). This indicates that the difference of constituents in diketopiperazines may be responsible for the distinct pharmacological effect of PLH.
- mice Male BDF1 mice (6 weeks old) were inoculated subcutaneously in the right flank region with Lewis Lung Carcinoma cells (1 ⁇ 10 5 cells/body) on day 0.
- PLH [( ⁇ )-PLH content; 41.7%] was suspended in 10% ethanol-saline, and was administered daily at a dose of 24 mg/kg, 72 mg/kg, or 240 mg/kg intraperitoneally, as a single injection (0.2 ml/body), from days 1 to 14.
- Each group consisted of six mice. Mice were weighed, and the length (L) and the width (W) of the tumor were measured three times a week. On day 15, mice were sacrificed, and the tumor was excised and weighed.
- TWt represents the mean tumor weight of the treated group and TWc indicates that of the control group. Average and standard errors were calculated for each group. Variance analysis was performed by the Bartlett method (significance level: 5%), and if the variance was uniform, a Dunnett's multiple comparison test was performed. However, if the variance was not uniform, rank conversion was performed followed by variance analysis again by the Bartlett method (significance level: 5%). Significance was established at the p ⁇ 0.05 level. Based on the weight of the excised tumors in the control group, the suppression rate was calculated for each group, and the ED 50 and 95% confidence limit were then determined by linear regression analysis.
- the estimated tumor weight (ETW) was 105 mg on day 7, and gradually increased to 2,306 mg on day 15.
- the ETW was slightly lower in the 24 mg/kg/day group, in which it increased from 86 mg on day 7 to 2,244 mg on day 15.
- the ETW was slightly lower in the 72 mg/kg/day group, in which it increased from 34 mg on day 7 to 2,142 mg on day 15.
- the ETW was the lowest, increasing from 34 mg on day 7 to 617 mg on day 15.
- Significant suppression of the ETW was observed on days 10, 13 and 15 (81.8, 82.3 and 73.2%, respectively).
- the weight of the excised tumor on the fifteenth day was 3,264 mg for the control group, and 2,941 and 2,380 mg for 24 and 72 mg/kg/day groups, respectively, indicating a rate of suppression of 9.9% and 27.1%, respectively.
- the excised tumor weight was 619 mg, indicating a rate of suppression of 81.0%.
- the ED 50 and 95% confidence limit was 105.3 mg/kg/day [calculated dose of ( ⁇ )-PLH: 43.9 mg/kg/day] and 22.0 ⁇ 504.1 mg/kg/day [( ⁇ )-PLHL: 9.2 ⁇ 210.2 mg/kg/day], respectively.
- mice Male CDF1 mice (6 weeks old) were inoculated subcutaneously in the right flank region with Colon 26 cells (1 ⁇ 10 5 cells/body) on day 0. Each group consisted of six mice. Preparation and administration of PLH, and the evaluation of antitumor activity was carried out as described for Lewis Lung Carcinoma, in EXAMPLE 14.
- mice subcutaneously inoculated Colon 26 cells The antitumor activity of PLH (( ⁇ )-PLH content: 41.7%) in mice subcutaneously inoculated Colon 26 cells was determined. No mice died during the experimental period in the control, 24 mg/kg/day and 72 mg/kg/day groups. However, in the 240 mg/kg/day group, one mouse died on day 12, two died on day 13 and one died on day 14. No marked changes in the weight of the control was observed, 24 mg/kg/day and 72 mg/kg/day groups, whereas, in the 240 mg/kg/day group, the body weight was lower than that of the control group from day 3, and was lower from day 3 to day 10.
- the ETW gradually increased from 51 mg on day 7 to 1067 mg on day 15.
- the ETWs increased but the increments were slightly lower than those of the control group.
- the increments of ETW were significantly lower at 14 mg on day 7 and 254 mg on day 15.
- the suppression rates were 64.4% on day 10, 78.8% on day 13 and 85.4% on day 15.
- the weight of the excised tumor on the fifteenth day was 1,159 mg for the control group, and 1,113 and 843 mg for 24 and 72 mg/kg./day groups, respectively, indicating a rate of suppression of 4.0% and 27.3%, respectively.
- the excised tumor weight was 211 mg, indicating a rate of suppression of 81.8%.
- the ED 50 and 95% confidence limit was 107.3 mg/kg/day [calculated dose of ( ⁇ )-PLH: 44.7 mg/kg/day] and 29.0 ⁇ 397.7 mg/kg/day [( ⁇ )-PLII: 12.1 ⁇ 165.8 mg/kg/day], respectively.
- (+)- and ( ⁇ )-phenylahistin Antitumor activity of (+)- and ( ⁇ )-phenylahistin was examined against seven human cancer cell lines including A431, WiDr, TE-671, Hela, MCF7, A-549 and K562 cells.
- the IC 50 values of each enantiomer were shown in Table 7.
- ( ⁇ )-Phenylahistin exhibited antitumor activity with the IC 50 values ranging from 1.8 ⁇ 10 ⁇ 7 (against WiDr cells) to 3.7 ⁇ 10 ⁇ 5 (against TE-671). While (+)-PLH exhibited approximately 33 to 100-fold less activity than ( ⁇ )-PLH.
- Mono-methylated derivative 14 at the ⁇ nitrogen of the imidazole ring whose methylation site was detected by NMR analysis (note that the low filed shift of 8(N)—H ( ⁇ 12.20 ppm) in the 1 H NMR spectrum was maintained in compound 14) and was predominantly obtained with equivalent of the reagents at ⁇ 30° C., and a tri-methylated derivative 15 was obtained in the reaction with 30 equivalents of the reagents at room temperature.
- Compound 14 and 15 with the L-phenylalanine residue were separated by HPLC with a chiral column.
- the benzyl group of the Phe residue was stacked over the diketopiperazine ring by sticking out from this plane, whose conformation is reported as the energetically most favored one in diketopiperazine with an aromatic amino acid residue, according to the method of Liwo, A. et al. Tetrahedron Lett., 26, 1873 (1985).
- the 1,1-dimethyl-2-propenyl group at the imidazole ring was also restricted its movement by the steric hindrance of a hydrogen atom at the ⁇ -position (C6) of the ⁇ , ⁇ -unsaturated His derivative. Therefore, it is indicated that the conformation of (+)-phenylahistin is highly restricted.
- (+)-phenylahistin with the L-Phe residue was 50 times more active than (+)-phenylahistin in anti-proliferative assays.
- (+)-Phenylahistin also exhibited relatively weak inhibitory activity against microtubule polymerization (15% inhibition at 200 ⁇ M) compared with ( ⁇ )-phenylahistin.
- the orientation of the benzyl group of the phenylalanine residue is important to the biological activity of the compounds of the present invention.
- IC 50 Microtubule Protein a P388 compound polymerization proliferation ( ⁇ )-11 25 0.21 ( ⁇ 0.02) b (+)-11 >200 [15%] c 10 ( ⁇ 1.5) ( ⁇ )-12 30 0.23 ( ⁇ 0.05) (+)-12 >200 [12%] 19 ( ⁇ 4.2) ( ⁇ )-13 >200 >200 (+)-13 >200 >200 14 100 0.95 ( ⁇ 0.03) 15 >200 160 ( ⁇ 5.5) 19 >200 [11%] >200 20 >200 ⁇ 9%] 15 ( ⁇ 4.5) Cyclo(His-Phe) d >200 >200 colchicine d 16 0.031 ( ⁇ 0.01) a Microtubule protein was prepared from bovine brain by two cycle of assembly and disassembly method.
- the concentration of microtubule protein used for the assay was 1.5 mg/mL.
- b Values are means ( ⁇ SEM) of three experiments.
- c The inhibition percentage at 200 ⁇ M was indicated in the parenthesis when the inhibition was observed, since the diketopiperazine derivatives are insoluble in the concentration more than 200 ⁇ M. 19 and 20 were chiral-purified.
- Cyclo(His-Phe) and colchicine are each commercially available; each was purchased from Sigma.
- Compound 20 in which the 1,1-dimethyl-2-propenyl group was replaced with a methyl group at this position, also showed no activity in the anti-microtubule assay, although weak inhibition on P388 cell proliferation was observed.
- This drastic decreased in biological activity in 19 indicates that an alkyl group with a proper length or a quaternary carbon at the 5-position of the imidazole ring is important for the activity.
- the results of the x-ray crystallographic analysis and the biological evaluation of the phenylahistin derivatives elucidate a structural factor of phenylahistin necessary for its anti-microtubule activity.
- This factor is that the rigid and planar pseudo three-ring structure formed by a hydrogen bond are important for the biological activity of ( ⁇ )-phenylahistin.
- microtubule protein polymerization assay was performed as follows. Microtubule protein was prepared from bovine brain tissue by two cycles of assembly and disassembly. Polymerization of microtubule protein was monitored by an increase in turbidity at 37° C. in microtubule assembly buffer containing 100 mM MES, 0.5 mM MgCl 2 , 1 mM EGTA and 1 mM GTP. The polymerization of microtubule protein was initiated by a temperature shift from 0° C. to 37° C. Turbidity was measured on a thermo-controlled spectrophotometer (Beckman DU-20, Fullerton, Calif.) at 360 nm. Compounds were dissolved in DMSO, which was used in all experiments at a final concentration of 2% (v/v).
- the Alamar BlueTM assay was performed as follows. Exponentially growing P388 cells were seeded into 96-well tissue culture plates (5 ⁇ 10 3 cells/100 ⁇ l/well) and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum for 16 h. Compounds (DMSO solution) were then added to each well at various concentrations, and the cells were cultured for an additional 48 h. Living cells were counted using Alamar BlueTM (BioSource International, Camarillo, Calif.), according to the method of Ahmed, S. A. et al., J. Immunol. Methods, 170, 211 (1994).
- the residual white powder (150 mg) was chromatographed over 20 g of silica gel and eluted with CHCl 3 -MeOH (50:1) as an eluent to give 130 mg (63%) of 14 as white powder:
- the ( ⁇ )-form of 14 was isolated by HPLC using chiral column (CHIRALCEL OD, 10 ⁇ 250 mm) eluted with a mixture of hexane and ethanol (3:1) at a flow rate of 6.0 mL/min on a Waters system (600E series).
- Cyclo-[glycinyl-L-phenylalanine] 16 To a solution of H-Phe-Gly-OMe, which was prepared from Boc-Phe-Gly-OMe with 4N HCl-dioxane (20 g, 59 mmol), in MeOH (100 mL) was refluxed for 16 h. The white precipitate occurred during reflux was washed with 10 mL of MeOH for three times and collected to give 7.5 g (62%) of 16 as a white powder, mp 262-263° C.
- Cyclo-N,N′-diacetyl-[glycinyl-L-phenylalanine] 17 The mixture of compound 16 (0.5 g, 2.45 mmol) and fused sodium acetate (201 mg, 2.45 mmol) in acetic anhydride (10 mL) was heated for 16 h at 100° C. under nitrogen. After acetic anhydride was removed in vacuo at 45° C., the residue was solved in EtOAc and the resulted organic layer was washed with saturated NaCl, dried over Na 2 SO 4 and 17 was crystallized from EtOAc.
- Cyclo-[dehydrohistidinyl-L-phenylalanine] 19 To a solution of 17 (311 mg, 0.93 mmol) in dimethoxyethanol (DME) (10 mL) was added 0.6 mL of 2M lithium diisopropylamide (LDA, 1.2 mmol) and the mixture was stirred at ⁇ 70° C. for 10 min. To this solution was added a solution of 4(5)-formylimidazole (120 mg, 1.25 mmol, Maybridge Chemical Co. Ltd., Cornwall, U.K.) in HMPA (4 mL)-DME (6 mL) at ⁇ 70° C. This mixed solution was allowed to warm to ⁇ 30° C.
- DME dimethoxyethanol
- HMPA lithium diisopropylamide
- the resultant residue was purified by HPLC with a reverse phase column (Waters, ⁇ Bondasphere 19 ⁇ 150 mm, 10 ⁇ m, C-18) employing a gradient from 60 to 80% CH 3 CN in 0.1% TFA at a flow rate of 17 mL/min on a Waters system (600E series).
- purified compound 19 contained 28% of a racemized compound with D-phenylalanine (44% ee)
- further purification by HPLC with a chiral column was performed using the same procedure described for the purification of ( ⁇ )14. 8% yield from 7; white powder; mp 208-209° C.
- Cyclo-[(5-methyl)dehydrohistidinyl-L-phenylalanine] 20 This compound was prepared from compound 17 with 4-methyl-5-imidazolecarboxaldehyde according to the same procedure for the preparation of 19.3% yield from 17; colorless solid; mp 285-286° C.
- Vials containing 5 g of powdered glucose are each added aseptically with 10 mg of the invention compound and sealed. After being charged with nitrogen, helium or other inert gas, the vials are stored in a cool, dark place. Before use, the contents are dissolved in ethanol and added to 100 ml of a 0.85% physiological salt water solution. The resultant solution is administered as a method of inhibiting the growth of a cancerous tumor in a human diagnosed as having such a tumor at between approximately 10 ml/day to approximately 1000 ml/day, intravenously, by drip, or via a subcutaneous or intraperitoneal injection, as deemed appropriate by those of ordinary skill in the art.
- a mixture obtained by thoroughly blending 1 g of the compound of the invention, 98 g of lactose and 1 g of hydroxypropyl cellulose is formed into granules by any conventional method.
- the granules are thoroughly dried and sifted to obtain a granule preparation suitable for packaging in bottles or by heat sealing.
- the resultant granule preparations are orally administered at between approximately 100 ml/day to approximately 1000 ml/day, depending on the symptoms, as deemed appropriate by those of ordinary skill in the are of treating cancerous tumors in humans.
- PLH is administered according to the formulation of EXAMPLE 17 to a human patient afflicted with lung cancer. PLH is administered at between approximately 10 mg per day to approximately 1000 mg per day, and in an preferred amount of 50 mg per day, until the growth of the tumor is inhibited.
- ( ⁇ )-PLH is isolated according to the method of EXAMPLE 6, substantially purified, and administered according to the formulation of EXAMPLE 17 to a human patient, afflicted with ovarian cancer, at between approximately 10 mg per day to approximately 100 mg per day, and in a preferred amount of 50 mg per day, until the growth of the tumor is
- 2-isopropyl-( ⁇ )-phenylahistin i.e., compound 3 of EXAMPLE 7 is synthesized according to the method of EXAMPLE 7, substantially purified, and administered according to the formulation of EXAMPLE 17 to a human patient afflicted with breast cancer at between approximately 10 mg per day to approximately 100 mg per day, and in a preferred amount of 50 mg per day, until the growth of the tumor is inhibited.
- 2-dichloroisopropyl-( ⁇ )-phenylahistin is synthesized in the following manner: ( ⁇ )-Phenylahistin, compound 1 of EXAMPLE 7, is placed in the presence of Cl 2 and in the presence of water and heat to yield 2 dichloroisopropyl-( ⁇ )-phenylahistin.
- 2-dichloroisopropyl-( ⁇ )-phenylahistin as synthesized in EXAMPLE 22, is substantially purified and administered according to the formulation of EXAMPLE 17 to a human patient afflicted with Lewis Lung Carcinoma at between approximately 10 mg per day to approximately 100 mg per day, and in a preferred amount of 50 mg per day, until the growth of the tumor is inhibited.
- phenylahistin are its derivatives are screened using an efficient solid phase combinatorial synthesis for a typical diketopiperazine library. By using such technique, phenylahistin is utilized as a prototype for the development of promising new antitumor agents.
- Vials containing 5 g of powdered glucose are each added aseptically with 10 mg of compound synthesized by the method and sealed. After being charged with nitrogen, helium or other inert gas, the vials are stored in a cool, dark place. Before use, the contents are dissolved in ethanol and added to 100 ml of a 0.85% physiological salt water solution. The resultant solution is administered as a method of inhibiting the growth of a cancerous tumor in a human diagnosed as having such a tumor at between approximately 10 ml/day to approximately 1000 ml/day, intravenously, by drip, or via a subcutaneous or intraperitoneal injection, as deemed appropriate by those of ordinary skill in the art.
- a mixture obtained by thoroughly blending 1 g of a compound synthesized by the method, 98 g of lactose and 1 g of hydroxypropyl cellulose is formed into granules by any conventional method.
- the granules are thoroughly dried and sifted to obtain a granule preparation suitable for packaging in bottles or by heat sealing.
- the resultant granule preparations are orally administered at between approximately 100 ml/day to approximately 1000 ml/day, depending on the symptoms, as deemed appropriate by those of ordinary skill in the art of treating cancerous tumors in humans.
- Administration to an individual of an effective amount of the compound can also be accomplished topically by administering the compound(s) directly to the affected area of the skin of the individual.
- the compound administered or applied is in the form of a composition including a pharmacologically acceptable topical carrier, such as a gel, an ointment, a lotion, or a cream, which includes, without limitation, such carriers as water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils.
- topical carriers include liquid petroleum, isopropyl palmitate, polyethylene glycol, ethanol (95%), polyoxyethylene monolaurate (5%) in water, or sodium lauryl sulfate (5%) in water.
- the compound may be disposed within devices placed upon, in, or under the skin. Such devices include patches, implants, and injections which release the compound into the skin, by either passive or active release mechanisms.
- the in vitro efficacy studies performed with t-butyl phenylahistin included: A) a panel of six tumor cell lines, B) studies in multidrug-resistant tumor cells, and C) studies to determine the mechanism of action.
- HT29 human colon tumor; ATCC; HTB-38
- PC3 human prostate tumor; ATCC; CRL-1435
- MDA-MB-231 human breast tumor; ATCC; HTB-26
- NCI-H292 human non-small cell lung tumor; ATCC; CRL-1848
- OVCAR-3 human ovarian tumor; ATCC; HTB-161
- B16-F10 murine melanoma; ATCC; CRL-6475
- CCD-27sk normal human fibroblast; ATCC; CRL-1475
- Cytotoxicity assays were performed as described above in Example 4, using Resazurin fluorescence as an indicator of cell viability.
- the disclosed compounds are effective agents against a variety of different and distinct tumor cell lines.
- t-butyl-phenylahistin exhibited its greatest potency against the PC-3 tumor cell line, although the greatest efficacy was displayed against the HT-29 cell line.
- t-butyl-phenylahistin displayed a marked differential between normal fibroblasts and the tumor cell lines, with a ratio ranging from >20->100, except for the OVCAR-3 cell line.
- chemotherapeutic agents in clinical oncology
- resistance to the drug effect by the tumor cells.
- mechanisms for the development of resistance include increased expression of ATP-dependent efflux pumps such as the P-glycoprotein encoded by MDR1 or the multidrug-resistance associated protein 1 encoded by MRP1.
- Reduced drug uptake, alteration of the drug's target, increasing repair of drug-induced DNA damage, alteration of the apoptotic pathway and the activation of cytochrome P450 enzymes are other examples of mechanisms by which cancer cells become resistant to anticancer drugs.
- the selected compounds were studied in three different cell lines that exhibit two different mechanisms of resistance; the overexpression of the P-glycoprotein and altered topoisomerase II activity.
- MES-SA Texol Sensitive
- MES-SA DX Texol Resistant
- This cell line expresses elevated mdr-1 mRNA and P-glycoprotein (an extrusion pump mechanism).
- Pretreatment with cyclosporin-A (CsA) blocks P-glycoprotein and reinstates activity in the resistant cell line for those compounds for which the resistance is due to elevated P-glycoprotein.
- This cell line is considered to have atypical drug resistance properties with altered topoisomerase II catalytic activity without overexpression of P-glycoprotein.
- t-butyl-phenylahistin is not susceptible to the same resistance mechanisms as Mitoxantrone in this cell line, and there is no cross-resistance from Mitoxantrone to t-butyl phenylahistin in this model.
- TABLE 12 Activity of t-butyl-phenylahistin and Mitoxantrone in the HL-60 Human Acute Promyelocytic Leukemia Tumor Sensitive and Resistant Cell Line Pair HL-60 Resistant HL-60 Sensitive Ratio Compound IC50 nM IC50 nM to Sensitive t-butyl-phenylahistin 255 175 0.69 Mitoxantrone 202 4870 24.1
- Human umbilical vein endothelial cells (HuVEC from Cambrex) were used in this study, for evaluating the effects of t-butyl-phenylahistin in comparison to colchicine and taxol on tubulin by staining for ⁇ -tubulin.
- Caspase-3 Several enzymes in the caspase cascade are activated during apoptosis, including Caspase-3, -8 and -9.
- the activity of Caspase-3 was monitored in Jurkat cells following treatment with t-butyl-phenylahistin.
- PARP poly(ADP-ribose) polymerase
- PARP is a 116 kDa nuclear protein that is one of the main intracellular targets of Caspase-3.
- the cleavage of PARP generates a stable 89 kDa product, and this process can be easily monitored by western blotting.
- Cleavage of PARP by caspases is one of the hallmarks of apoptosis, and as such serves as an excellent marker for this process.
- Halimide was active at inducing cleavage of PARP in Jurkat cells 10 hours after exposure of the cells to the compound.
- t-butyl-phenylahistin Studies with t-butyl-phenylahistin were performed.
- the novel compound was studied as monotherapy and in combination with a clinically-used chemotherapeutic agent.
- the doses of the selected novel compound were determined from the acute tolerability testing (Maximally Tolerated Dose, MTD) and were adjusted if necessary during each study.
- the doses of the clinically-used chemotherapeutic agents were selected on the basis of historical studies.
- t-butyl-phenylahistin was were compared in the HT-29 human colon tumor, the DU-145 human prostate and the MCF-7 human breast tumor xenograft models.
- the above models all use the subcutaneous xenograft implantation technique and are potentially subject to selective effects of a compound on the subcutaneous vasculature producing a magnified (or apparent) antitumor activity.
- two other tumor models have been incorporated in the research.
- One of these is the observation of lung metastases following the intravenous injection of B16-F10 mouse melanoma tumor cells.
- the other model is the implantation of MDA-231 human breast tumor cells in the mouse mammary fat pad. While this latter model is a xenograft model, the subcutaneous vasculature does not play a role.
- mice used were (exceptions are indicated for individual studies): female nude mice (nu/nu) between 5 and 6 weeks of age ( ⁇ 20 g, Harlan); group size was 9-10 mice per group unless otherwise indicated.
- Cell lines used for tumor implantation were: HT-29 human colon tumor; MCF-7 human breast tumor; A549 human non small cell lung tumor; MiaPaCa-2 human pancreas tumor; DU-145 human prostate tumor.
- the selected novel compound was administered as monotherapy via the intraperitoneal (i.p.) route at the doses indicated for the individual study; for the combination studies the selected reference chemotherapy agents were injected 15-30 min prior to the compound.
- Vehicles used in these studies were: 12.5% DMSO, 5% Cremaphor and 82.5% peanut oil for the selected novel compounds; (1:3) Polysorbate 80:13% ethanol for taxotere; (1:1) Cremaphor:ethanol for paclitaxel; for CPT-11 each mL of solution contained 20 mg of irinotecan hydrochloride, 45 mg of sorbitol NF powder, and 0.9 mg of lactic acid, the pH being adjusted to 7.4 with NaOH or HCl. Saline dilutions are used to achieve the injection concentrations used for the reference compounds.
- mice Animals were implanted subcutaneously (s.c.) by trocar with fragments of HT-29 tumors harvested from s.c. growing tumors in nude mice hosts. When the tumor size reached 5 mm ⁇ 5 mm (about 10-17 days) the animals were matched into treatment and control groups. Mice were weighed twice weekly and tumor measurements were obtained using calipers twice weekly, starting on Day 1. The tumor measurements were converted to estimated mg tumor weight using the formula (W 2 ⁇ L)/2. When the estimated tumor weight of the control group reached an average of 1000 mg the mice were weighed, sacrificed and the tumor removed. The tumors were weighed and the mean tumor weight per group was calculated and the tumor growth inhibition (TGI) was determined for each group (100% minus the change in the mean treated tumor weight/the change in the mean control tumor weight ⁇ 100.
- TGI tumor growth inhibition
- the selected novel compound was injected intraperitoneally every third day for 15 days [1, 4, 8, 11 and 15 (q3dx5)]; CPT-11 was administered intraperitoneally on days 1, 8 and 15 (qwx3).
- mice Female nude mice ( ⁇ 20 g) were implanted s.c. with 21-day release estrogen (0.25 mg) pellets 24 hours prior to the s.c. implantation with MCF-7 tumor fragments (harvested from s.c. tumors in nude mice hosts). The study then proceeded as described for the HT-29 model, using taxotere as the standard chemotherapy agent.
- the novel compound was injected via the intraperitoneal route daily on Days 1-5, inclusive (qdx5); taxotere was administered intravenously on Days 1, 3 and 5 (qodx3).
- Animals were implanted s.c. by trocar with fragments of A549 tumors harvested from s.c. growing tumors in nude mice hosts. When the tumor size reached 5 mm ⁇ 5 mm (about 10-17 days) the animals were matched into treatment and control groups. The rest of the study proceeded as described for the HT-29 model, using taxotere and CPT-11 as the standard chemotherapy agents.
- the tested compound was administered via the intraperitoneal route on a q3dx5 dose schedule for the CPT-11 combination or on a qdx5 dose regimen for the combination with taxotere; CPT-11 was administered via the intraperitoneal route on a qwx3 schedule; taxotere was administered intravenously on a qodx3 dose regimen.
- test compound was administered every third day via the intraperitoneal route on Days 1, 4, 7, 10 and 15 (q3dx5); gemcitabine was administered via the intraperitoneal route on Days 1, 4, 7 and 10 (q3dx4).
- mice Male mice were implanted s.c. by trocar with fragments of DU-145 tumors harvested from s.c. growing tumors in nude male mice hosts. When the tumors reached ⁇ 5 mm ⁇ 5 mm (at about 13-17 days) the animals were matched into treatment and control groups. The remainder of the study proceeded as for the HT-29 model, using taxotere as the standard chemotherapy agent.
- test compound was administered via the intraperitoneal route on Days 1, 3, 5, 8 and 11 (q3dx5); taxotere was administered intravenously on Days 1, 3 and 5 (q2dx3).
- mice Female nude mice (nu/nu) (MDA-231 study) or B6D2F1 (B16-F10 studies) mice between 5 and 6 weeks of age ( ⁇ 20 g, Harlan); group size was 10 mice per group unless otherwise indicated.
- the cell lines used were: MDA-MB-231 human breast tumor and B16-F10 murine melanoma cells.
- Compound was administered as monotherapy via the intraperitoneal route at the does indicated for the individual study; for the combination studies the selected reference chemotherapy agents were injected 15-30 min prior to the NPI compound.
- mice Female nude mice were injected in the mammary fat pad with 2 ⁇ 10 6 MDA-231 cells harvested from in vitro cell culture. When the tumor size reached 5 mm ⁇ 5 mm (about 14-28 days) the animals were matched into treatment and control groups. The study then proceeded as described for the HT-29 model, using paclitaxel as the standard chemotherapy agent.
- test compound was administered via the intraperitoneal route on Days 1, 4, 8, 11 and 15 (q3dx5); paclitaxel was administered via the intraperitoneal route on Days 1-5 (qdx5).
- mice received B16-F10 cells (prepared from an in vitro cell culture of B16-F 10 cells) by the iv route on Day 0. On Day 1 mice were randomized into treatment and control groups and treatment commenced. Mice were weighed twice weekly, starting on Day 1. All mice are sacrificed on Day 16, the lungs removed, weighed and the surface colonies counted. Results are expressed as mean colonies of treated mice/mean colonies of control mice (T/C) ⁇ 100%). The metastasis growth inhibition (MGI) is this number subtracted from 100%. Paclitaxel was the standard chemotherapy agent used in this study.
- test compounds were administered via the intraperitoneal route on Days 1-5 (qdx5); paclitaxel was administered intravenously on Days 1-5(qdx5).
- the results of this study are presented in FIG. 17 and Table 14.
- the combination therapy group indicated a marked synergy between the novel compound and CPT-11.
- the individual tumor weights demonstrate the effectiveness of the cotherapy treatment ( FIG. 18 ).
- the TGI for the combination group surpasses the NCI criterion for a positive effect, whereas the TGI for CPT-11 monotherapy did not reach this level.
- the excised tumor weights at autopsy confirmed the observations made during the in-life segment of the study.
- the tumor growth inhibition indices indicated a marked inhibition of tumor growth. Taxotere alone did not reach the NCI established criterion for a positive effect (TGA ⁇ 58%).
- the selected novel compound has early onset, statistically significant effects when used in combination with taxotere in this model, apparently almost completely blocking estimated tumor growth ( FIG. 10 ).
- t-butyl-phenylahistin exhibited a significant potentiation of taxotere.
- This study examined the effect of t-butyl-phenylahistin alone and in combination with paclitaxel on the number of metastases appearing on the surface of the lung 16 days after the intravenous injection of B16 F10 melanoma cells to the mouse.
- This model is not a xenograft model; however, it does not involve a high degree of vascularization into the tumor mass.
- Comparative activity of a phenylahistin or its analog against a pathogenic fungus, relative to known antifungal compounds recited above, for use in determining the phenylahistin or its analog's AF/IS value is measured directly against the fungal organism, e.g. by microtiter plate adaptation of the NCCLS broth macrodilution method described in Diagn Micro and Infect Diseases 21:129-133 (1995).
- Antifungal activity can also be determined in whole-animal models of fungal infection. For instance, one may employ the steroid-treated mouse model of pulmonary mucormycosis (Goldaill, L. Z. & Sugar, A. M. 1994 J Antimicrob Chemother 33:369-372).
- a number of animals are given no phenylahistin or its analog, various doses of phenylahistin or its analog (and/or combinations with one or more other antifungal agents), or a positive control (e.g. Amphotericin B), respectively, beginning before, at the time of, or subsequent to infection with the fungus.
- Animals may be treated once every 24 hours with the selected dose of phenylahistin or its analog, positive control, or vehicle only. Treatment is continued for a predetermined number of days, e.g. up to ten days. Animals are observed for some time after the treatment period, e.g. for a total of three weeks, with mortality being assessed daily.
- Models can involve systemic, pulmonary, vaginal and other models of infection with or without other treatments (e.g. treatment with steroids) designed to mimic a human subject susceptible to infection.
- one method for determining the in vivo therapeutic efficacies is a rodent model system.
- a mouse is infected with the fungal pathogen such as by intravenous infection with approximately 10 times the 50% lethal dose of the pathogen (10 6 C. albicans cells/mouse).
- phenylahistin compounds are given to the mouse at a predetermined dosed volume.
- the ED 50 is calculated by the method of Van der Waerden ( Arch Exp Pathol Pharmakol 195:389-412, 1940) from the survival rate recorded on 20th day post-infection. Generally, untreated control animals die 7 to 1 3 days post-infection.
- C. albicans Wisconsin (C43) and C. tropicalis (C112) grown on Sabouraud dextrose agar (SDA) slants for 48 h at 28° C., are suspended in saline and adjusted to 46% transmission at 550 nm on a spectrophotometer. The inoculum is further adjusted by hemacytometer and confirmed by plate counts to be approximately 1 or 5 ⁇ 10 7 CFU/ml.
- CF-1 mice are infected by injection 1 or 5 ⁇ 10 6 CFU into the tail vein.
- Antifungal agents are administered intravenously or subcutaneously in ethanol:water (10:90), 4 h post infection and once daily thereafter for 3 or 4 more days. Survival is monitored daily.
- the ED 50 can be defined as that dose which allows for 50% survival of mice.
- Benzimidazoles and griseofulvin are anti-tubulin agents capable of binding to fungal microtubules. Once bound, these compounds interfere with cell division and intracellular transport in sensitive organisms, resulting in cell death.
- benzimidazoles are used as fungicidal agents in veterinary medicine and plant disease control.
- a wide variety of fungal species, including Botrytis cinerea, Beauveria bassiana, Helminthosporium solani, Saccharomyces cerevisiae and Aspergillus are susceptible to these molecules. Toxicity concerns and increasing drug resistance, however, have negatively impacted their usage.
- Griseofulvin is used clinically to treat ringworm infections of the skin, hair and nails, caused by Trichophyton sp., Microsporum sp., and Epidermophyton floccosum . Its antifungal spectrum, however, is restricted to this class of fungal organisms. Genotoxicity is also a significant side effect. Terbinafine, while an alternative first-line treatment, is more costly. Further, clinical resistance recently has been observed in Trichophyton rubrum (the major causative agent for all dermatophyte infections).
- microtubule/microfilament formation is affected where cells are exposed to the microtubule inhibitors nocodazole and chloropropham.
- test compounds and controls used in this study: ( ⁇ )-Phenylahistin and t-butyl phenylahistin, Colchicine (commercial microtubulin inhibitor tested versus 3 Candida isolates), Benomyl (commercial microtubulin inhibitor tested versus 3 Candida isolates), Griseofulvin (commercial microtubulin inhibitor and antibiotic control for testing versus 6 dermatophyte isolates), Amphotericin B (antibiotic control for testing versus 3 Candida isolates), Itraconazole (antibiotic control for testing versus 2 Aspergillus isolates).
- Candida albicans Candida glabrala, Aspergillus fumigatus, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophylon floccosum .
- Candida glabrata one isolate
- two isolates of each species were tested.
- Antifungal susceptibility testing was accomplished according to the methods outlined in the National Committee for Clinical Laboratory Standards, M38-A “Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi; Approved Standard.” This includes testing in RPMI-1640 with glutamine and without bicarbonate, an inoculum size of 0.4-5 ⁇ 10 4 , and incubation at 30 or 35° C. for 48 hours. The minimum inhibitory concentration (MIC) was defined as the lowest concentration that resulted in an 80% reduction in turbidity as compared to a drug-free control tube. Drug concentrations were 0.03-16 ⁇ g/ml for the investigational compounds, 0.015-8 ⁇ g/ml for itraconazole and griseofulvin.
- the minimum inhibitory concentration (MIC) at which a compound prevented the growth of the target microorganism was assessed according to the modified version of the NCCLS protocol.
- Minimum inhibitory concentrations (MIC) were determined at the first 24-hour interval where growth could be determined in the drug-free control tube. The defined MIC was the lowest concentration that exhibited an 80% reduction in turbidity as compared to the growth control.
- the minimum lethal concentration (MLC) was determined by plating 0.1 ⁇ l from the MIC concentration and each concentration above the MIC. The MLC was called at the first concentration that exhibited five or fewer colonies of fungal growth representing a 99.95% kill.
- MFC minimum fungicidal concentration
- T. rubrum is the principal causative agent for human dermatophytic infections, and would be the key organism to target in the development of a clinical agent.
- Compound t-butylphenylahistin at least was equivalent in potency compared to griseofulvin, a current, standard pharmaceutical agent used for treating dermatophytic infections.
- Compound ( ⁇ )-Phenylahistin also was potent when tested versus T. rubrum and even more potent versus the sensitive T mentagrophytes isolate.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
-
- R1, R2, R5, R7, and R8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,
- R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
- X1 and X2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
- the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond. Most preferably, R3 and R4 are hydrogen, and each are involved in hydrogen bonds, and/or the dashed bond is a double bond, such that the chemical backbone of the compound substantially retains a substantially planar conformation.
Description
- This application is a continuation of U.S. application Ser. No. 10/632,688, filed Aug. 1, 2003, which is a continuation-in-part of U.S. application Ser. No. 09/995,851, filed Nov. 27, 2001, U.S. Pat. No. 6,713,480, which is a continuation of U.S. application Ser. No. 09/440,316, filed Nov. 12, 1999, U.S. Pat. No. 6,358,957, which application claimed priority from U.S. Provisional Application Ser. No. 60/108,211, PHENYLAHISTIN AS AN ANTI-TUMOR COMPOUND, filed Nov. 12, 1998, by Fukumoto et al., and also claimed priority from U.S. Provisional Application Ser. No. 60/108,736, PHENYLAHISTIN AS AN ANTI-TUMOR COMPOUND, filed Nov. 17, 1998, by Fukumoto et al. Each of the above-mentioned applications is incorporated herein by reference in its entirety.
- This application is also related to U.S. application Ser. No. 10/632,531, entitled DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF, filed Aug. 1, 2003, and which is incorporated hereby by reference in its entirety.
- 1. Field of the Invention
- The present invention relates to the fields of chemistry and medicine. More specifically, the present invention relates to compounds and procedures useful in the treatment of cancer, or in the treatment of fungal infections.
- 2. Description of the Related Art
- It is thought that a single, universal cellular mechanism controls the regulation of the eukaryotic cell cycle process. See, e.g., Hartwell, L. H. et al., Science (1989), 246: 629-34. It is also known that when an abnormality arises in the control mechanism of the cell cycle, cancer or an immune disorder may occur. Accordingly, as is also known, antitumor agents and immune suppressors may be among the substances that regular the cell cycle. Thus, new eukaryotic cell cycle inhibitors are needed as antitumor and immune-enhancing compounds, and should be useful in the treatment of human cancer as chemotherapeutic, anti-tumor agents. See, e.g., Roberge, M. et al., Cancer Res. (1994), 54, 6115-21.
- Recently, it has been reported that tryprostatins A and B (which are diketopiperazines consisting of proline and isoprenylated tryptophan residues), and five other structurally-related diketopiperazines, inhibited cell cycle progression in the M phase, see Cui, C. et al., J. Antibiotics (1996), 49, 527-33; Cui, C. et al. J. Antibiotics (1996), 49, 534-40, and that these compounds also affect the microtubule assembly, see Usui, T. et al. Biochem J. (1998) 333, 543-48; Kondon, M. et al. J. Antibiotics (1998) 51, 801-04. Furthermore, natural and synthetic compounds have been reported to inhibit mitosis, thus inhibit the eukaryotic cell cycle, by binding to the colchicine binding-site (CLC-site) on tubulin, which is a macromolecule that consists of two 50 kDa subunits (α- and β-tubulin) and is the major constituent of microtubules. See, e.g., Iwasaki, S., Med. Res. Rev. (1993) 13, 183-198; Hamel, E. Med. Res. Rev. (1996) 16, 207-31; Weisenberg, R. C. et al., Biochemistry (1969) 7, 4466-79. Microtubules are thought to be involved in several essential cell functions, such as axonal transport, cell motility and determination of cell morphology. Therefore, inhibitors of microtubule function may have broad biological activity, and be applicable to medicinal and agrochemical purposes. It is also possible that colchicine (CLC)-site ligands such as CLC, steganacin, see Kupchan, S. M. et al., J. Am. Chem. Soc. (1973) 95, 1335-36, podophyllotoxin, see Sackett, D. L., Pharmacol. Ther. (1993) 59, 163-228, and combretastatins, see Pettit, G. R. et al., J. Med. Chem. (1995) 38, 166-67, may prove to be valuable as eukaryotic cell cycle inhibitors and, thus, may be useful as chemotherapeutic agents.
- Although diketopiperazine-type metabolites have been isolated from various fungi as mycotoxins, see Horak R. M. et al., J.C.S. Chem. Comm. (1981) 1265-67; Ali M. et al., Toxicology Letters, (1989) 48, 235-41, or as secondary metabolites, see Smedsgaard J. et al., J. Microbiol. Meth. (1996) 25, 5-17, little is known about the specific structure of the diketopiperazine-type metabolites and their antitumor activity, particularly in vivo. Furthermore, even though known antitumor substances isolated from microorganism metabolites (including anthracyclins and mitomycins that exhibit antitumor activity by binding to DNA) have been used as antitumor agents, see Microorganic Pharmaceutical Chemistry, revised 2nd edition, edited by Yoshio Ueno & Satoshi Ohmura, Nankohdo Publishing Co., (1986)), and even though anti-tumor substances having non-DNA binding operating mechanism have been isolated from microorganism metabolites, see Minoru Yoshida, M. Protein Nucleic Acid Enzymes (1993) 38, 1753; and Iwasaki, N., Chemistry and Living Organisms, (1994) 32, No. 3, 153, there is a particular need for new microorganism metabolite-derived compounds having animal cell-specific proliferation-inhibiting activity and high antitumor activity and selectivity. There is therefore a related need for substantially purified, and structurally and biologically characterized fungal diketopiperazine-type metabolites and fungal diketopiperazine-type metabolite-derivatives.
-
-
- wherein:
- R1, R2, R5, R7, and R8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups, and
- R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
- X1 and X2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
- the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
- In a preferred embodiment, the invention comprises, in substantially purified form, the compound herein named alternatively “(−)-phenylahistin,” “(−)-NSCL-96F037,” or “(−)-PLH,” which is a diketopiperazine composed of L-phenylalanine and isoprenylated dehydrohistidine. This compound has the following stereo-specific chemical structure:
- The invention also comprises a method of treating cancer comprising administering an effective tumor-growth-inhibiting amount of the compound, and any pharmaceutically acceptable salt or pro-drug ester of generic structure (I), and preferably, phenylahistin, and more preferably, (−)-phenylahistin, and pharmaceutically acceptable salt and pro-drug esters thereof. In preferred embodiments of the compound, salt, or pro-drug ester of the present invention, R3 and R4 are hydrogen, and each are involved in hydrogen bonds, and/or the dashed bond is a double bond.
- Other embodiments relate to methods of treating and/or preventing at least one fungal infection in a mammal afflicted with at least one fungal infection. The methods can include, for example, administering an antifungally effective amount of a compound sufficient for such treating or preventing. The compound can have, for example, the following structure:
- wherein:
- R1, R2, R5, R7, and R8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,
- R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
- X1 and X2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
- the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
- The fungal infection can be for example, an Aspergillosis infection, a blastomycosis infection, a Candidiasis infection, a Coccidioidomycosis infection, a Cryptococcosis infection, a Histopolasmosis infection, a Paracoccidioidomycosis, a Sporotrichosis and, a Mucormycosis infection, and the like. Preferably, the Aspergillosis infection can be invasive pulmonary aspergillosis. Further, preferably, the Mucormycosis infection can be craniofacial mucormycosis, pulmonary mucormycosis and the like. Also, preferably, the Candidiasis infection can be retrograde candidiasis of the urinary tract, for example.
-
- wherein:
- R1, R2, R5, R7, and R8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,
- R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
- X1 and X2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
- the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
- Preferably, the fungal infection can be an Aspergillosis infection, a blastomycosis infection, a Candidiasis infection, a Coccidioidomycosis infection, a Cryptococcosis infection, a Histopolasmosis infection, a Paracoccidioidomycosis, a Sporotrichosis and, a Mucormycosis infection, and the like. Preferably, the Aspergillosis infection can be invasive pulmonary aspergillosis. Further, preferably, the Mucormycosis infection can be craniofacial mucormycosis, pulmonary mucormycosis and the like. Also, preferably, the Candidiasis infection can be retrograde candidiasis of the urinary tract, for example.
- Embodiments also relate to methods and materials for treating or preventing cancers and infection by a pathogenic fungus in a mammalian subject, particularly a human patient, by administering to the subject a phenylahistin or its analog. The methods can include administering to the subject a composition comprising an effective antitumor or antifungal amount of a phenylahistin or its analog.
- The accompanying drawings, which are incorporated in and form part of the specification, merely illustrate embodiments of the present invention. Together with the remainder of the specification, they are meant to serve to explain preferred modes of making certain compounds of the invention to those of skilled in the art. In the drawings:
-
FIG. 1 illustratesReaction Scheme 1, which shows the preparation of certain reduced derivatives of (−)- and (+)-phenylahistin from the enantiomers of phenylahistin. -
FIG. 2 illustratesReaction Scheme 2, which shows a synthetic method for producing a compound of the invention, PLH-Cl, from H2N-Phe-Gly-OMe. (The asterisk indicates that racemation occurred; (−):(+)=79:21.). -
FIG. 3 illustratesReaction Scheme 3, which shows the preparation of two reduced derivatives of (−)-phenylahistin, compounds identified as (−)-12 and (−)-13, which are respectively, identical tocompounds FIG. 1 . InFIG. 3 , (a) refers to H2/10% Pd—C, MeOH, room temperature, reaction time of 2 hours, and (b) refers to H2/10% Pd—C, MeOH, room temperature, reaction time of 24 hours. -
FIG. 4 illustratesReaction Scheme 4, which shows the preparation of two N-methylated derivatives of (−)-phenylahistin. InFIG. 4 , (a) refers to MeI, NaH, DMF, −30° C., reaction time of 2 hours, (b) refers to MeI, NaH, DMF, room temperature, reaction time of 2 hours; and (c) refers to chiral HPLC separation as described herein. -
FIG. 5 illustratesReaction Scheme 5, which shows the preparation of two derivatives of (−)-phenylahistin, compounds identified as 19 and 20, which is the (−)-enantiomer ofcompound 9 ofFIG. 2 . InFIG. 5 , (a) refers to MeOH at reflux for 14 hours, (b) refers to AcO2, AcONa, 80° C., reaction time of 14 hours, and (c-e) refers to reaction in a mixture ofcompound 18, LDA, HMPA, DMF, at −60° C. for 30 minutes, followed by cooling to room temperature and placing in a solution of Tf2O, pyridine for 10 minutes, followed by overnight reaction in NH4OH at room temperature. -
FIG. 6 depicts the effect of t-butyl-phenylahistin in comparison to colchicine and taxol on HuVEC monolayer permeability to FITC-Dextran. -
FIG. 7 depicts the effects of t-butyl-phenylahistin alone and in combination with CPT-11 on estimated tumor growth in the HT-29 human colon tumor xenograft model. -
FIG. 8 depicts the effects of t-butyl-phenylahistin alone and in combination with CPT-11 on the weight of tumors excised at autopsy in individual mice in the HT-29 Human Colon Tumor Xenograft model. -
FIG. 9 depicts the effects of t-butyl-phenylahistin alone and in combination with Taxotere on the estimated tumor growth based on observations made during the in-life portion of the DU-145 Human Prostate Tumor Xenograft Model. -
FIG. 10 depicts the effects of t-butyl-phenylahistin alone and in combination with Taxotere in MCF-7 Human Breast Tumor Xenograft model. -
FIG. 11 depicts effects of t-butyl-phenylahistin alone and in combination with Paclitaxel in the Murine Melanoma B16 F10 Metastatic Tumor Model. - Numerous references are cited herein. These references are to be considered incorporated by reference into this specification.
- Objects of this invention include (1) providing a class of new compounds, including pharmaceutically acceptable salts of the class of compounds, that exhibit animal cell-specific proliferation inhibiting, tumor-growth inhibiting activity, anti-fungal activity, and/or cell-cycle inhibiting activity, and (2) providing a class of fungi for producing, and (3) providing a method for producing said class of compounds, as well as a class of pharmaceutically acceptable cell cycle inhibitors, antitumor agents, and anti-fungal agents comprising said compounds and/or their derivatives as active ingredients. It is also an object of this invention to provide a method of treating cancer, particularly human cancer, comprising the step of administering an effective tumor-growth inhibiting amount of a member of a class of new anti-tumor compounds. Further, it is an object of this invention to provide a method of treating fungal infections or pathogenic fungus, including those affecting animals and humans, comprising the step of administering an effective tumor-growth inhibiting amount of a member of a class of new anti-tumor compounds. In the preferred embodiment of the present invention, but not necessarily in all embodiments of the present invention, these objectives are simultaneously met.
-
- wherein:
- R1, R2, R5, R7, and R8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups, all having, where applicable, up to 24 carbon atoms,
- R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, all having, where applicable, up to 12 carbon atoms,
- X1 and X2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and the dashed bond represents either a carbon-carbon single bond or a carbon-carbon double bond, of any tertiary conformation, in a particular embodiment of the invention.
- The invention also provides pharmaceutically acceptable salts and pro-drug esters of the compound of Formula (I).
- The term “pro-drug ester,” especially when referring to a pro-drug ester of the compound of Formula (I), refers to a chemical derivative of the compound that is rapidly transformed in vivo to yield the compound, for example, by hydrolysis in blood. The term “pro-drug ester” refers to derivatives of the compound of the present invention formed by the addition of any of several ester-forming groups that are hydrolyzed under physiological conditions. Examples of pro-drug ester groups include pivoyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art, including a (5-R-2-oxo-1,3-dioxolen-4-yl)methyl group. Other examples of pro-drug ester groups can be found in, for example, T. Higuchi and V. Stella, in “Pro-drugs as Novel Delivery Systems”, Vol. 14, A.C.S. Symposium Series, American Chemical Society (1975); and “Bioreversible Carriers in Drug Design: Theory and Application”, edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987) (providing examples of esters useful as prodrugs for compounds containing carboxyl groups).
- The term “pharmaceutically acceptable salt,” especially when referring to a pharmaceutically acceptable salt of the compound of Formula (I), refers to any pharmaceutically acceptable salts of a compound, and preferably refers to an acid addition salt of a compound. Preferred examples of pharmaceutically acceptable salt are the alkali metal salts (sodium or potassium), the alkaline earth metal salts (calcium or magnesium), or ammonium salts derived from ammonia or from pharmaceutically acceptable organic amines, for example C1-C7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine or tris-(hydroxymethyl)-aminomethane. With respect to compounds of the invention that are basic amines, the preferred examples of pharmaceutically acceptable salts are acid addition salts of pharmaceutically acceptable inorganic or organic acids, for example, hydrohalic, sulfuric, phosphoric acid or aliphatic or aromatic carboxylic or sulfonic acid, for example acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, p-toluensulfonic or naphthalenesulfonic acid.
- Preferred pharmaceutical compositions of the present invention include pharmaceutically acceptable salts and pro-drug esters of the compound of Formula (I). Accordingly, if the manufacture of pharmaceutical formulations involves intimate mixing of the pharmaceutical excipients and the active ingredient in its salt form, then it is preferred to use pharmaceutical excipients which are non-basic, that is, either acidic or neutral excipients.
- In preferred embodiments of the compounds of the present invention, a relatively rigid, planar pseudo three-ring structure is formed. To stable such a relatively rigid, planar pseudo three-ring structure, R3 and R4 are hydrogen, each involved in hydrogen bonds. Furthermore, such a relatively rigid, planar pseudo three-ring structure is stabilized wherein the dashed bond is a double bond.
- The term “halogen atom” means any one of the radio-stable atoms of
column 17 of the Periodic Table of the Elements, i.e., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred. - The term “alkyl” means any unbranched or branched, substituted or unsubstituted, saturated hydrocarbon, with C1-C6 unbranched, saturated, unsubstituted hydrocarbons, being preferred, with methyl, ethyl, iosbutyl, and tert-butyl being most preferred. Among the substituted, saturated hydrocarbons, C1-C6 mono- and di- and per-halogen substituted saturated hydrocarbons and amino-substituted hydrocarbons are preferred, with perfluromethyl, perchloromethyl, perfluoro-tert-butyl, and perchloro-tert-butyl being the most preferred. The term “cycloalkyl” refers to any non-aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring.
- The term “alkenyl” means any unbranched or branched, substituted or unsubstituted, unsaturated hydrocarbon including polyunsaturated hydrocarbons, with C1-C6 unbranched, mono-unsaturated and di-unsaturated, unsubstituted hydrocarbons being preferred, and mono-unsaturated, di-halogen substituted hydrocarbons being most preferred. In the R1 and R8 positions, of the compound of structure (I) a z-isoprenyl moiety is particularly preferred. The term “cycloalkenyl” refers to any non-aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring.
- The terms “aryl,” “substituted aryl,” “heteroaryl,” and “substituted heteraryl” refer to aromatic hydrocarbon rings, preferably having five, six, or seven atoms, and most preferably having six atoms comprising the ring. “Heteroaryl” and “substituted heteroaryl,” refer to aromatic hydrocarbon rings in which at least one heteroatom, e.g., oxygen, sulfur, or nitrogen atom, is in the ring along with at least one carbon atom.
- The term “alkoxy” refers to any unbranched, or branched, substituted or unsubstituted, saturated or unsaturated ether, with C1-C6 unbranched, saturated, unsubstituted ethers being preferred, with dimethyl, diethyl, methyl-isobutyl, and methyl-tert-butyl ethers being most preferred. The term “cycloalkoxy” refers to any non-aromatic hydrocarbon ring, preferably having five to twelve atoms comprising the ring.
- The terms “purified,” “substantially purified,” and “isolated” as used herein refer to the compound of the invention being free of other, dissimilar compounds with which the compound of the invention is normally associated in its natural state, so that the compound of the invention comprises at least 0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75% of the mass, by weight, of a given sample. In one preferred embodiment, these terms refer to the compound of the invention comprising at least 95% of the mass, by weight, of a given sample.
- The terms “anti-tumor” and “tumor-growth-inhibiting,” when modifying the term “compound,” and the terms “inhibiting” and “reducing”, when modifying the terms “compound” and/or the term “tumor,” mean that the presence of the subject compound is correlated with at least the slowing of the rate of growth of the tumor. More preferably, the terms “anti-tumor,” “tumor-growth-inhibiting,” “inhibiting,” and “reducing” refer to a correlation between the presence of the subject compound and at least the temporary cessation of tumor growth. The terms “anti-tumor,” “tumor-growth-inhibiting,” “inhibiting,” and “reducing” also refer to, particularly in the most preferred embodiment of the invention, a correlation between the presence of the subject compound and at least the temporary reduction in the mass of the tumor.
- The invention also provides fungi of the genus Aspergillus that are capable of producing the anti-tumor compound of the invention, and specifically, fungi that are capable of producing the anti-tumor compound of the invention wherein R1, R2, R3, R4, R5, R6, R7, and R8 are each a hydrogen atom, and X1 and X2 are each separately an oxygen atom. Preferably, the fungi is an Aspergillus ustus capable of producing the antitumor compound of the invention in an amount of not less than 2 mg, preferably not less than 8 mg, per liter of the production medium as measured, by high performance liquid chromatography using the compound represented by Formula (I) as a standard with respect to what is obtained by placing, in 18 mm-diameter, 180 mm-length test tubes, 5 ml of production medium (production medium: glucose 5 g/l, glycerin 20 ml/l, cotton seed lees 20 g/l, yeast extract 2 g/l, sodium chloride 2.5 g/l, calcium carbonate 4 g/l (pH6.5)), and then inoculating each test tube with 50 μl of a fungus suspension prepared by suspending conidia of the fungal strain in sterilized water, incubating the culture broth for 5 days at 27° C. under reciprocal shaking (260 rpm), adding 10 ml of acetone to the culture broth in each test tube, effecting extraction for 1 day at room temperature, removing impurities by filtration, vacuum-concentrating the filtrate to distill off the acetone, making three additions of 5 ml of ethyl acetate to the remaining water layer to effect extraction, effecting vacuum-concentration and drying to obtain a solid, and dissolving the solid in methanol. The invention also provides a method of producing the anti-tumor compound of Formula (I) comprising the steps of incubating in a culture medium a microorganism belonging to the genus Aspergillus that is capable of producing the antitumor compound represented of Formula (I) and collecting the compound from the culture. The invention further provides a cell cycle inhibitor and an antitumor agent containing the antitumor substance of Formula (I) as an active ingredient, in combination with a pharmaceutically acceptable carrier or excipient.
- Most specifically, a preferred embodiment of the invention provides, phenylahistin, which exhibits the following physical and chemical characteristics:
- (i) molecular weight: 350 (FABMS M/Z 351 (M+H)),
- (ii) molecular formula: C20H22N4O2,
- (iii) infrared absorption spectrum (IR Vmax (KBr)(cm−1)): 3440, 3240, 1670, 1640, 1140;
- (iv) 1H-nuclear magnetic resonance spectrum (500 MHz, measured in CDCl3, chemical shift value of CHCl3 set to 7.24 ppm as internal standard) having intensities at (δ (ppm)): 1.47(6H, s), 2.94 (1H, dd, J=14, 10 Hz), 3.45(1H, dd, J=14, 4 Hz), 4.33(1H, brd, J=10 Hz), 5.10(1H, d, J=17 Hz), 5.14(1H, d, J-11 Hz), 5.88(1H, br), 6.00(1H, dd, J=17, 11 Hz), 6.86(1H, s), 7.21-7.26(3H, m), 7.31(2H, t, J=8 Hz), 7.53(1H,s), 9.61(1H, br), 12.08(1H,br);
- (v) 13C-nuclear magnetic resonance spectrum (400 MHz, measured in CDCl3, chemical shift value of CDCl3 set to 77.10 ppm as internal standard) having intensities at (δ (ppm)): 28.07(CH3), 28.07(CH3), 37.69(C), 41.33(CH2), 57.24(CH), 105.67(CH), 113.46(CH2), 123.77(CH), 127.56(CH), 129.18(CH), 129.18(CH), 129.62(CH), 129.62(CH), 132.29(C), 132.64(C), 135.55(C), 136.88(C), 144.75(CH), 160.04(C), 164.85(C);
- (vi) 15N-nuclear magnetic resonance spectrum (600 MHz, measured in CDCl3, chemical shift value of ammonia set to 0 ppm as internal standard) having intensities at (δ (ppm)): 112, 134, 161, 253;
- (vii) maximum absorption value of ultraviolet spectrum in methanol at 230 nm, and under neutral condition at 323 nm;
- (viii) excited under a neutral condition in methanol by 320-340 nm ultraviolet light, having a maximum value at 395-400 nm and emitting fluorescence having 350-550 nm wavelength width;
- (ix) soluble in ethyl acetate, chloroform, methanol, and pyridine, but only slightly soluble in water, benzene, and toluene;
- (x) negative in ninhydrin reaction, positive in color reaction with nitrous acid (orange); and
- (xi) substance color: white.
- According to the examples provided herein, phenylahistin has been isolated from Aspergillus ustus NSC-F038 and NSC-F037, two new strains of fungus; this phenylahistin exhibits cytotoxic and cell cycle inhibitory activities. Both of these strains of fungi have been deposited with the National Institute of Bioscience and Human-Technology, Japan, Agency of Industrial Science and Technology, Ministry of International Trade and Industry. These strains exhibit the following mycological characteristics:
- (1) Growth morphology in various culture media: Growth on Czapek's yeast extract agar medium (25° C.) is rapid, reaching 45-46 mm in 7 days. Growth on Czapek's yeast extract agar medium (37° C.) is somewhat slower, reaching 39-41 mm in 7 days. On malt extract agar medium, colony surface is gray and colony rear surface grayish green.
- (2) Morphological properties.
- Morphological properties on Czapek's agar medium are indicated.
- Condial heads: Radiate
- Conidiophore: Smooth surface, brown with length of 100-350 μm, 4-7 μm diameter
- Vesicles: Spherical-flask-shaped, 11-15 μm diameter, upper ⅔-½ forms metulae
- Metulae: covering upper half to two-thirds of the vesicles, 5-7×4-7 μm
- Phialides: amplliform, 5-8×3-4 μm
- Conidium: Brown, sperical, rough wall, 3×5 μm
- From these mycological properties, Aspergillus ustus NSC-F037 and Aspergullus ustus NSC-F038 were found, in accordance with the text Aspergillus, K. B. Raper and D. I. Fennel, Williams and Wilkins (1965), to belong to subphylum Fungi Imperfecti, order monilliales, genus Aspergillus, species ustus. The strains were therefore termed Aspergullus ustus NSC-F037 and Aspergillus ustus NSC-F038. It was concluded that Aspergullus ustus NSC-037 and Aspergillus ustus NSC-038 were both novel fungal strains, and they were respectively assigned the acquisition numbers FERM P-15829 and FERM P-15930.
- The compound of Formula (I), the compound of the invention, can be produced by ordinary methods, from a culture medium and via extracting the compound from a culture of either Aspergillus ustus NSC-037 or Aspergillus ustus NSC-038 in the following manner. Although the culture can be either liquid or solid, industrially advantageous culture can be achieved by inoculating a liquid medium with a fungus suspension of the microorganism and incubating the medium under aeration-mixing. Although the culture medium nutrients are not particularly limited, carbon sources, nitrogen sources and other culture medium ingredients ordinarily used to culture microorganisms may be included and are preferred. Usable carbon sources include starch, glycerin, glucose, sucrose, galactose, and the like. Usable nitrogen sources included peptone, soy bean powder, meat extract, corn-steeped liquor, cotton seed lees, ammonium salt, nitrates, and other organic and inorganic nitrogen compounds. In addition, inorganic salts and trace nutrients may be added as will be deemed appropriate by those of skill in the art. The culture temperature, culture time period, and other culture conditions are preferably chosen as conditions that are appropriate for growth of the selected fungus, and also to maximize production of the compound represented by Formula (1). For instance, the pH of the culture medium is preferably between approximately 4 and approximately 9, and more preferably between 5 and 8, and the culture temperature is preferably between 15 and 35° C., and more preferably between 23 and 28° C. The culture period is preferably between 48 and 192 hours, and more preferably between 72 and 192 hours. However, the culture medium composition, culture medium pH, culture medium temperature, culture period and other culture conditions should naturally be appropriately adjusted according to the type of fungus used, the external conditions, and the like so as to obtain the desired results of producing the compound of the present invention.
- The compound represented by Formula (1) can be collected from such a culture by appropriate use of means ordinarily used for collecting metabolites. For example, any means utilizing the difference in affinity for and organic solvent between the compound represented by Formula (1) and other substances contained in the culture, means utilizing difference in solubility and means utilizing difference in adsorptive affinity for various resins can be used independently, in appropriate combination, or repeatedly. Specifically, ion-exchange chromatography, chromatography using a nonionic adsorptive resin, gel-filter chromatography, chromatography using an adsorbent such as activated carbon, alumina or silica gel, high-speed liquid chromatography, various other types of liquid chromatography, crystallization, vacuum concentration, freeze-drying and other such means can be used independently, in appropriate combination, or repeatedly.
- When used as a cell cycle inhibitor, anti-fungal, or tumor-growth-inhibiting compound, the compound of Formula (I) can be administered by either oral or a non-oral pathways. When administered orally, it can be administered in capsule, tablet, granule, spray, syrup, or other such form. When administered non-orally, it can be administered as an aqueous suspension, an oily preparation or the like or as a drip, suppository, salve, ointment or the like, when administered via injection, subcutaneously, intreperitoneally, intravenously, intramuscularly, or the like. Similarly, it may be administered topically, rectally, or vaginally, as deemed appropriate by those of skill in the art for bringing the compound of the invention into optimal contact with a tumor, thus inhibiting the growth of the tumor. Local administration at the site of the tumor is also contemplated, either before or after tumor resection, as are controlled release formulations, depot formulations, and infusion pump delivery.
- To formulate the compound of Formula (I) as a cell cycle inhibitor or tumor-growth-inhibiting compound, known surface active agents, excipients, smoothing agents, suspension agents and pharmaceutically acceptable film-forming substances and coating assistants, and the like may be used. Preferably alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surface active agents; sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium methasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium acid carbonate, calcium hydrogen phosphate, calcium carboxymethyl cellulose, and the like may be used as excipients; magnesium stearate, talc, hardened oil and the like may be used as smoothing agents; coconut oil, olive oil, sesame oil, peanut oil, soya may be used as suspension agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methylacetate-methacrylate copolymer as a derivative of polyvinyl may be used as suspension agents; and plasticizers such as ester phthalates and the like may be used as suspension agents. In addition to the foregoing preferred ingredients, sweeteners, fragrances, colorants, preservatives and the like may be added to the administered formulation of the compound of the invention, particularly when the compound is to be administered orally.
- The cell cycle inhibitor and antitumor agent of the invention may be orally or non-orally administered to a human patient in the amount of about 0.001 mg/kg/day to about 10,000 mg/kg/day of the active ingredient, and more preferably about 0.1 mg/kg/day to about 100 mg/kg/day of the active ingredient at, preferably, one time per day or, less preferably, over two to about ten times per day. Alternatively and also preferably, the compound of the invention may preferably be administered in the stated amounts continuously by, for example, an intravenous drip. Thus, for the example of a patient weighing 70 kilograms, the preferred daily dose of the active anti-tumor ingredient would be about 0.07 mg/day to about 700 grams/day, and more preferable, 7 mg/day to about 7 grams/day. Nonetheless, as will be understood by those of skill in the art, in certain situations it may be necessary to administer the anti-tumor compound of the invention in amounts that excess, or even far exceed, the above-stated, preferred dosage range to effectively and aggressively treat particularly advanced or lethal tumors.
- In the case of using the cell cycle inhibitor of the invention as a biochemical test reagent, the compound of the invention inhibits the progression of the cell cycle when it is dissolved in an organic solvent or hydrous organic solvent and it is directly applied to any of various cultured cell systems. Usable organic solvents include, for example, methanol, methylsulfoxide, and the like. The formulation can, for example, be a powder, granular or other solid inhibitor, or a liquid inhibitor prepared using an organic solvent or a hydrous organic solvent. While a preferred concentration of the compound of the invention for use as a cell cycle inhibitor is generally in the range of about 1 to about 100 μg/ml, the most appropriate use amount varies depending on the type of cultured cell system and the purpose of use, as will be appreciated by persons of ordinary skill in the art. Also, in certain applications it may be necessary or preferred to persons of ordinary skill in the art to use an amount outside the foregoing range.
- From a pharmaceutical perspective, certain embodiments provide methods for preventing or treating fungal infections and/or a pathogenic fungus in a subject, involve administering to the subject a composition including a phenylahistin or its analog, for example, administering the phenylahistin or its analog in an amount and manner which provides the intended antifungal effect.
- Other embodiments include the treatment or prevention of infection in a patient by a pathogenic fungus such as those listed above or referred to below.
- Another embodiment relates to the treatment or prevention of infection in a patient by a pathogenic fungus which is resistant to one or more other antifungal agents, especially an agent other than phenylahistin or its analog, including e.g. amphotericin B or analogs or derivatives thereof (including 14(s)-hydroxyamphotericin B methyl ester, the hydrazide of amphotericin B with 1-amino-4-methylpiperazine, and other derivatives) or other polyene macrolide antibiotics, including, e.g., nystatin, candicidin, pimaricin and natamycin; flucytosine; griseofulvin; echinocandins or aureobasidins, including naturally occurring and semi-synthetic analogs; dihydrobenzo[a]napthacenequinones; nucleoside peptide antifungals including the polyoxins and nikkomycins; allylamines such as naftifine and other squalene epoxidease inhibitors; and azoles, imidazoles and triazoles such as, e.g., clotrimazole, miconazole, ketoconazole, econazole, butoconazole, oxiconazole, terconazole, itraconazole or fluconazole and the like. For additional conventional antifungal agents and new agents under deveopment, see e.g. Turner and Rodriguez, 1996 Current Pharmaceutical Design, 2:209-224. Another embodiment involves the treatment or prevention of infection in a patient by a pathogenic fungus in cases in which the patient is allergic to, otherwise intolerant of, or nonresponsive to one or more other antifungal agents or in whom the use of other antifungal agents is otherwise contra-indicated. Those other antifungal agents include, among others, those antifungal agents disclosed above and elsewhere herein.
- In the foregoing methods for treatment or prevention, a phenylahistin or its analog, is administered to the subject in an effective antifungal amount.
- Other embodiments relate to the treatment or prevention of infection by a pathogenic fungus in a patient by administration of a phenylahistin or its analog, in conjunction with the administration of one or more other antifungal agents, including for example, any of the previously mentioned agents or types of agents (e.g. in combination with treatment with amphotericin B, preferably in a lipid or liposome formulation; an azole or triazole such as fluconazole, for example; an aureobasidin; dihydrobenzo[a]napthacenequinone; or an echinocardin) as well as with a different phenylahistin or its analog.
- The phenylahistin or its analog may be administered before, after or at the same time the other antifungal agent is administered. In certain embodiments, the combination therapy will permit the use of reduced amounts of one or both antifungal components, relative to the amount used if used alone.
- Still other embodiments relate to administration of a phenylahistin or its analog to a subject for the treatment or prevention of infection by a pathogenic fungus, where the subject is immunosuppressed or immunocompromised, e.g. as the result of genetic disorder, disease such as diabetes or HIV or other infection, chemotherapy or radiation treatment for cancer or other disease, or drug- or otherwise induced immunosuppression in connection with tissue or organ transplantation or the treatment of an autoimmune disorder. Where the patient is being or will be treated with an immunosuppressive agent, e.g., in connection with a tissue or organ transplantation, a phenylahistin or its analog may be co-administered with the immunosuppressive agent(s) to treat or prevent a pathogenic fungal infection.
- Another aspect of this invention is the treatment or prevention of infection by a pathogenic fungus in a patient infected, or suspected of being infected, with HIV, by administration of an antifungal phenylahistin or its analog, in conjunction with the administration of one or more anti-HIV therapeutics (including e.g. HIV protease inhibitors, reverse transcriptase inhibitors or anti-viral agents). The phenylahistin or its analog may be administered before, after or at the same time as administration of the anti-HIV agent(s).
- Another aspect of this invention is the treatment or prevention of infection by a pathogenic fungus in a patient by administration of an antifungal phenylahistin or its analog, in conjunction with the administration of one or more other antibiotic compounds, especially one or more antibacterial agents, preferably in an effective amount and regiment to treat or prevent bacterial infection. Again, the phenylahistin or its analog may be administered before, after or at the same time as administration of the other agent(s).
- Pathogenic fungal infections which may be treated or prevented by the disclosed methods include, among others, Aspergillosis, including invasive pulmonary aspergillosis; Blastomycosis, including profound or rapidly progressive infections and blastomycosis in the central nervous system; Candidiasis, including retrograde candidiasis of the urinary tract, e.g. in patients with kidney stones, urinary tract obstruction, renal transplantation or poorly controlled diabetes mellitus; Coccidioidomycosis, including chronic disease which does not respond well to other chemotherapy; Cryptococcosis; Histopolasmosis; Mucormycosis, including e.g. craniofacial mucormycosis and pulmonary mucormycosis; Paracoccidioidomycosis; and Sporotrichosis. It should be noted that administration of a composition comprising an antifungal amount of one or more phenylahistin or its analogs may be particularly useful for treating or preventing a pathogenic fungal infection in a mammalian subject where the fungus is resistant to one or more other antifungal therapies, or where the use of one or more other antifungal therapies is contraindicated, e.g., as mentioned above.
- Antifungal pharmaceutical compositions containing at least one antifungal phenylahistin or its analog, are also provided for use in practicing the disclosed methods. Those pharmaceutical compositions may be packaged together with an appropriate package insert containing, inter alia, directions and information relating to their antifungal use. Pharmaceutical compositions are also provided which contain one or more phenylahistin or its analog together with a second antifungal agent.
- Certain embodiments disclosed herein relate to methods for treating or preventing a pathogenic fungal infection, including for example Aspergillosis, including invasive pulmonary aspergillosis; Blastomycosis, including profound or rapidly progressive infections and blastomycosis in the central nervous system; Candidiasis, including retrograde candidiasis of the urinary tract, e.g. in patients with kidney stones, urinary tract obstruction, renal transplantaion or poorly controlled diabetes mellitus; Coccidioidomycosis, including chronic disease which does not respond well to other chemotherapy; Cryptococcosis; Histopolasmosis; Mucormycosis, including e.g. craniofacial mucormycosis and pulmonary mucormycosis; Paracoccidioidomycosis; and Sporotrichosis. The methods may involve administering at least one antifungal phenylahistin or its analog, as described above, to a human subject such that the fungal infection is treated or prevented. In certain embodiments the phenylahistin or its analog may be administered in conjunction with administration of one or more non-phenylahistin or its analog antifungal agents such as amphotericin B, or an imidazole or triazole agent such as those mentioned previously.
- The pathogenic fungal infection may be topical, e.g., caused by, among other organisms, species of Candida, Trichophyton, Microsporum or Epiderinophyton or micosal, e.g., caused by Candida albicans (e.g. thrush and vaginal candidiasis). The infection may be systemic, e.g., caused by Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Coccidiodes, Paracocciciodes, Histoplasma or Blastomyces spp. The infection may be also involve eumycotic mycetoma, chromoblastomycosis, cryptococcal meningitis or phycomycosis.
- Further embodiments relate to methods for treating or preventing a pathogenic fungal infection selected from the group consisting of Candida spp. including C. albicans, C. tropicalis, C. kefyr, C. krusei and C. galbrata; Aspergillus spp. including A. fumigatus and A. flavus; Cryptococcus neoibrmans; Blastomyces spp. including Blastomyces dermatilidis; Pneumocvstis carinii; Coccidioides immitis; Basidiobolus ranarum; Conidiobolus spp.; Histoplasma capsulatum; Rhizopus spp. including R. oryzae and R. microsporus; Cunninghamella spp.; Rhizoniucor spp.; Paracoccidioides brasiliensis; Pseudallescheria boydii; Rhinosporidium seeberi; and Sporothrix schenckii. Again, the method may involve administering a non-immunosuppressive antifungal phenylahistin or its analog to a patient in need thereof such that the fungal infection is treated or prevented without inducing an untoward immunosuppressive effect.
- Further embodiments relate to methods for treating or preventing a pathogenic fungal infection which is resistant to other antifungal therapy, including pathogenic fungal infections which are resistant to one or more antifungal agents mentioned elsewhere herein such as amphotericin B, flucytosine, one of the imidazoles or triazoles (including e.g. fluconazole, ketoconazole, itraconazole and the other previously mentioned examples). The methods may involve administering to the patient one or more antifungal phenylahistin or its analog, in an amount and dosing regimen such that a fungal infection resistant to another antifungal therapy in the subject is treated or prevented.
- Further embodiments relate to methods for treating or preventing a pathogenic fungal infection in a patient who is allergic to, intollerant of or not responsive to another antifungal therapy or in whom the use of other antifungal agents is otherwise contra-indicated, including one or more other antifungal agents mentioned elsewhere herein such as amphotericin B, flucytosine, one of the imidazoles or triazoles (including e.g. fluconazole, ketoconazole, itraconazole and the other previously mentioned examples). The methods may involve administering to such patient one or more antifungal phenylahistin or its analog, in an amount such that a fungal infection is treated or prevented.
- Certain embodiments relate to packaged phenylahistin or its analogs, preferably packaged nonimmunosuppressive antifungal phenylahistin or its analogs, which term is intended to include at least one phenylahistin or its analog, as described above, packaged with instructions for administering the phenylahistin or its analog(s) as an antifungal agent without causing a untoward immunosuppressive effects within a human subject. In some embodiments, the non-immunosuppressive antifungal phenylahistin or its analog is a member of one of the preferred subsets of compounds described above. The phenylahistin or its analog can be packaged alone with the instructions or can be packaged with another phenylahistin or its analog, raparnycin or another ingredient or additive, e.g., one or more of the ingredients of the pharmaceutical compositions. The package can contain one or more containers filled with one or more of the ingredients of the phan-naceutical compositions. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- The following examples are meant to describe the preferred modes of making and using the invention, i.e., of isolating, preparing, characterizing, and using certain preferred embodiments of the invention. Variations in the details of the particular methods employed and in the precise chemical compositions obtained will undoubtedly be appreciated by those of skill in the art.
- During the course of screening for new cell cycle inhibitors, see Roberge, M.; Tudan, C; Hung, S. M. F.; Harder, K. W.; Jirik, F. R.; Anderson, H. Cancer Res. 1994, 54, 6115, a novel compound NSCL-96F037 was found in the culture broth of Aspergillus ustus NSC-F038. see Fukumoto; K.; Asari, T.; Harada, T. Japanese Patent P409188749, Sep. 4, 1996 (Japanese). A. ustus NSC-F038 and NSC-F037 fungal strains were deposited with the National Institute of Bioscience and Human-Technology, Japan, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, A. ustus NSC-F037 was designated FERM P-15829 and A. ustus NSC-F038 was designated FERM P-15830. The structure and biological activity of the compound initially designated NSCL-96F037 and of several of its derivatives were determined and are herein described. The compound initially designated NSCL-96F037 is herein also termed “phenylahistin” (PLH), and has the following structure:
A. Production, Isolation and Purification of PLH from Aspergillus ustus NSC-F037 - In each of 18 mm-diameter, 180 mm-length test tubes, 5 ml of sterilized production medium (production medium: glucose 5 g/l,
glycerin 20 ml/l, cotton seed lees 20 g/l, yeast extract 2 g/l, sodium chloride 2.5 g/l, calcium carbonate 4 g/l (pH6.5)) was placed. The number of so-prepared test tubes was 1,700 (total culture medium: 8.5 liter). Each test tube was inoculated with 50 μl of Aspergillus ustus NSC-F037 fungus suspension prepared by suspending conidia of the strain in sterilized water and the culture broth was incubated for 5 days at 27° C. under reciprocal shaking (260 rpm). The culture broth in each test tube was added with 10 ml. of acetone and was extracted for one (1) day at room temperature. Impurities were then removed by filtration and the filtrate (approximately 20 liters) was vacuum-concentrated to distill off the acetate. Nine liters of ethyl acetate was added to the remaining water layer to effect extraction. The ethyl acetate layer was de-watered with sodium sulfate. Vacuum concentration and drying were conducted to obtain a solid which was subjected to silica gel open column chromatography (chloroform-methanol system) to isolate the antitumor activity fraction. This fraction was vacuumed-concentrated and dried to a solid, dissolved in a small amount of 70% methanol, subjected to high performance liquid chromatography using a Senshu Pack ODS-5251-SS 20 mm-diameter×250 mm (Senshu Science Kabushiki Kaisha) to conduct purification with a mobile phase: methanol/water 7/3 condition and to isolate a fraction exhibiting antitumor activity. This fraction was vacuum-concentrated and dried to a solid, subject to high performance liquid chromatography using a Senshu Pack Aquaseal SS5251(60) 20 mm-diameter×250 mm (Senshu Science Kabushiki Kaisha) to conduct purification with a mobile phase: chloroform/methanol 95/5 and to isolate the antitumor activity fraction. This fraction was vacuum-concentrated to obtain a transparent oily substance. This was suspended in a small amount of benzene and the result was vacuum concentrated and dried to a solid, thereby yielding 25 mg of NSCL-96F037, also herein termed phenylahistin (PLH). - B. Production, Isolation and Purification of PLH from Aspergillus ustus NSC-F038
- The same steps as above were conducted except Aspergillus ustus NSC-F038 was used instead of Aspergillus ustus NSC-F037. It was determined that the ability of Aspergillus ustus NSC-F038 to produce the antitumor substance NSCL-95F037 was approximately four times that of NSC-F037. Specifically, from NSC-F037, approximately 2.9 mg phenylahistin was purified per liter of culture medium, while from NSC-F038, approximately 11.8 mg of phenylahistin was purified per liter of culture medium.
- The production of phenylahistin by A. ustus NSC-F038 was also determined to be related to the conidia formation of the fungus. Therefore, the fungus was cultured on an agar medium containing glucose (0.5%), glycerol (2%), yeast extract (0.2%), Pharmamedia (Traders Protein) (2%), NaCl (0.25%) and agar (1.5%), adjusted to pH 6.5 before sterilization. This medium was suitable for the conidia formation at 28° C. for 8 days. The cultured agar media (200 plates; 4 L) were then extracted with ethyl acetate. The extract was initially subject to silica gel column chromatography under an ethyl acetate-acetone stepwise gradient, followed by a second silica gel column and eluted with 2% methanol in chloroform. The fractions that exhibited cell cycle inhibitory activity were collected and evaporated, then dissolved in ethyl acetate and left two days at room temperature. The active substance was precipitated to yield 330 mg of a white amorphous powder with the following physical and spectroscopic characteristics: melting point: 233-236° C.; [α]D 22+123° (c=0.13, MeOH); UV (MeOH) λmax (log ε): 202 (4.38), 233 sh (4.05), 320 (4.43); IR (KBr pellet) νmax: 3440, 3240, 1670, 1640, 1440 cm−1; HR-FAB-MS (m/z) 350.1741 (M+, calcd. for C20H22N4O2: 350.1743).
- The fungus A. ustus NSC-F038 was, alternatively, cultured is 20 ml of a culture medium comprising 0.5% glucose, 2% glycerin, 0.2% yeast extract, 2% cotton seed lees, 0.25% sodium chloride 2.5 g/l and 1.5% agar (pH6.5) to form a planar medium in a 9 cm-diameter Petri dish. The culture medium was inoculated at 5 points with Aspergillus ustus NSC-F038 and incubated in the dark for 7 days at 26° C. to produce spores. The spores were harvested into 5 ml of sterilized
water having Tween 20 added to a concentration of 0.05%, thereby obtaining a spore suspension. Each of 400 Petri dishes containing 20 ml of the same culture medium was inoculated with 0.1 ml of the spore suspension. Incubation was conducted in the dark at 26° C. for 8 days. The cultures were comminuted with a mixer, 8 liters of ethyl acetate were added, and the mixture left standing 2 days before extraction. The recovered ethyl acetate was then vacuum-concentrated to obtain 15 g of a brown syrup. The syrup was dissolved in 20 ml of ethyl acetate, and the solution was subject to a silica gel column (bed volume: 8 cm diameter×20 cm length) chromatography under ethyl acetate and eluted with acetone ethyl acetate (1:5). The eluate was fractionated in 500 ml lots in the order eluted. The active compound was eluted in the fifth to tenth lots. These elutes were then vacuum-concentrated to afford a dark-brown powder in a total amount of approximately 4.65 g. The dark-brown powder was then dissolved in 10 ml of chloroform and the solution was subject to silica gel column (bed volume: 5 cm diameter×30 cm length) chromatography under ethyl acetate and eluted first with 500 ml chloroform and then with methanol in chloroform (1:50). - The active compound was eluted with methanol in chloroform (1:50) to obtain a brown powder in a total amount of approximately 1.05 g. The brown powder was then thoroughly mixed with ethyl acetate and left to stand 2 days to precipitate out approximately 628 mg of a white powder (A) containing the active compound. A portion of the white powder (A) was hydrolyzed. The so-obtained phenylalanine was analyzed by high performance liquid chromatography using a chiral column. The presence of R-configuration and S-configuration phenylalanine was then confirmed in a standard manner, and it was determined that the white powder (A) was a racemic mixture of the enantiomers of phenylahistin.
- Another portion of the white powder (A) was dissolved in ethyl acetate containing a small amount of methanol and left to stand for 7 days. As a result a light yellow crystalline solid 187 mg of a purified specimen of (+)-phenylahistin was obtained. These specimens were used in the following four examples, EXAMPLES 2 through 5, as therein described, to verify the cell-proliferation, antimicrobial, cell-cycle inhibiting effects of the compound of the invention.
- Into each well of a 96-well microtiter plate, 10 μl of A-549 cells derived from human lung cancer prepared to 105 cells/ml in a culture medium obtained by adding 10% bovine fetus serum to EMEM culture medium (Nissui Seiyaku Co., Ltd.) having antitumor effect against A-549 cells derived from human lung cancer was placed. Methanol solution of racemic NSCL-96F037 obtained as in Example 1 was added to the wells of the uppermost row, specimens were diluted by the half-log dilution method and added, and the plate was incubated in a carbon dioxide gas incubator at 37° C. for 48 hours. The result was added in lots of 10 μl with MTT reagent (3-(4,5-dimethyl-2-thiazole)-2,5-diphenyl-2H-tetra bromide)(1 mg/ml·PBS), followed by incubation in a carbon dioxide gas incubator at 37° C. for 6 hours. The culture medium was discarded and the crystal of produced in the cells was dissolved in 100 μl/well of dimethylsulfoxide. Absorption of 595 nm light was then measured with a microplate reader. By comparing the light absorptions of the untreated cells to that of cells treated with a specimen of a known concentration, the specimen concentration that inhibited
cell proliferation 50% (IC50) was calculated, thus obtaining an IC50=0.3 μg/ml. - Using colibacillus strain JM109 as a gram-negative bacterium, Bacillus natto as a gram-negative bacterium and Aspergillus niger IFO6341 as a mold, the following antimicrobial test was conducted by the filter paper agar flat plate method, wherein 100 μg of specimen was placed on 9 mm filter paper, dried in air, and standard agar culture medium was used for bacteria and potato dextrose agar culture medium for mold. No antimicrobial activity was observed. An antimicrobial test was further conducted by the liquid culture medium dilution method using the yeast strain Saccharomyces cerevisise HF7C. Again, no antimicrobial activity was observed, indicating that the racemic NSCL-96F037 (phenylahistin) obtained in EXAMPLE 1 had high animal cell-specific proliferation inhibiting activity.
- Cell strain A431 derived from human lung cancer was used. EMEM culture medium containing 10% bovine fetus serum and 1% MEM nonessential amino acid solution (SIGMA M2025) was used to incubate A431 cells at 37° C. in an incubator saturated with 5% carbon dioxide gas and water vapor. The refined specimen of racemic phenylahistin obtained in EXAMPLE 1 was added to the cells in the log-growth phase and progression of the cell cycle was analyzed by flow cytometer and microscopic observation. The results, shown in Table 1, indicate that this phenylahistin was useful as a cell cycle inhibitor.
TABLE 1 Cell cycle inhibiting activity Concentration (μg/ml) Inhibiting effect 0.5 Absent 1.0 Absent 2.0 Slight 4.0 Slight 8.0 Present 16.0 Present 32.0 Present
Inhibiting effect evaluation criteria were as follows:
Present: The cell cycle stopped at the G2/M phase in not less that 50% of the cells.
Slight: The cell cycle stopped at the G2/M phase in not less than 10% and less than 50% of the cells.
Absent: The cell cycle stopped at the G2/M phase in less than 10% of the cells.
- K-562, human chronic myelogenic leukemia cells were cultured in RPMI164 culture medium (containing 10% bovine fetus serum) and A-431 human pudendal epithelial squamous cancer cells were cultured in DMEM culture medium, containing 10% bovine fetus serum. To these a continuous dilution series of the (+)-phenylahistin obtained in EXAMPLE 1 was added. After 48-hours incubation, a MTT reagent was added to measure growth. The human chronic myelogenic leukemia cells exhibited an IC50 of 13.3 μg/ml, while the human pudendal epithelial squamous cancer cells exhibited an IC50 of 2.9 μg/ml, indicate that (+)-phenylahistin was useful as an antitumor agent.
- A. Racemic Phenylahistin
- Phenylahistin (PLH) had the molecular formula, C20H22N402, which was determined by HR-FAB-MS (mz found: 350.1741 (M+), calcd. for C20H22N4O2: 350.1743). In the IR spectrum, the absorption at 3440 cm−1 corresponds to the N—H group, and strong absorptions at 1670 and 1640 (cm−1 indicated the existence of amide groups. These findings together with the absence of the amide II band near 1550 cm−1 in the spectrum suggested the presence of the diketopiperazine system in phenylahistin, according to the technique described in Steyn, P. S. Tetrahedron 1973, 29, 107, which was also supported by the negative ninhydrin reaction.
- The 13C-NMR spectrum of phenylahistin, with atomic positions as indicated in Structure (IV), summarized in the first column of Table 2, showed 17 resolved peaks with three overlapping carbon signals. The multiplicity of these peaks was determined by analysis of its DEPT spectra. The 1H-NMR spectrum displayed 22 proton signals, listed in the second column of Table 2, including three exchangeable protons. All bond connections between proton and carbon were interpreted by 1H-13C COSY.
TABLE 2 Table13C and 1H NMR Assignment of Phenylahistin in CDCl3 Positions δ C* δ H** 1(NH) — 9.48 (1H, br s) 2 132.56 d 7.55 (1H, s) 4 132.18 s — 5 136.83 s — 6 105.62 d 6.88 (1H, s) 7 123.64 — 8(NH) — 12.08 (1H, br s) 9 164.73 s — 10 57.14 d 4.35 (1H, ddd, J = 10, 4, 3# Hz) 11(NH) — 5.82 (1H, br s) 12 159.94 s — 13 41.23 t 2.95 (1H, dd, J = 14, 10 Hz) 3.49 (1H, dd, J = 14, 4 Hz) 14 135.45 s — 15, 19 129.52 d 7.25 (2H, d, J = 7 Hz) 16, 18 129.07 d 7.33 (2H, t, J = 7 Hz) 17 127.45 d 7.27 (1H, t, J = 7 Hz) 20 37.61 s — 21 144.66 d 6.02 (1H, dd, J = 18, 11 Hz) 22 113.29 t 5.13 (1H, d, J = 18 Hz) 5.17 (1H, d, J = 11 Hz) 23, 24 27.97 q 1.49 (6H, s)
*125 MHz, including multiplicity assignment on the basis of DEPT summary. Chemical shifts in ppm from CDCl3 as an internal standard (77.00 ppm).
**500 MHz, Chemical shifts in ppm from TMS as an internal standard (0.00 ppm).
#Coupling with 11-H was observed by decoupling experiment.
(IV) - The 1H NMR and 1H-1H COSY spectra revealed only the presence of four partial structures: a monosubstituted benzene ring, methylene protons being coupled to a methine proton, which was also coupled to an exchangeable proton, one geminal methyl group and a vinyl group. Since quaternary carbons prevented constructing further partial structures, the PFG-HBMC spectrum were t measured. A partial structure was determined on the basis of the long-range correlations of C-9, C-13, and C-14, which were observed in the spectrum. The carbon chemical shift of C-9 (δ 164.73) indicated that it was a carbonyl carbon. Therefore, that partial structure was determined to be a phenylalanine residue. In the same manner, a second partial structure was determined from the correlations of C-5, C-20, C-21, C-23 and C-24, which showed an isoprenyl group binding to quaternary sp2 carbon (δ 136.83). The diketopiperazine ring was also constructed from the interpretation of correlations between respectively, C-7 and 11-H, C-10 and 8-H, C-12 and 8-H, and C-12 and 10-H in the PFG-HMBC spectrum. The dehydrohistidine moiety was estimated from the remaining three carbons, two nitrogens and three hydrogens, and this structure was supported by correlation signals of C-4, C-s, C-7, and C-12. The correlation signal between C-5 and H-6 indicated that the isoprenyl group was placed in the C-5 of the imidazole ring. This structure was confirmed by analysis of the PFG-15N-HMBC spectrum. The nitrogen residues were assigned as follows: N1 (δ 159); N3 (δ 253); N8 (δ 133); N11 (δ 109) (15N-formamide internal standard at δ 112.4 ppm).
- From these data, the planar structure of phenylahistin was established. The stereochemistry of the C-6-C-7 double bond was suggested to be Z by the low field shift of 8-H(NH: δ 12.08), which was further explained by hydrogen-bonding between the 8-H proton and N-3 of the imidazole ring, as in the case of aurantiamine.
- It was also determined that phenylahistin has a chiral center at the C-10 position. Chiral HPLC analysis of the phenylalanine was conducted according to methods described in Larsen, T. O et al. Phytochemistry (1992) 31, 1613, under the following conditions: HPLC conditions: column; Crownpak CR(+)φ4.0×150 mm (Daicel Chemical Industries, Ltd.), mobile phase; H2O (
pH 2, adjusted with perchloric acid), flow rate; 0.8 ml/min, detector;UV λ 200 nm. Phenylalanine was obtained from the acidic hydrolysate of the amorphous white powder of phenylahistin, see Yamazaki, M. et al., Tetrahedron Lett. (1975) 27. The phenylalanine obtained from the hydrolysate of phenylahistin was identified using an amino acid analyzer and by measurement of EI-MS [(m+H)+:166.2]); chrial HPLC indicated that the phenylahistin was a mixture of enantiomers in the ratio of approximately R:S=3.1. In order to examine the biological activity of each enantiomer, chiral resolution was carried out by chiral HPLC under the following conditions: column; Chiracel OD φ4.6×250 mm (Daicel Chemical Industries, Ltd), mobile phase; n-hexane/ethanol=75/25, flow rate; 1.0 ml/min, temperature; 25° C. Absolute configuration was determined by analysis of phenylalanine obtained from (+)-phenylahistin using chiral HPLC. - B. Single-Crystal X-Ray Diffraction Analysis of Phenylahistin
- A pale yellow crystal having approximately dimension 0.4×0.4×0.8 mm was obtained from the ethyl acetate solution of phenuylahistin. All X-ray measurements were made on a Rigaku AFC7R diffractometer with graphite monochromated CuKa radia and a rotating anode generator. Cell constants and an orientation matrixed for data collection were obtained from a least-squares refinement using the setting angles of 25 carefully centered reflections in the range of 77.59<26<79.03°. These crystal data are summarized in Table 3.
TABLE 3 Crystal data of (−)-phenylahistin Empirical formula C20H22N4O2 Formula weight 350.42 Crystal system tetragonal Lattice parameters: a = 15.3509(7) Å o = 8.309(2) Å V = 1958.0(2) Å3 Z = 4 Space group P42(#77) D calc. 1.189 g/cm3 μ (CuKα) 6.37 cm−1 - Of the 2229 reflections which were collected, 2064 were unique (Rint=0.019). The intensities of the three representative reflections were measured after every 150 reflections. No decay collection was applied. The linear absorption coefficient: μ for CuKα is 6.37 cm−1. Azimuthal scans of several reflections indicated no need for an absorption correction. The data were corrected for Lorentz and polarization effects. A correction for secondary extinction was applied. The structure was solved by direct methods, see SAPA91: Fan Hai-Fu (1991). Structure Analysis Programs with Intelligent Control, Rigaku Corporation, Tokyo, Japan, and expanded using Fourier techniques, see DIRDIF94: Beurskens, P. T. et al. (1994) the DIRDIF94 program system, Technical Report of the Crystallography Laboratory, University of Nijmegen, The Netherlands. Nonhydrogen atoms except for C22 were refined anisotropically, while C22 was refined isotropically. Some hydrogen atoms were refined isotropically, the est included in fixed positions. The final cycle of full-matrix least-squares refinement was based on 1724 observed reflections (I>1.50σ(I)) and 242 variable parameters and converged (largest parameter shift was 0.30 times its esd) with unweighted and weighted factors of: R=0.057, Rw=0.067. The maximum and minimum peaks on the final difference Fourier map corresponded to 0.20 and −0.12 e−/A8, respectively. All calculations were performed using the teXscan crystallographic software package of Molecular Structure Corporation.
- The stereochemistry of C6-C7 double bond was confirmed to be Z, and the hydrogen bonding between 8(N)—H and N-3 was observed as speculated from low field-shift of 8(N)—H (δ12.08 ppm) in NMR study. Since the absolute configuration of C-10 position could not be determined by this X-ray analysis, we analyzed the configuration of phenylalanine which was obtained from acidic hydrolysate of the crystalline sample using chiral HPLC. The phenylalanine obtained from the crystalline sample was identical with the authentic sample of D-(+)-phenylalanine (R-configuration). Therefore, the absolute configuration of this crystalline sample of phenylahistin was established to be R.
- Other derivatives of phenylahistin can be synthesized using the foregoing techniques or others well known organic synthesis techniques.
- A. Synthesis of Various Derivatives of Phenylahistin
- Structural derivatives of phenylahistin were synthesized from the resolved enantiomers according to the following reaction schemes. In
Reaction Scheme 1, shown inFIG. 1 , the enantioners of phenylahistin were resolved, as described in Example 6, and each was subject to palladium-based catalytic reduction conditions for 2 hours, yielding two mono-reduced phenylahistin derivatives herein designatedcompounds compounds - In
Reaction Scheme 2, as shown inFIG. 2 , the synthesis of the phenylahistin derivative designated PLH-Cl, and alternatively designatedcompound 9, is described. This reaction scheme treats H2N-Phe-Gly-OMe, a commercially available dipeptide derivative to yield PLH-Cl, a derivative of PLH in which the isoprenyl moiety is replaced with a methyl group. Since partially racemization was occurred (21%), chiral resolution was carried out to obtain optically pure PLH-Cl. - In
Reaction Scheme 3, as shown inFIG. 3 , the synthesis of (−)-PLH-Cl is described. In the course of synthesizing this compound, another phenylahistin derivative, designated compound 7 is synthesized. - B. Physical Characteristics
- These above-identified compounds were characterized as follows:
-
Compound 3. Colorless solid; mp 224-226° C.; [α]D 25−295° (c=0.15, MeOH), UV (MeOH) nm 322 (ε 23300), 231 (ε 8830), 203 (ε 16800); IR (KBr) cm−1 3310, 3220, 2970, 1440; 1H NMR (270 MHz, CDCl3) δ 12.09 (br s, 1H), 8.98 (br s. 1H), 7.56 (s, 1H), 7.29-7.38 (m, 5H), 6.87 (s, 1H), 5.67 (s, 1H), 4.34 (ddd, J=2, 3, 10 Hz, 1H), 3.51 (dd, J=3, 14 Hz, 1H), 2.29 (dd, J=10, 14 Hz, 1H), 1.74 (q, J=7 Hz, 2H), 1.40 (s, 6H), 0.74 (t, J=7 Hz 3H); 13C NMR (67.5 MHz, CDCl3) δ 164.6, 159.9, 138.1, 135.5, 132.2, 132.1, 129.5 (2C), 129.1 (2C), 127.4, 123.6, 105.4, 57.2, 41.3, 36.2, 35.4, 27.9 (2C), 9.2; High-resolution MS m/z 352.1926 (M+) (Calcd for C20H24N4O2: 352.1899). Anal. calculated for C20H24N4O2: C, 68.16; H, 6.86; N, 15.90. Found: C, 68.34, 6.78, 15.82. - Compound 4: Colorless solid; mp 222-223° C.; [α]D 25+284° (c=0.10, MeOH), UV (MeOH) nm 322 (68 22800), 231 (ε 8720), 203 (ε 16300); IR (KBr) cm−1 3310, 3220, 2970, 1670, 1440; 1H NMR (270 MHz, CDCl3) δ 12.09 (br s, 1H), 8.98 (br s. 1H), 7.56 (s, 1H), 7.29-7.38 (m, 5H), 6.87 (s, 1H), 5.67 (s, 1H), 4.34 (ddd, J=2, 3, 10 Hz, 1H), 3.51 (dd, J=3, 14 Hz, 1H), 2.29 (dd, J=10, 14 Hz, 1H), 1.74 (q, J=7 Hz, 2H), 1.40 (s, 6H), 0.74 (t, J=7 Hz 3H); 13C NMR (67.5 MHz, CDCl3) δ 164.6, 159.9, 138.1, 135.5, 132.2, 132.1, 129.5 (2C), 129.1 (2C), 127.4, 123.6, 105.4, 57.2, 41.3, 36.2, 35.4, 27.9 (2C), 9.2; High-resolution MS m/z 352.1932 (M+) (Calcd for C20H24N4O2: 352.1899). Anal. calculated for C20H24N4O2: C, 68.16; H, 6.86; N, 15.90. Found: C, 68.09, 6.87, 15.84.
- Compound 5: Colorless solid; mp 224-225° C.; [α]D 25−96° (c=0.16, MeOH), UV (MeOH) nm 257 (ε 194), 205 (ε 18100), IR (KBr) cm−1 3380, 3200, 2970, 1670, 1440; 1H NMR (270 MHz, DMSO-d6) δ 11.55 (br s, 1H), 8.25 (br s 1H), 7.86 (br s 1H), 7.41 (s, 1H), 7.29-7.14 (m, 5H), 4.24 (br s, 1H), 3.94 (brd, J=11 Hz, 1H), 3.11 (dd, J=14, 4 Hz, 1H), 2.88 (dd, J=14, 5 Hz, 1H), 2.82 (dd, J=15, 2 Hz, 1H), 1.45 (q, J=7 Hz, 2H), 1.32 (dd, J=15, 11 Hz, 1H), 1.13 (s, 3H), 1.12 (s, 3H), 0.60 (t, J=7 Hz, 3H); 13C NMR (67.5 MHz, DMSO-d6) δ 166.9 165.4, 135.9, 132.5, 131.2, 130.3 (2C), 127.9 (2C), 126.6, 55.7, 54.3, 38.2, 35.0, 34.3, 31.9, 27.6, 27.5, 9.1; High-resolution MS m/z 354.2098 (M+) (Calcd for C20H26N4O2: 354.2055). Anal. calculated for C20H26N4O2:⅓H2O: C, 66.64; H, 7.46; N, 15.54. Found: C, 66.75, 7.41, 15.52.
- Compound 6: Colorless solid; mp 226-227° C.; [α]D 25+99° (c=0.10, MeOH), UV (MeOH) nm 257 (ε 174), 205 (ε 18200), IR (KBr) cm−1 3380, 3200, 2970, 1670, 1440; 1H NMR (270 MHz, DMSO-d6) δ 11.55 (br s, 1H), 8.25 (br s. 1H), 7.86 (br s, 1H), 7.41 (s, 1H), 7.29-7.14 (m, 5H), 4.24 (br s, 1H), 3.94 (br d, J=11 Hz, 1H), 3.11 (dd, J=14, 4 Hz, 1H), 2.88 (dd, J=14, 5 Hz, 1H), 2.82 (dd, J=15, 2 Hz, 1H), 1.45 (q, J=7 Hz, 2H), 1.32 (dd, J=15, 11 Hz, 1H), 1.13 (s, 3H), 1.12 (s, 3H), 0.60 (t, J=7 Hz, 3H); 13C NMR (67.5 MHz, DMSO-d6) δ 166.9, 165.4, 135.9, 132.5, 131.6, 131.2, 130.3 (2C), 127.9 (2C), 126.6, 55.7, 54.3, 38.2, 35.0, 34.3, 31.9, 27.6, 27.5, 9.1; High-resolution MS m/z 354.2110 (M+) (Calcd for C20H26N4O2: 354.2055). Anal. calcd for C20H26N4O2: ½H2O: C, 66.09; H, 7.49; N, 15.41. Found: C, 65.80, 7.50, 15.30.
- Compound 7: Cyclo-Gly-Phe (7). White powder; mp 262-263° C. (decomp.); [α]D 25+60° (c=0.15, DMSO); UV (MeOH) nm 257 (ε 101), 206 (ε 5770) IR (KBr) cm−1 3340, 3200, 3060, 1680, 1470, 1340; 1H NMR (270 MHz, DMSO-d6) δ 8.16 (br s, 1H), 7.90 (br s. 1H), 7.32-7.15 (m, 5H), 4.07 (br dd, J=7, 4 Hz, 1H), 3.35 (dd, J=18, 3 Hz, 1H), 3.10 (dd, J=14, 4 Hz, 1H), 2.88 (dd, J=14, 5 Hz, 1H), 2.75 (d, J=18 Hz, 1H); 13C NMR (DMSO-d6) δ 167.1, 165.7, 136.0, 130.1 (2C), 128.1 (2C), 126.8, 55.5, 43.7, 38.8; Anal. calculated for C11H12N2O2: ⅕H2O: C, 63.57; H, 6.01; N, 13.48. Found: C, 63.85, H, 5.86, N, 13.40.
- Compound 8: Colorless solid; mp 84-85° C.; [α]D 25+7.8° (c=0.52, MeOH); UV (MeOH) nm 209 (ε 20400); IR (KBr) cm−1 1720, 1400, 1380, 1240; 1H NMR (270 MHz, CDCl3) δ 7.33-7.26 (m, 3H), 7.08-7.05 (m, 2H), 5.44 (t, J=5 Hz, 1H), 4.49 (d, J=19 Hz, 1H), 3.35 (dd, J=14, 5 Hz, 1H), 3.20 (dd, J=14, 5 Hz, 1H), 2.58 (s, 3H), 2.55 (s, 3H), 2.48 (d, J=19 Hz, 1H); 13C NMR (67.5 MHz, CDCl3) δ 171.2, 171.0, 167.9, 166.0, 134.3, 129.7 (2C), 129.1 (2C), 128.2, 59.0, 46.0, 38.7, 27.1, 26.8; MS (ESI) m/z 205 (M+H); MS (ESI) m/z 311 (M+Na)+; Anal. calculated for C15H16N2O4: C, 62.49; H, 5.59; N, 9.72. Found: C, 62.50, H, 5.50, N, 9.67.
- Compound 9: Colorless solid; mp 285-286° C. (decompose); [α]D 25−267° (c=0.21 DMSO); UV (MeOH) nrm 319 (ε 22800); IR (KBr) cm−1 3400, 3180, 1680, 1450; 1H NMR (270 MHz, DMSO-d6) δ 11.50 (br s, 1H), 8.35 (br s, 1H), 7.74 (s, 1H), 7.24-7.14 (m, 5H), 6.20 (s, 1H), 4.48 (m, 1H), 3.33 (br s, 1H), 3.20 (dd, J=14, 4 Hz, 1H), 2.93 (dd, J=14, 5 Hz, 1H), 2.19 (s, 1H); 13C NMR (67.5 MHz, DMSO-d6) δ 164.2, 158.7, 135.6, 134.6, 132.3, 130.0 (2C), 128.0 (2C), 127.5, 126.6, 123.4, 101.7, 55.9, 38.7, 8.9; High-resolution MS m/z 296.1261 (M+) (Calcd for C16H16N4O2: 296.1273). Anal. calculated for C16H16N4O2.⅕H2O; C, 64.07; H, 5.51; N, 18.68. Found: C, 64.39, H, 5.65, N, 18.29.
- The cytotoxic effects of the enantiomers of phenylahistin on P388 murine leukemia cells were examined. IC50 values of (−)-phenylahistin (S-configuration) (92.2% e.e.) and (+)-phenylahistin (R-configuration) (97.8% e.e.) were 3.5×10−7 M and 3.8×10−5 M, respectively. Judging from the content of (−)-phenylahistin in (+)-phenylahistin, (+)-phenylahistin was considered to have relatively low cytotoxicity to P388 cells.
- The biological activity of phenylahistin and its derivatives, synthesized as described in EXAMPLE 7 and established according to the methods described in EXAMPLES 5 and 11, are summarized in Table 4.
TABLE 4 Comparative Biological Activity of Phenylahistin and its Derivatives IC50 for P388 Proliferation* IC50 for Microtubule Protein Compound (μM) Polymerization** (μM) 1 0.21 25 2 10 >200 3 0.23 30 4 19 >200 5 >200 >200 6 >200 >200 7 >200 >200 9 7.5 >200 Cyclo-His-Phe*** >200 >200
*IC50 was determined by Alamar Blue ™ assay.
**Microtubule protein was prepared from bovine brain by two cycles of assembly and disassembly method. The concentration of microtubule protein used for the assay was 1.5 mg/ml.
***Obtained from SIGMA (code No. C2615)
- The effect of phenylahistin on the cell cycle progression of P388 cells was also investigated using a flow cytometer, as described in Krishan, A., J. Cell Biol. (1975) 66, 188-193. P388 cells in the log growth phase were seeded into flasks and cultured for 14 hours, and then various concentrations of phenylahistin were added to each flask. After an 8-hour incubation, the cells were harvested and fixed with 50% MeOH at −20° C. overnight. The cells were washed with 30% MeOH and then with 10 mM PBS, and treated with 50 μg/ml propidium iodide at 4° C. for 2 hours. DNA histograms were obtained using a flow cytometer (Cyto ACE-300:JASCO).
- (−)-Phenylahistin exhibited cell cycle inhibitory activity at 1×10−6 M, but (+)-phenylahistin (97.8% e.e.) had no effect at 1×10−5 M. Therefore, the active configuration of phenylahistin was determined to be S, and it was determined that this configuration most effectively inhibited cell cycle progression in the G2/M phase.
- (−)-Phenylahistin ((−)-PLH) was shown to effect microtubule function, specifically via effecting the proliferation, mitosis, and microtubule structure of A549 cells (human lung carcinoma), and via inhibiting the in vitro polymerization of bovine brain microtubule protein and purified tubulin. In addition, competitive binding experiments using colchicine (CLC) and vinblastine (VLB), two typical antimitotic agents that bind to individual binding sites on tubulin, were used to establish the effect of (−)-PLH on the distinct binding sites on tubulin.
- A. Materials. (−)-PLH was isolated from the agar-culture medium of A. ustus NSC-F038 (See, Kanoh, K. et al.: Bioorg. Med. Chem. Lett. (1997), 7, 2847-52, as disclosed in Example 1. CLC was obtained from Sigma (St. Louis, Mo.) and VLB was from Wako Pure Chemicals (Tokyo, Japan). [3H]CLC was purchased from Du Pont/Boston Nuclear (New England, Mass.) and [3H]VLB was from Amersham (Buckinghamshire, UK). A549 cell line (human lung carcinoma) was obtained from American Type Culture Collection (Rockville, Md.). A549 cells were cultured in phenol red free EMEM medium from Nissui Pharmaceuticals (Tokyo, Japan), supplemented with MEM non-essential amino acids (Sigma) and 10% fetal bovine serum from JRH Biosciences, (Lenexa, Kans.).
- B. Alamar Blue™ assay. Exponentially growing A549 cells were seeded into 96-well tissue culture plates (2×103 cells/100 μl/well) and cultured for 16 hours. (−)-PLH or CLC was then added to each well at various concentrations, and the cells were cultured for an additional 48 hours. Live cells were counted using Alamar Blue™ from BioSource International (Camarillo, Calif.) as described in Ahmed, S. A., J. Immunol. Methods, (1994), 170, 211-24.
- C. Mitotic Index. Exponentially growing A549 cells were seeded into 96-well tissue culture plates (2×103 cells/100 μl/well) and cultured for 16 hours. (−)-PLH or CLC was then added to each well at various concentrations, and the plates were incubated for an additional 24 hours. The number of cells in mitosis (round cells) and total cells in eight randomly selected fields were counted under a phase-contrast microscope. In a series of preliminary studies, it was confirmed that the round cells in this condition were cells in mitosis by using flow cytometry and Hoechst 33258 staining. The mitotic index represented the percentage of round cells among the total number of cells in the eight selected fields.
- D. Immunocytochemistry. Immunocytochemical staining was performed using the method described by Yahara, I. et al., Cell (1978) 15, 251-259. A549 cells were cultured on glass coverslips and incubated with the test drug for 6 hours. The cells were then fixed with 3.7% formaldehyde for 30 min, permeabilized with 0.2% Triton X-100 for 5 min, and incubated with a mouse monoclonal antibody against α-tubulin (Calbiochem®, Oncogene Research Products, Cambridge, Mass.), followed by incubation with fluorescein isothiocyanate-conjugated goat anti-mouse IgG from Cosmo Bio Co., (Tokyo, Japan), and the cells were examined under an immunofluorescent microscope.
- E. Microtubule protein and tubulin preparation. Microtubule protein was prepared from bovine brain tissue by two cycles of assembly and disassembly according to the method of Tiwari, S. C. et al. Anal. Biochem, (1993), 215, 96-103. Tubulin was purified from microtubule protein by phosphocellulose chromatography see Algaier, J. et al. Biochim. Biophys. Acta, (1988), 954, 235-43, and tubulin purity was evaluated by polyacrylamide gel electrophoresis, as in Laemmli, U.K., Nature, (1970), 277, 680-85. Essentially, no microtubule-associated proteins were detected in this preparation. Protein concentrations were determined using the Coomassie® Protein Assay Reagent from Pierce (Rockford, Ill.).
- F. Polymerization assay. Polymerization of microtubule protein was monitored by an increase in turbidity at 37° C. in microtubule assembly buffer containing 100 mM MES, 0.5 mM MgCl2, 1 mM EGTA and 1 mM GTP. See Johnson, K. A. et al., J. Mol. Biol., (1977), 117, 1-31. Polymerization of purified tubulin was measured using the same method except the microtubule assembly buffer contained 4 M glycerol. See Lee, J. C. et al., Biochemistry, (1975), 14, 5183-87. Microtubule protein and tubulin polymerization was initiated by a temperature shift from 0° C. to 37° C. and turbidity was measured on a DU-20 thermocontrolled spectrophotometer from Beckman (Fullerton, Calif.) at 360 nm. Drugs were dissolved in dimethyl sulfoxide (DMSO), which was used in all experiments at a final concentration of 2% (v/v).
- G. Electron microscopy. Microtubule protein (1.5 mg/ml) was polymerized at 37° C. for 20 min in the presence of 100 μM (−)-PLH or vehicle (DMSO). A portion of each sample was diluted 5-fold with 1% glutaraldehyde in the microtubule assembly buffer. Samples were then placed on formvar- and carbon-coated grids, stained with 2% uranyl acetate, and examined using a JEOLJEM-1200 EXII electron microscope JEOL (Tokyo, Japan).
- H. Competition assay. [3H]CLC binding to tubulin was evaluated by the ultrafiltration method of Takahashi, M., et al., Biochim. Biophys. Acta, (1987) 926, 215-23, with only slight modifications: bovine brain tubulin (0.2 mg/ml) was incubated in the microtubule assembly buffer with various concentrations of [3H]CLC for 20 min at 37° C.; each sample (200 μl) was applied to the reservoir of a UFC3LTK00 ultrafiltration unit from Nihon Millipore Ltd. (Yonezawa, Japan) and centrifuged at 1,500×g for 4 min at room temperature to obtain approximately 60 μl of filtrate. The concentration of unbound [3H]CLC in the filtrates was determined using a EcoLite™(+) liquid scintillator from ICN Pharmaceuticals Inc. (Costa Mesa, Calif.). Specific bound [3H]CLC concentrations were determined by adding an excess (×100) of unlabeled CLC to the reaction mixture.
- For the competition assay, bovine brain tubulin (0.2 mg/ml) was incubated in the microtubule assembly buffer with 0.5 μM [3H]CLC and various concentrations of competitors for 20 min at 37° C. [3H]CLC binding was measured as described above. DMSO was used as a co-solvent at a concentration that did not affect drug binding to tubulin (final 2% v/v). Measurement of [3H]VLB binding was followed by the DEAE-cellulose filter method of Borisy, G. G., Anal. Biochem. (1972) 373-85, and the competition assay was carried out as described for CLC.
- I. Inhibitory Effects of (−)-PLH on proliferation and mitosis of A549 cells. The effects of (−)-PLH on the proliferation and mitosis of A549 cells was examined. (−)-PLH inhibited the proliferation of A549 cells in a dose-dependent manner with a 50% inhibitory concentration (IC50) value of 0.3 μM, indicating that (−)-PLH was 5-fold less potent than CLC under the assay conditions. However, the mitotic index increased, which correlated with decreased cell proliferation. These results indicated that (−)-PLH arrested the cell cycle during mitosis, which subsequently reduced cell proliferation, similar to the effect observed for other mitotic inhibitors such as CLC and VLB. See Yoshimatsu, K., et al., Cancer Res., (1997), 57, 3208-13. The anti-mitotic effect of (−)-PLH seemed to be reversible, because cells that arrested in M phase by (−)-PLH returned to proliferate again following washing of (−)-PLH and replacement with a fresh medium.
- J. Immunofluorescence staining of microtubules in A549 cells. The effects of (−)-PLH on microtubule structure in A549 cells using an anti α-tubulin antibody and a secondary antibody conjugated with FITC were also investigated. It was determined that (−)-PLH inhibited the microtubule assembly like CLC, but did not hyper-stabilize microtubules in a manner similar to that of paclitaxel (Taxol®).
- In control cells, a network of cytoskeletal microtubules was clearly visible, and mitotic spindles could be observed in mitotic cells. The addition of (−)-PLH resulted in the disappearance of the microtubule network, and the entire mitotic cell was uniformly stained with α-tubulin antibody, whereas mitotic spindles were never seen. Cells incubated with CLC exhibited a staining profile similar to that of (−)-PLH-treated cells. Paclitaxel, a potent microtubule-stabilizer, produced thick microtubule bundles and multiple bright fluorescent aster formation. See Rowinsky, E. K. et al., J. Natl. Cancer Inst. (1990) 82:1247-59. These results suggested that (−)-PLH inhibited microtubule assembly in A549 cells, but did not stabilize microtubules.
- K. (−)-PLH effects microtubule protein polymerization and purified tubulin. The effect of (−)-PLH on the polymerization of microtubule protein obtained from bovine brain were also examined. Accordingly, the time course of the turbidity change in the presence of various concentrations of (−)-PLH and CLC was examined. (−)-PLH inhibited the in vitro polymerization of microtubule protein in a concentration-dependent manner, 80 μM of (−)-PLH completely inhibited the polymerization of microtubule protein, while (+)—PLH did not affect microtubule assembly at concentrations ranging up to a concentration of 200 μM.
- It is reported that VLB, see Luduena, R. F.; J. Biol. Chem. (1984) 259:12890-98, or
dolastin 10, see Li, Y., et al., Chem. Biol. Interact., (1994), 93, 175-83 increases the turbidity in microtubule protein polymerization at concentrations higher than those required for inhibition. However, (−)-PLH did not increase the turbidity at concentrations up to 200 μM. - To determine whether (−)-PLH acts on tubulin directly or on associated proteins, further tests were performed on the assembly using phosphocellulose-purified tubulin, which was free of microtubule associated proteins. Like microtubule protein, (−)-PLH inhibited tubulin polymerization in a concentration-dependent manner. The IC50 value of CLC was 6.6±1.7 μM under the same experimental conditions. These results indicated that (−)-PLH was as effective as CLC in inhibiting tubulin polymerization, and that (−)-PLH acted on tubulin directly rather than on tubulin-associated proteins.
- The effect of (−)-PLH on polymerization of the microtubule protein were also studied by electron microscopy. The control sample contained singular microtubules with a normal cylindrical structure, whereas a sample treated with 100 μM (−)-PLH did not contain such structures. These findings confirmed the turbidity measurements and indicated that (−)-PLH inhibited the polymerization of microtubule protein.
- L. (−)-PLH inhibited CLC binding to tubulin. To investigate the binding site of (−)-PLH on tubulin, competitive binding studies using [3H]CLC and [3H]VLB were conducted. [3H]CLC and [3H]VLB are antimitotic agents that bind to CLC and VLB binding sites, respectively. [3H]CLC binding was measured by the ultrafiltration method as described above. Under the experimental conditions, the Kd value of CLC to tubulin was 5.3×10−7M, which is in good agreement with the previously reported value, see Sherline, P., et al., J. Biol. Chem., (1975), 250, 5481-86. (−)-PLH inhibited CLC binding to tubulin in a dose-dependent manner, with an estimated Ki value for CLC binding of 7.4×10−6M according to a Dixon plot, assuming that (−)-PLH is the competitive inhibitor of CLC binding to tubulin. VLB slightly enhanced CLC binding to tubulin, likely an effect of the stabilization of VLB on the CLC binding activity of tubulin. See Lacey, E. et al., Biochem. Pharmacol. (1987) 36:2133-38. On the other hand, the binding of [3H]VLG was not inhibited by (−)-PLH. CLC enhanced and (−)-PLH slightly enhanced [3H]VLG binding to tubulin. These results suggested that (−)-PLH binds to the CLC binding site (CLC-site) on tubulin or to a site overlapping the CLC-site.
- (−)-PLH dose-dependently increased the mitotic index in parallel with inhibition of proliferation of A549 cells, indicating that it prevents cell proliferation by arresting the cell cycle in M phase. Most antimitotic agents such as CLC and VLB are known to exert anti-microtubule activity, including disruption of the process of mitotic spindle formation, resulting in cell arrest in mitosis. (−)-PLH also exhibited an anti-microtubule activity, as evident by depolymerization of cytoskeletal microtubule in A549 cells treated with (−)-PLH. To investigate the mechanism underlying the anti-microtubule activity of this compound, an in vitro polymerization assay using a microtubule protein and phosphocellulose-purified tubulin from bovine brain was performed. (−)-PLH inhibited polymerization of both microtubule protein and purified tubulin, suggesting that (−)-PLH directly acted on tubulin, rather than interacting with microtubule associated proteins. Although (−)-PLH was as effective as CLC in inhibiting the polymerization of purified tubulin, it was 5-fold less potent than CLC in inhibiting the proliferation of A549 cells. These differences may be due to a low permeability of the cell membrane to (−)-PLH compared to CLC. Alternatively, the difference may be due to intracellular transformation of (−)-PLH to an inactive form. The competitive binding assay using radiolabeled CLC and VLB showed that (−)-PLH inhibited the binding of CLC to tubulin, suggesting that (−)-PLH is a competitive inhibitor of CLC binding to tubulin and its binding site may be similar or very close to that of CLC.
- As noted above, several natural and synthetic antimitotic agents have been reported to inhibit mitosis by binding to the CLC-site on tubulin. See Iwasaki, S., et al., Med. Res. Rev., (1993), 13, 183-98; Hamel, E., Med. Res. Rev., (1996), 16, 207-31. It seems likely that these CLC-site ligands such as CLC, steganacin, see Kupchan, S. M., et al., J. Am. Chem. Soc., (1973), 95, 1335-1336, podophyllotoxin, see Sackett, D. L., Pharmacol. Ther., (1993), 59, 163-228 and combretastatins (Pettit, G. R., et al., J. Med. Chem., (1995), 38, 1666-1672, interact at two hydrophobic sites on tubulin with biaryl groups located at appropriate distances and angles, whereas curacin A, see Verdier-Pinard, P., et al., Mol. Pharmacol., (1998), 53, 62-76, probably interacts in a different manner. In the case of (−)-PLH, the spatial arrangement of two aryl groups, the phenyl group and imidazole moiety, is probably important for binding to tubulin, because the enantiomer (+)-PLH showed little or no effect on mitosis and tubulin polymerization (data not shown).
- Recently, Usui and colleagues, see Usui, T., et al., Biochem, J., (1998), 333, 543-48; Kondoh, M., et al., J. Antibiot, (1998), 51, 801-04, reported that tryprostatin A and its related compounds, which are diketopiperazines consisting of isoprenylated tryptophan and proline, affect the microtubule assembly. They also showed that tryprostatin A inhibited microtubule polymerization by interacting with MAP2/tau-binding site rather than with CLC binding site, at relatively higher concentrations, see Usui, T., et al., Biochem, J., (1998), 333, 543-48; Kondoh, M., et al., J. Antibiot., (1998), 51, 801-04. Although tryprostatin A and (−)-PLH have a similar structural motif, the diketopiperazine ring composed of isoprenylated heterocyclic amino acids, the binding site and effective concentration against microtubule polymerization are different. It is interesting that the two diketopiperazine compounds, which have different constituent amino acids, bind to distinct sites of tubulin molecule and exert a similar biological activity.
- For this and the following three examples, EXAMPLES 13, 14 and 15, phenylahistin was prepared as described above in EXAMPLE 1. Agar-cultured medium of Aspergillus ustus NSC-F038 was extracted with ethyl acetate, and the extract was purified by silica gel column chromatography twice. PLH was then precipitated in ethyl acetate as a white powder which contained (−) and (+)-PLH. Two separate batches of PLH were used, the (−)-PLH contents of which has been analyzed by chiral HPLC. One contained 24.1% (−)-PLH, which was used for evaluating in vitro antitumor activity and antitumor activity against P388 Leukemia in vivo (Examples 12 and 13), and the other contained 41.7% (−)-PLH, which was used for evaluation of in vivo antitumor activity against Lewis Lung Carcinoma and Colon 26 (Examples 14 and 15).
- The antitumor activity of PLH was evaluated by the Human Cancer Cell Line Panel (HCC panel) assay, see Yamori T., Jap. J. Cancer Chemother., (1997), 24, 129-35. This HCC panel consists of 38 tumor cell lines including 7 lung cancer, 6 stomach, 6 colon, 5 ovary, 6 central nerve system, 5 breast, 2 kidney and 1 melanoma cell lines. Each tumor cell was seeded in 96-well tissue culture plates and incubated overnight. Various concentrations (5 doses; final 10−4, 10−5, 10−6, 10−7 and 10−8 M) of PLH were added, and the cells were incubated for 48 hours. The number of living cells was then measured using the sulforhodamine B assay, see Keepers Y. P., et al., Eur. J. Cancer, 27, 897-900 (1991), and the drug concentration that inhibited cell growth by 50% of control cell growth (GI50), the drug concentration that inhibited cell growth by 100% of control cell growth (TGI) and the drug concentration that reduced the number of living cells by 50% of the initial cell number (LC50) then obtained. All mice were obtained from Japan SLC (Shizuoka, Japan), P388 leukemia cells were obtained from Dainippon Pharmaceuticals Inc. (Osaka, Japan), Lewis Lung Carcinoma from Riken Cell Bank (Tsukuba, Japan), and Colon 26 cells from the National Cancer Center, Japan (Tokyo, Japan).
- The results of the HCC panel assay (GI50, TGI, and LC50 for 38 cell lines) are shown in Table 5. PLH [(−)-PLH content: 24.1%] exhibited anti-proliferative activity against 38 cell lines with G150 values ranging from 2.3×10−7M to 4.0×10−5M. The mean graph, see Yamori T., Jap. J. Cancer Chemother. (1997) 24, 129-135, of GI50 was used for analyzing the mode of action of newly found antitumor agents. The GI50 mean graph of PLH revealed that the inhibition profile, showing a relatively wide antitumor spectrum, was similar to that of the vinca alkaloids or paclitaxel, suggesting that the target of the action of PLH may be the microtubule system.
TABLE 5 Cancer Cell Line GL50 (M) TGI (M) LC50 (M) Breast HBC-4 4.6 × 10−7 >1.0 × 10−4 >1.0 × 10−4 BSY-1 2.3 × 10−7 6.7 × 10−7 >1.0 × 10−4 HBC-5 6.0 × 10−7 >1.0 × 10−4 >1.0 × 10−4 MCF-7 4.7 × 10−7 >1.0 × 10−4 >1.0 × 10−4 MDA-MB-231 6.4 × 10−7 6.0 × 10−6 >1.0 × 10−4 CNS U251 4.4 × 10−7 1.0 × 10−5 >1.0 × 10−4 SF-268 4.1 × 10−7 >1.0 × 10−4 >1.0 × 10−4 SF-295 3.2 × 10−7 2.4 × 10−6 >1.0 × 10−4 SF-539 2.3 × 10−7 6.0 × 10−7 1.1 × 10−5 SNB-75 3.7 × 10−7 >1.0 × 10−4 >1.0 × 10−4 SNB-78 1.3 × 10−6 >1.0 × 10−4 >1.0 × 10−4 Colon HCC2998 1.1 × 10−6 5.3 × 10−6 >1.0 × 10−4 KM-12 3.8 × 10−7 >1.0 × 10−4 >1.0 × 10−4 HT-29 4.0 × 10−7 >1.0 × 10−4 >1.0 × 10−4 WiDr 2.7 × 10−7 7.9 × 10−7 >1.0 × 10−4 HCT-15 4.9 × 10−7 >1.0 × 10−4 >1.0 × 10−4 HCT-116 4.8 × 10−7 >1.0 × 10−4 >1.0 × 10−4 Lung NCI-H23 9.1 × 10−7 9.2 × 10−5 >1.0 × 10−4 NCI-H226 4.1 × 10−7 3.1 × 10−5 >1.0 × 10−4 NCI-H522 2.5 × 10−7 8.1 × 10−7 >1.0 × 10−4 NCI-H460 4.1 × 10−7 >1.0 × 10−4 >1.0 × 10−4 A549 9.7 × 10−7 >1.0 × 10−4 >1.0 × 10−4 DMS273 2.9 × 10−7 >1.0 × 10−4 >1.0 × 10−4 DM5114 3.3 × 10−7 2.4 × 10−6 >1.0 × 10−4 Melanoma LOX-IMVI 1.3 × 10−6 >1.0 × 10−4 >1.0 × 10−4 Ovary OVCAR-3 30. × 10−7 >1.0 × 10−4 >1.0 × 10−4 OVCAR-4 4.0 × 10−5 >1.0 × 10−4 >1.0 × 10−4 OVCAR-5 1.2 × 10−6 >1.0 × 10−4 >1.0 × 10−4 OVCAR-8 5.2 × 10−7 5.6 × 10−5 >1.0 × 10−4 SK-OV-3 3.7 × 10−7 >1.0 × 10−4 >1.0 × 10−4 Renal RXF-6311 1.9 × 10−6 >1.0 × 10−4 >1.0 × 10−4 ACHN 2.8 × 10−5 >1.0 × 10−4 >1.0 × 10−4 Stomach St-4 4.0 × 10−5 >1.0 × 10−4 >1.0 × 10−4 MKN1 4.0 × 10−7 2.1 × 10−5 >1.0 × 10−4 MKN7 3.9 × 10−7 >1.0 × 10−4 >1.0 × 10−4 MKN28 4.2 × 10−7 >1.0 × 10−4 >1.0 × 10−4 MKN45 1.5 × 10−6 >1.0 × 10−4 >1.0 × 10−4 MKN74 4.8 × 10−7 >1.0 × 10−4 >1.0 × 10−4 - The TGI values were relatively high, i.e., even at 100 μM PLH, and proliferation of 25 of the 38 cell lines was not completely suppressed. PLH did not exhibit intrinsic cytotoxicity under these experimental conditions, and significant LC50 values were not obtained except for SF-539 cells.
- Male CDF1 mice (4 weeks old) were inoculated intraperitoneally with P388 leukemia cells (1×106 cells/body) on
day 0. PLH [(−)-PLH content; 24%] was suspended in 10% ethanol-saline, and administered daily at a dose of 4.2 mg/kg, 12.5 mg/kg, 42 mg/kg or 125 mg/kg intraperitoneally, as a single injection (0.2 ml/body), fromdays 1 to 12. Each group consisted of six mice. A T/C (%) was calculated according to the following formula:
T/C(%)=[(mean number of survival days of treated group)/(mean number of survival days of control group)]×100 - The antitumor activity of PLH [(−)-PLH content: 24.1%] in mice inoculated intraperitoneally with murine P388 leukemia is shown in Table 6. PLH showed significant antitumor activity with a T/C of 129% and 151% at a daily dosage of 41.5 (the calculated dose of (−)-PLH) and 124 (30) mg/kg respectively, for 12 days. The increases in body weight seen in the control group were also suppressed by daily administrations of PLH 41.5 and 124 mg/kg.
TABLE 6 Antitumor Activity of PLH against P388 Leukemia 4.2 mg/kg 12.5 mg/kg 42 mg/kg 125 mg/kg Control (1 mg/kg)# (3 mg/kg)# (10 mg/kg)# (30 mg/kg)# Mean Body weight 25.2 ± 0.6 25.3 ± 0.4 24.1 ± 0.6 23.0 ± 0.5 22.3 ± 0.3 on day 12 (g) Mean Number of 12.5 ± 0.4 14.6 ± 0.6* 14.6 ± 0.5** 16.1 ± 0.8** 18.9 ± 0.9** Survival days T/C (%) 100 117 117 129 151
#Calculated dose of (−)-PLH.
*p < 0.05,
**p < 0.01, Mann-Whitney U-Test
- Many fungal diketopiperadine metabolites isolated as micotoxins, for example, fumitremorgin B, a diketopiperazine metabolite consisting of proline and isoprenylated tryptophane and identified as cell cycle inhibitors, exert tremorgenic activity when administered to mice. In spite of the structural and biological similarities between PLH and fumitremorgin B, PLH did not induce such side effects, even at the highest dose (124 mg/kg/day). This indicates that the difference of constituents in diketopiperazines may be responsible for the distinct pharmacological effect of PLH. Also, PLH seems not to be long-acting in vivo, as a single administration of PLH (415 mg/kg PLH [(−)-
PLH 100 mg/kg]) was not particularly effective (T/C=115%). - Male BDF1 mice (6 weeks old) were inoculated subcutaneously in the right flank region with Lewis Lung Carcinoma cells (1×105 cells/body) on
day 0. PLH [(−)-PLH content; 41.7%] was suspended in 10% ethanol-saline, and was administered daily at a dose of 24 mg/kg, 72 mg/kg, or 240 mg/kg intraperitoneally, as a single injection (0.2 ml/body), fromdays 1 to 14. Each group consisted of six mice. Mice were weighed, and the length (L) and the width (W) of the tumor were measured three times a week. Onday 15, mice were sacrificed, and the tumor was excised and weighed. The estimated tumor weight (ETW) was calculated according to the following formula:
ETW(mg)=L(mm)×W2(mm2)/2, - where L represents the length of the tumor and W represents the width of the tumor. The suppression rate was calculated according to the following formula:
Suppression rate(%)=[1−(TWt/TWc)]×100, - where TWt represents the mean tumor weight of the treated group and TWc indicates that of the control group. Average and standard errors were calculated for each group. Variance analysis was performed by the Bartlett method (significance level: 5%), and if the variance was uniform, a Dunnett's multiple comparison test was performed. However, if the variance was not uniform, rank conversion was performed followed by variance analysis again by the Bartlett method (significance level: 5%). Significance was established at the p<0.05 level. Based on the weight of the excised tumors in the control group, the suppression rate was calculated for each group, and the ED50 and 95% confidence limit were then determined by linear regression analysis.
- None of the control and 24 mg/kg/day group mice died. In the 72 mg/kg/day group, 1 mouse died on
day 11, and in the 240 mg/kg/day group, 1 mouse died onday 13. - In the control group, body weight changed very little during drug administration. Similarly, little change in body weight was observed in the 24 and 72 mg/kg/day groups. However, in the 240 mg/kg/day group, the body weight was markedly lower than control values after
day 3, and significantly lower onday 6. - In the control group, the estimated tumor weight (ETW) was 105 mg on day 7, and gradually increased to 2,306 mg on
day 15. The ETW was slightly lower in the 24 mg/kg/day group, in which it increased from 86 mg on day 7 to 2,244 mg onday 15. Similarly, the ETW was slightly lower in the 72 mg/kg/day group, in which it increased from 34 mg on day 7 to 2,142 mg onday 15. In the 240 mg/kg/day group, the ETW was the lowest, increasing from 34 mg on day 7 to 617 mg onday 15. Significant suppression of the ETW was observed ondays - The weight of the excised tumor on the fifteenth day was 3,264 mg for the control group, and 2,941 and 2,380 mg for 24 and 72 mg/kg/day groups, respectively, indicating a rate of suppression of 9.9% and 27.1%, respectively. In the 240 mg/kg/day group, the excised tumor weight was 619 mg, indicating a rate of suppression of 81.0%. The ED50 and 95% confidence limit was 105.3 mg/kg/day [calculated dose of (−)-PLH: 43.9 mg/kg/day] and 22.0˜504.1 mg/kg/day [(−)-PLHL: 9.2˜210.2 mg/kg/day], respectively.
- Male CDF1 mice (6 weeks old) were inoculated subcutaneously in the right flank region with Colon 26 cells (1×105 cells/body) on
day 0. Each group consisted of six mice. Preparation and administration of PLH, and the evaluation of antitumor activity was carried out as described for Lewis Lung Carcinoma, in EXAMPLE 14. - The antitumor activity of PLH ((−)-PLH content: 41.7%) in mice subcutaneously inoculated Colon 26 cells was determined. No mice died during the experimental period in the control, 24 mg/kg/day and 72 mg/kg/day groups. However, in the 240 mg/kg/day group, one mouse died on
day 12, two died onday 13 and one died onday 14. No marked changes in the weight of the control was observed, 24 mg/kg/day and 72 mg/kg/day groups, whereas, in the 240 mg/kg/day group, the body weight was lower than that of the control group fromday 3, and was lower fromday 3 today 10. - In the control group, the ETW gradually increased from 51 mg on day 7 to 1067 mg on
day 15. In the 24 mg/kg/day and 72 mg/kg/day groups, the ETWs increased but the increments were slightly lower than those of the control group. In the 240 mg/kg/day group, the increments of ETW were significantly lower at 14 mg on day 7 and 254 mg onday 15. The suppression rates were 64.4% onday 10, 78.8% onday 13 and 85.4% onday 15. - The weight of the excised tumor on the fifteenth day was 1,159 mg for the control group, and 1,113 and 843 mg for 24 and 72 mg/kg./day groups, respectively, indicating a rate of suppression of 4.0% and 27.3%, respectively. In the 240 mg/kg/day group, the excised tumor weight was 211 mg, indicating a rate of suppression of 81.8%. The ED50 and 95% confidence limit was 107.3 mg/kg/day [calculated dose of (−)-PLH: 44.7 mg/kg/day] and 29.0˜397.7 mg/kg/day [(−)-PLII: 12.1˜165.8 mg/kg/day], respectively.
- The in vitro antitumor activity of a scalemic mixture of (−)-PLH and (+)-PLH using HCC panel assay consisting of 38 human cell lines and in vivo antitumor activity using P388 Leukemia, Lewis Lung Carcinoma, and Colon 26 cells were also analyzed in light of the data illustrating that (−)-PLH exhibits anti-proliferative activity against P388 cells with an IC50 value of 3.5×10−7 M and completely inhibits the cell cycle progression of P388 cells in G2/M phase at 1×10−6 M, while (+)-PLH exhibited little or no effect on proliferation or cell cycle progression even at higher concentrations. See EXAMPLES 3, 4, 5, and 12, 13, 14. It was concluded that the antitumor activity of PLH was due to the active S-configuration enantiomer, (−)-PLH.
- In order to examine detailed biological activity, especially antitumor activity of both (+)- and (−)-phenylahistin, resolution of (+)- and (−)-phenylahistin using chiral HPLC was conducted. By repeating chiral separation twice or three times, each enantiomer with an optical purity over 99.8% was obtained, and each enantiomer was recrystallizes from ethanol-hexane mixture. Antitumor activity of each enanriomer is summarized in Table 7.
TABLE 7 Antiproliferative activities of (−)-PLH and (+)-PLH IC50 (M) Cell Line (position) (−)-phenylahistin (+)-phenylahistin A-431 (damal) 2.2 × 10−7 2.0 × 10−5 A549 (lung) 3.0 × 10−7 3.0 × 10−5 Hela (ovary) 2.0 × 10−7 1.0 × 10−5 MCF7 (breast) 3.3 × 10−7 1.1 × 10−5 TE-671 (CNS) 3.7 × 10−6 1.3 × 10−4 WiDr (colon) 1.8 × 10−7 8.5 × 10−6 K562 (leukemia) 1.9 × 10−7 1.0 × 10−5
*IC50 values were determined by MTT assay.
- Antitumor activity of (+)- and (−)-phenylahistin was examined against seven human cancer cell lines including A431, WiDr, TE-671, Hela, MCF7, A-549 and K562 cells. The IC50 values of each enantiomer were shown in Table 7. (−)-Phenylahistin exhibited antitumor activity with the IC50 values ranging from 1.8×10−7 (against WiDr cells) to 3.7×10−5 (against TE-671). While (+)-PLH exhibited approximately 33 to 100-fold less activity than (−)-PLH.
- To characterize the anti-tumor phenylahistin derivatives of the present invention, the structural factors that are required to exhibit the anti-microtubule activity of these compounds have been determined. These factors serve to distinguish active derivatives of the invention from relatively less-active compounds.
- In this and the following example, X-ray crystallographic analyses of phenylahistin, the synthesis and physical characterization of various phenylahistin derivatives, and analyses of the structural factors necessary for anti-microtubule activity were conducted. These analyses, which were focused on the structure of unique isoprenylated dehydrohistidine, indicate that this isoprenylated dehydrohistidine forms a rigid planar pseudo three-ring structure, composed of the diketopiperazine and imidazole rings through a hydrogen bond between N8-H and N3 and α,β-unsaturated bond (C6-C7). It is concluded that this structural feature is important for the activity of the anti-tumor activity of the compounds of the present invention.
- The derivatives analyzed in this and the following example were prepared in the following manner. As shown in
FIG. 3 (Reaction Scheme 3), simple alkylation and reduction of phenylahistin (labeled “11” inFIG. 3 ) and the modification of cyclo(Gly-Phe) with imidazole derivatives were useful to synthesized the derivatives of phenylahistin for analyzing the structural factors. Derivatives 12-15 were synthesized from phenylahistin by alkylation or reduction. As shown inFIG. 3 ,Reaction Scheme 2, compounds 12 and 13 were synthesized by hydrogenation of each enantiomer of phenylahistin over 10% palladium on carbon in MeOH under atmospheric hydrogen at room temperature. Two (2) hours of hydrogenation yieldedderivative 12, in which the 1,1-dimethyl-2-propenyl group of phenylahistin was reduced, and further hydrogenation (24 h) ofcompound 12 yieldedcompound 13, in which the dehydrohistidine part was reduced. In this second reduction, only one diastereomer, which has the same polarity in optical rotation as that ofcompound 12, was obtained. The diastereoselective hydrogenation ofcompound 13 may be due to the steric hindrance of the phenyl ring of the Phe residue. - As shown in
FIG. 4 ,Reaction Scheme 4, methylation of phenylahistin (labeled “I” inFIG. 4 ) with MeI and NaH in DMF gave mono- and tri-methylated compounds. The extent of the methylation could be controlled by reaction temperature rather than amounts of the reagents. Mono-methylatedderivative 14 at the τ nitrogen of the imidazole ring, whose methylation site was detected by NMR analysis (note that the low filed shift of 8(N)—H (δ 12.20 ppm) in the 1H NMR spectrum was maintained in compound 14) and was predominantly obtained with equivalent of the reagents at −30° C., and a tri-methylated derivative 15 was obtained in the reaction with 30 equivalents of the reagents at room temperature.Compound - As shown in
FIG. 5 ,Reaction Scheme 5, compounds 19 and 20 were synthesized from cyclo(Gly-Phe),compound 16, that was prepared by cyclization of H-Phe-Gly-OMe. After acetylation of the two amide nitrogens of the diketopiperazine ring in 16, 4(5)-imidazolecarboxaldehyde or 4-methyl-5-imidazolecarboxaldehyde (18) was introduced in the presence of lithium diisopropylamide (LDA) and hexamethylphosphoramide (HMPA), according to the method of Bond, R., et al. Synthetic Commun., 19, 2551 (1989), and subsequent dehydration with triflic anhydride-pyridine and deacetylation with aqueous NH4OH gavecompounds - According to X-ray crystallographic analyses of (+)-phenylahistin, as provided in Table 8, the stereochemistry of C6-C7 double bond was confirmed to be Z, and the existence of a hydrogen bond between N8-H and N3 was observed. This result was in good agreement with the observation in the NMR studies (low field-shift of N8-H (δ 12.08 ppm). These findings suggested that two heterocycles, i.e., the diketopiperazine and imidazole rings, were fixed in the same plane by forming a pseudo three-ring structure. The benzyl group of the Phe residue was stacked over the diketopiperazine ring by sticking out from this plane, whose conformation is reported as the energetically most favored one in diketopiperazine with an aromatic amino acid residue, according to the method of Liwo, A. et al. Tetrahedron Lett., 26, 1873 (1985). The 1,1-dimethyl-2-propenyl group at the imidazole ring was also restricted its movement by the steric hindrance of a hydrogen atom at the β-position (C6) of the α,β-unsaturated His derivative. Therefore, it is indicated that the conformation of (+)-phenylahistin is highly restricted. Since the (−)-form of 11, i.e., the biologically active enantiomer, also takes the same conformational feature as that of its (+)-form only with the opposite configuration at the α-position of the Phe residue, this rigid conformation of phenylahistin may be important for the binding to the microtubule protein.
TABLE 8 Data of the x-ray crystallographic analysis of (+)-phenylahistin Crystal parameters — Empirical formula C20H22N4O2 Formula weight 350.42 Crystal system tetragonal Lattice parameters: a = 15.3509(7) Å c = 8.309(2) Å V = 1958.0(2) Å3 Z = 4 Space group P42 (#77) Dcalc. 1..189 g/cm3 μ (CuKα) 6.37 cm−1 Refinement parameters — Reflections measured 2229 Nonzero reflections 1724 R-indexResiduals: Ra 0.057 Residuals: RWb 0.067 Goodness of fit indicatorc 4.31
aΣ||Fo| − |Fc||Σ|Fo|
b[Σw ((|Fo| − |Fc|)2/ΣwFo2)]1/2
c[(Σw (|Fo| − |Fc|)2/(No − Nv)]1/2
- To study the relationship between the rigid plane structure of (−)-phenylahistin and that compound's biological activity, the derivatives of (−)-phenylahistin were synthesized and the anti-microtubule effect on the polymerization of microtubule protein prepared from bovine brain and the anti-proliferative effect on P388 cells were studied, as described in prior examples. As described above, (−)-phenylahistin exhibits the colchicine-like inhibition of microtubule polymerization (IC50=25 μM). This inhibitory activity of (−)-phenylahistin was almost the same as that of colchicine (IC50=16 μM), although the anti-proliferative activity of (−)-phenylahistin (IC50=0.21 μM) was about 10 times less active than that of colchicine (IC50=0.031 μM). The difference of these activities is due either to the unaccounted-for biological activities of colchicine or to lower cellular permeability of (−)-phenylahistin in anti-proliferative assay, since (−)-phenylahistin has more hydrophilic structure than colchicine. Furthermore, as described above, (−)-phenylahistin with the L-Phe residue was 50 times more active than (+)-phenylahistin in anti-proliferative assays. (+)-Phenylahistin also exhibited relatively weak inhibitory activity against microtubule polymerization (15% inhibition at 200 μM) compared with (−)-phenylahistin. Thus, the orientation of the benzyl group of the phenylalanine residue is important to the biological activity of the compounds of the present invention.
- As shown in Table 9,
compound 12, in which the 1,1-dimethyl-2-propenyl group of phenylahistin was reduced, showed the same activity as phenylahistin, indicating that this double bond is not important for the anti-microtubule activity. However, compound (−)-13, in which the dehydrohistidine of (−)-12 was reduced, completely lost the inhibitory activity. Since this modification disrupts the substantially planar characteristic of the pseudo three-ring structure in the same plane as the phenylahistin backbone, this result suggests that, for the inhibitory activity, it is important that the two rings, i.e., diketopiperazine and imidazole rings, are fixed in the same plane.TABLE 9 Biological activity of phenylahistin, its derivatives, and selected structurally-related compounds. IC50 (μM) Microtubule Proteina P388 compound polymerization proliferation (−)-11 25 0.21 (±0.02)b (+)-11 >200 [15%]c 10 (±1.5) (−)-12 30 0.23 (±0.05) (+)-12 >200 [12%] 19 (±4.2) (−)-13 >200 >200 (+)-13 >200 >200 14 100 0.95 (±0.03) 15 >200 160 (±5.5) 19 >200 [11%] >200 20 >200 {9%] 15 (±4.5) Cyclo(His-Phe)d >200 >200 colchicine d16 0.031 (±0.01)
aMicrotubule protein was prepared from bovine brain by two cycle of assembly and disassembly method. The concentration of microtubule protein used for the assay was 1.5 mg/mL.
bValues are means (±SEM) of three experiments.
cThe inhibition percentage at 200 μM was indicated in the parenthesis when the inhibition was observed, since the diketopiperazine derivatives are insoluble in the concentration more than 200 μM.
19 and 20 were chiral-purified.
dCyclo(His-Phe) and colchicine are each commercially available; each was purchased from Sigma.
- In further syntheses, the nitrogen atoms of phenylahistin were modified by methylation.
Compound 14, in which the τ nitrogen of the imidazole ring of (−)-phenylahistin was methylated, was about 5 times less active than (−)-phenylahistin, suggesting this imidazole nitrogen probably participates in the binding with the microtubule protein or this methylation affords the structural hindrance to the conformation of the 1,1-dimethyl-2-propenyl group on the imidazole ring.Tri-methylated compound 15 almost lost the inhibitory activity. This result also suggests that the rigid plane conformation of (−)-phenylahistin is important to the anti-microtubule activity, since the methylation of a diketopiperazine nitrogen (N8) disrupts the formation of hydrogen bond on N8-H necessary for the rigid pseudo three-ring conformation. - The importance of an alkyl group at the 5-position on the imidazole ring to the biological activity of the compounds of the present invention was analyzed via the following analyses of
compounds compound 16. In compounds 19 and 20, the 1,1-dimethyl-2-propenyl group of (−)-phenylahistin was replaced with a hydrogen atom or a methyl group, respectively.Compound 19, in which the 1,1-dimethyl-2-propenyl group was replaced with the hydrogen atom at this position, showed no inhibitory activity.Compound 20, in which the 1,1-dimethyl-2-propenyl group was replaced with a methyl group at this position, also showed no activity in the anti-microtubule assay, although weak inhibition on P388 cell proliferation was observed. This drastic decreased in biological activity in 19 indicates that an alkyl group with a proper length or a quaternary carbon at the 5-position of the imidazole ring is important for the activity. - Accordingly, the results of the x-ray crystallographic analysis and the biological evaluation of the phenylahistin derivatives elucidate a structural factor of phenylahistin necessary for its anti-microtubule activity. This factor is that the rigid and planar pseudo three-ring structure formed by a hydrogen bond are important for the biological activity of (−)-phenylahistin.
- For this example, the microtubule protein polymerization assay was performed as follows. Microtubule protein was prepared from bovine brain tissue by two cycles of assembly and disassembly. Polymerization of microtubule protein was monitored by an increase in turbidity at 37° C. in microtubule assembly buffer containing 100 mM MES, 0.5 mM MgCl2, 1 mM EGTA and 1 mM GTP. The polymerization of microtubule protein was initiated by a temperature shift from 0° C. to 37° C. Turbidity was measured on a thermo-controlled spectrophotometer (Beckman DU-20, Fullerton, Calif.) at 360 nm. Compounds were dissolved in DMSO, which was used in all experiments at a final concentration of 2% (v/v).
- For this example, the Alamar Blue™ assay was performed as follows. Exponentially growing P388 cells were seeded into 96-well tissue culture plates (5×103 cells/100 μl/well) and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum for 16 h. Compounds (DMSO solution) were then added to each well at various concentrations, and the cells were cultured for an additional 48 h. Living cells were counted using Alamar Blue™ (BioSource International, Camarillo, Calif.), according to the method of Ahmed, S. A. et al., J. Immunol. Methods, 170, 211 (1994).
- For this example, the Single-Crystal X-ray Diffraction Analysis was performed as follows. A pale yellow crystal of (+)-phenylahistin having approximately dimension 0.4×0.4×0.3 mm, which was crystallized from EtOAc, was used for single-crystal x-ray diffraction analysis. All x-ray measurements were made on a Rigaku AFC7R diffractometer with graphite monochromated Cukα radiation and a rotating anode generator. The crystal data and refinement parameters were summarized in Table 8. Of the 2229 reflections which were collected, 2064 were unique (Rint=0.019). The data were corrected for Lorentz and polarization effects. A correction for secondary extinction was applied. The structure was solved by direct methods and expanded using standard Fourier techniques. All calculations were performed using the teXscan crystallographic software package of Molecular Structure Corporation.
- The melting points of the phenylahistin derivatives described in the previous example were determined on a Mettler FP62 apparatus and are uncorrected. 1H-NMR and 13C-NMR spectra were recorded on JEOL GSX27OJ spectrometer. The spectra were recorded with tetramethylsilane (δ=0.0 for 1H); DMSO-d6 (δ=39.5 for 13C); CDCl3 (δ=77.0 for 13C) as internal reference. Mass spectra (electrospray ionization, methanol as the mobile phase) were analyzed with Finnigan SSQ 7000 spectrometer. High-resolution fast atom bombardment mass spectra were analyzed with JEOL JMS-DX303 spectrometer. Infrared spectra were recorded on a JEOL JIR-5500 infrared spectrophotometer in KBr pellets. A silica-gel column chromatography was performed using Merck 70-230 mesh silica gel 60. Optical rotations were measured on a Horiba SEPA-200 polarimeter, and are given in units of 10−1 deg cm2g−1. Elemental analyses were performed by Fisons EA 1108 elemental analyzer.
- The precise synthetic routes and physical characteristics of the phenylahistin derivatives described in the previous example are as follows.
- (−)-Cyclo-[5-(1,1-dimethylpropyl)dehydrohistidinyl-phenylalanine] (−)-12: To a solution of (−)-phenylahistin (30 mg, 0.086 mmol) in MeOH (10 mL) was added 10 mg of 10% palladium on carbon and the mixture was stirred at room temperature for 2 h under hydrogen at atmospheric pressure. After the catalyst was filtered off and the filtrate was concentrated under reduced pressure, the residue was purified by column chromatography on silica (5 g) using CHCl3-MeOH (50:1) as an eluent. Desired fractions were collected and the solvent was evaporated. The residual white powder was recrystallized from EtOH-hexane to give 12 mg (39% of (−)-12 as a colorless solid: mp 224-226° C.; [α]D 25−295(c=0.15, MeOH), UV (MeOH) nm 322 (ε 23300), 231 (ε 8830), 203 (ε 16800); IR (KBr) cm−1 3310, 3220, 2970, 1670, 1440; 1H NMR (270 MHz, CDCl3) δ 12.09 (br s, 1H), 8.98 (br s. 1H), 7.56 (s, 1H), 7.29-7.38 (m, 5H), 6.87 (s, 1H), 5.67 (s, 1H), 4.34 (ddd, J=2, 3, 10 Hz, 1H), 3.51 (dd, J=3, 14 Hz, 1H), 2.29 (dd, J=10, 14 Hz, 1H), 1.74 (q, J=7 Hz, 2H), 1.40 (s, 6H), 0.74 (t, J=7 Hz 3H); 13C NMR (67.5 MHz, CDCl3) δ 164.6, 159.9, 138.1, 135.5, 132.2, 132.1, 129.5 (2C), 129.1 (2C), 127.4, 123.6, 105.4, 57.2, 41.3, 36.2, 35.4, 27.9 (2C), 9.2; HRMS m/z 352.1926 (M+) (calcd for C20H24N4O2: 352.1899). Anal. calcd for C20H24N4O2: C, 68.16; H, 6.86; N, 15.90. Found: C, 68.34, 6.78, 15.82.
- (+)-Cyclo-[5-(1,1-dimethylpropyl)dehydrohistidinyl-phenylalanine] (+)-12: This compound was prepared according to the same procedure for the preparation of (−)-12.44% yield from (+)-1; colorless solid; mp 222-223° C.; [α]D 25+284(c=0.10, MeOH), UV (MeOH) nm 322 (ε 22800), 231 (ε 8720), 203 (ε 16300); IR (KBr) cm−1 3310, 3220, 2970, 1670, 1440; 1H NMR (270 MHz, CDCl3) δ 12.09 (br s, 1H), 8.98 (br s. 1H), 7.56 (s, 1H), 7.29-7.38 (m, 5H), 6.87 (s, 1H), 5.67 (s, 1H), 4.34 (ddd, J=2, 3, 10 Hz, 1H), 3.51 (dd, J=3, 14 Hz, 1H), 2.29 (dd, J=10, 14 Hz, 1H), 1.74 (q, J=7 Hz, 2H), 1.40 (s, 6H), 0.74 (t, J=7 Hz 3H); 13C NMR (67.5 MHz, CDCl3) δ 164.6, 159.9, 138.1, 135.5, 132.2, 132.1, 129.5 (2C), 129.1 (2C), 127.4, 123.6, 105.4, 57.2, 41.3, 36.2, 35.4, 27.9 (2C), 9.2; HRMS m/z 352.1932 (M+) (calcd for C20H24N4O2: 352.1899). Anal. calcd for C20H24N4O2: C, 68.16; H, 6.86; N, 15.90. Found: C, 68.09, 6.87, 15.84.
- (−)-Cyclo-[5-(1,1-dimethylpropyl)histidinyl-L-phenylalanine] (−)-13: This compound was prepared from (−)-12, according to the same procedure for the preparation of (−)-12, with 24 h of reaction time. 60% yield from (−)-12; white powder; mp 224-225° C.; [α]D 25−96(c=0.16, MeOH), UV (MeOH) nm 257 (ε 194), 205 (ε 18100), IR (KBr) cm−1 3380, 3200, 2970, 1670, 1440; 1H NMR (270 MHz, DMSO-d6) δ 11.55 (br s, 1H), 8.25 (br s. 1H), 7.86 (br s, 1H), 741 (s, 1H), 7.29-7.14 (m, 5H), 4.24 (br s, 1H), 3.94 (br d, J=11 Hz, 1H), 3.11 (dd, J=14, 4 Hz, 1H), 2.88 (dd, J=14.5 Hz, 1H), 2.82 (dd, J=15, 2 Hz, 1H), 1.45 (q, J=7 Hz, 2H), 1.32 (dd, J=15, 11 Hz, 1H), 1.13 (s, 3H), 1.12 (s, 3H), 0.60 (t, J=7 Hz 3H); 13C NMR (67.5 MHz, CDCl3) δ 166.87, 165.42, 135.93, 132.54, 131.58, 131.23, 130.32 (2C), 127.94 (2C), 126.61, 55.70, 54.31, 38.16, 35.04, 34.31, 31.85, 27.63, 27.57, 9.05; HRMS m/z 354.2098 (M+) (calcd for C20H24N4O2: 354.2055). Anal. calcd for C20H24N4O2:⅓H2O: C, 66.64; H, 7.46; N, 15.54. Found: C, 66.75, 7.41, 15.52.
- (+)-Cyclo-[5-(1,1-dimethylpropyl)histidinyl-L-phenylalanine] (+)-13: This compound was prepared from (+)-12 according to the same procedure for the preparation of (−)-13.46% yield from (+)-12; white powder; mp 226-227° C.; [α]D 25+99(c=0.10, MeOH), UV (MeOH) nm 257 (ε 174), 205 (ε 18200), IR (KBr) cm−1 3380, 3200, 2970, 1670, 1440; 1H NMR (270 MHz, DMSO-d6) δ 11.55 (br s, 1H), 8.25 (br s. 1H), 7.86 (br s, 1H), 7.41 (s, 1H), 7.29-7.14 (m, 5H), 4.24 (br s, 1H), 3.94 (br d, J=11 Hz, 1H), 3.11 (dd, J=14.4 Hz, 1H), 2.88 (dd, J=14.5 Hz, 1H), 2.82 (dd, J=15, 2 Hz, 1H), 1.45 (q, J=7 Hz, 2H), 1.32 (dd, J=15, 11 Hz, 1H), 1.13 (s, 3H), 1.12 (s, 3H), 0.60 (t, J=7 Hz 3H); 3C NMR (67.5 MHz, CDCl3) δ 166.87, 165.42, 135.93, 132.54, 131.58, 131.23, 130.32 (2C), 127.94 (2C), 126.61, 55.70, 54.31, 38.16, 35.04, 34.31, 31.85, 27.63, 27.57, 9.05; HRMS m/z 354.2110 (M+) (calcd for C20H24N4O2: 354.2055). Anal. calcd for C20H24N4O2:½H2O: C, 66.09; H, 7.49; N, 15.41. Found: C, 65.80, 7.50, 15.30.
- (−)-Cyclo-[(Nim-methyl-5-(1,1-dimethyl-2-propenyl))dehydrohistidinyl-L-phenylalanine] (−)-14: To a solution of phenylahistin (200 mg, 0.57 mmol) in DMF (15 mL) was added 45 mg (1.88 mmol) of sodium hydride (NaH) (60% in mineral oil) in portions and the mixture was stirred at −30° C. for 10 min. To this mixture, 1.0 mL (17.1 mmol) of MeI was added dropwise and stirred at −30° C. for 2 h. 20 mL of saturated aqueous NH4Cl was added to the reaction mixture and the mixture was extracted three times with 50 mL of EtOAc. The combined organic layers were washed with saturated NaCl, dried over Na2SO4 and concentrated in vacuo. The residual white powder (150 mg) was chromatographed over 20 g of silica gel and eluted with CHCl3-MeOH (50:1) as an eluent to give 130 mg (63%) of 14 as white powder: The (−)-form of 14 was isolated by HPLC using chiral column (CHIRALCEL OD, 10×250 mm) eluted with a mixture of hexane and ethanol (3:1) at a flow rate of 6.0 mL/min on a Waters system (600E series). 19% yield from 1; white powder; mp 214-215° C.; [α]D 25−285(c=0.30, MeOH), UV (MeOH) nm 317 (ε 25400), 232 (sh, ε 8640), 204 (ε 16800); IR (KBr) cm−1 3200, 2980, 1680, 1440; 1H NMR (270 MHz, CDCl3) δ 12.20 (br s, 1H), 7.39 (s. 1H), 7.38-7.24 (m, 5H), 7.09 (s, 1H), 6.01 (dd, J=18, 9 Hz, 1H), 5.68 (br s, 1H), 5.14 (d, J=9 Hz, 1H), 5.00 (d, J=18 Hz, 1H), 4.33 (m, 1H), 3.66 (s. 3H), 3.50 (dd, J=14, 3 Hz, 1H), 2.92 (dd, J=14, 10 Hz, 1H), 1.59 (s, 6H); 13C NMR (67.5 MHz, CDCl3) δ 164.6, 160.1, 145.6, 138.5, 136.5, 135.6, 134.6, 129.5 (2C), 129.1 (2C), 127.4, 124.0, 112.7, 106.6, 57.1, 41.3, 39.2, 34.9, 28.9, 28.8; HRMS m/z 364.1909 (M+) (calcd for C21H24N4O2: 364.1899). Anal. calcd for C21H24N4O2.¼H2O: C, 68.36; H, 6.69; N, 15.19. Found: C, 68.44, H, 6.67, N, 15.01.
- (−)-Cyclo-N,N′-dimethyl-[(Nim-methyl-5-(1, 1-dimethyl-2-propenyl))dehydro-histidinyl-L-phenylalanine] (−)-15: This compound was prepared from phenylahistin with 10 equivalents of NaH and 30 equivalent of MeI at room temperature according to the same procedure for the preparation of (−)-14. For the purification of (−)-15, a mixture of hexane and ethanol (4:1) was used as an eluent in the chiral column HPLC mentioned in the preparation of (−)-14.8% yield from phenylahistin: white powder; mp 95-98° C.; [a]D 25-632(c=0.50, MeOH), UV (MeOH) nm 287 (ε 11100), 203 (ε 15900); IR (KBr) cm−1 2900, 1690, 1640, 1380; 1H NMR (270 MHz, CDCl3) δ 8.76 (br s, 1H), 7.33-7.21 (m, 5H), 7.08 (s, 1H), 6.00 (dd, J=18, 11 Hz, 1H), 5.28 (d, J=11 Hz, 1H), 5.08 (d, J=18 Hz, 1H), 4.19 (dd, J=10.4 Hz, 1H), 3.86 (s, 3H), 3.38 (dd, J=14, 4 Hz, 1H), 3.13 (dd, J=14, 10 Hz, 1H), 2.92 (s, 3H), 2.55 (s, 3H), 1.60 (s, 3H), 1.57 (s, 3H); 13C NMR (67.5 MHz, CDCl3) δ 166.8, 160.2, 143.5, 137.8, 136.5, 134.8, 129.4 (2C), 128.8 (2C), 127.2, 124.6, 114.4, 105.6, 65.9, 40.6, 38.8, 36.6, 34.9, 28.4, 28.1; HRMS m/z 392.2223 (M+) (calcd for C23H28N4O2: 392.2212). Anal. calcd for C23H28N4O2: C, 70.38; H, 7.19; N, 14.27. Found: C, 70.26, H, 7.30, N, 14.27.
- Cyclo-[glycinyl-L-phenylalanine] 16: To a solution of H-Phe-Gly-OMe, which was prepared from Boc-Phe-Gly-OMe with 4N HCl-dioxane (20 g, 59 mmol), in MeOH (100 mL) was refluxed for 16 h. The white precipitate occurred during reflux was washed with 10 mL of MeOH for three times and collected to give 7.5 g (62%) of 16 as a white powder, mp 262-263° C. (decomp.); [α]D 25+60 (c=0.15, DMSO), UV (MeOH) nm 257 (ε 101), 206 (ε 5770); IR (KBr) cm−1 3340, 3200, 3060, 1680, 1470, 1340; 1H NMR (270 MHz, DMSO-d6) δ 8.16 (br s, 1H), 7.90 (br s. 1H), 7.32-7.15 (m, 5H), 4.07 (br dd, J=7.4 Hz, 11H), 3.35 (dd, J=18, 3 Hz, 1H), 3.10 (dd, J=14, 4 Hz, 1H), 2.88 (dd, J=14, 5 Hz, 11H), 2.75 (d, J=18 Hz, 1H), 3C NMR (67.5 MHz, DMSO-d6) δ 167.1, 165.5, 136.0, 130.1 (2C), 128.1 (2C), 126.8, 55.5, 43.7, 38.8; MS (ESI) m/z 205 (M+H)+; Anal. calcd for C11H12N2O2⅕H2O: C, 63.57; H, 6.01; N, 13.48. Found: C, 63.85, H, 5.86, N, 13.40.
- Cyclo-N,N′-diacetyl-[glycinyl-L-phenylalanine] 17: The mixture of compound 16 (0.5 g, 2.45 mmol) and fused sodium acetate (201 mg, 2.45 mmol) in acetic anhydride (10 mL) was heated for 16 h at 100° C. under nitrogen. After acetic anhydride was removed in vacuo at 45° C., the residue was solved in EtOAc and the resulted organic layer was washed with saturated NaCl, dried over Na2SO4 and 17 was crystallized from EtOAc. 88% yield (0.62 g); colorless solid; mp 84-85° C.; [α]D 25+7.8 (c=0.52, MeOH); UV (MeOH) nm 209 (ε 20400); IR (KBr) cm−1 1720, 1400, 1380, 1240; 1H NMR (270 MHz, CDCl3) δ 7.33-7.26 (m, 3H), 7.08-7.05 (m, 2H), 5.44 (t, J=5 Hz, 1H), 4.49 (d, J=19 Hz, 1H), 3.35 (dd, J=14, 5 Hz, 1H), 3.20 (dd, J=14, 5 Hz, 1H), 2.58 (s, 3H), 2.55 (s, 3H), 2.48 (d, J=19 Hz, 1H); 13C NMR (67.5 MHz, CDCl3) δ 171.2, 171.0, 167.9, 166.0, 134.3, 129.7 (2C), 129.1 (2C), 128.2, 59.0, 46.0, 38.7, 27.1, 26.8; MS (ESI) m/z 311 (M+Na)+; Anal. calcd for C15H15N2O4: C, 62.49; H, 5.59; N, 9.72. Found: C, 62.50, H, 5.50, N, 9.67.
- Cyclo-[dehydrohistidinyl-L-phenylalanine] 19: To a solution of 17 (311 mg, 0.93 mmol) in dimethoxyethanol (DME) (10 mL) was added 0.6 mL of 2M lithium diisopropylamide (LDA, 1.2 mmol) and the mixture was stirred at −70° C. for 10 min. To this solution was added a solution of 4(5)-formylimidazole (120 mg, 1.25 mmol, Maybridge Chemical Co. Ltd., Cornwall, U.K.) in HMPA (4 mL)-DME (6 mL) at −70° C. This mixed solution was allowed to warm to −30° C. After stirring for 30 min at this temperature, a triflic anhydride (370 μL, 2.2 mmol) and pyridine (180 μL, 2.2 mmol) were added and the solution was allowed to warm to room temperature. After additional stirring for 1 h, aqueous ammonia (3 mL) was added and stirred for 14 h at room temperature. The reaction mixture was extracted with CHCl3 for three times, dried over Na2SO4 and concentrated in vacuo. The resultant residue was purified by HPLC with a reverse phase column (Waters,
μBondasphere 19×150 mm, 10 μm, C-18) employing a gradient from 60 to 80% CH3CN in 0.1% TFA at a flow rate of 17 mL/min on a Waters system (600E series). However, since purifiedcompound 19 contained 28% of a racemized compound with D-phenylalanine (44% ee), further purification by HPLC with a chiral column was performed using the same procedure described for the purification of (−)14. 8% yield from 7; white powder; mp 208-209° C. [α]D 25−257 (c=0.21, DMSO); UV (MeOH) nm 307 (ε 16700); IR (KBr) cm−1 3400, 3120, 1680, 1440; 1H NMR (270 MHz, DMSO-d6) δ 12.88 (br s, 1H), 11.09 (br s, 1H), 8.44 (s, 1H), 8.13 (br s, 1H), 7.48 (s, 1H), 7.24-7.11 (m, 5H), 6.25 (s, 1H), 4.48 (m, 1H), 3.19 (dd, J=14, 4 Hz, 1H), 2.95 (dd, J=14, 5 Hz, 1H); 13C NMR (67.5 MHz, DMSO-d6) δ 164.8, 158.6, 135.8, 135.5, 132.3, 130.0 (2C), 128.0 (2C), 126.7, 125.6, 118.3, 101.8, 55.9, 38.9; (overlapping DMSO-d6); HRMS m/z 282.1084 (M+) (calcd for C15H14N4O2: 282.1117). Anal. calcd for C15H14N4O2—CF3COOH: C, 51.52; H, 3.81; N, 14.14, Found: C, 51.15, H, 3.62, N, 13.84. - Cyclo-[(5-methyl)dehydrohistidinyl-L-phenylalanine] 20: This compound was prepared from compound 17 with 4-methyl-5-imidazolecarboxaldehyde according to the same procedure for the preparation of 19.3% yield from 17; colorless solid; mp 285-286° C. (decomp); [α]D 25−267° (c=0.21, DMSO); UV (MeOH) nm 319 (ε 22800); IR (KBr) cm−1 3400, 3180, 1680, 1450; 1H NMR (270 MHz, DMSO-d6) δ 11.50 (br s, 1H), 8.35 (br s, 1H), 7.74 (s, 1H), 7.24-7.14 (m, 5H), 6.20 (s, 1H), 4.48 (m, 1H), 3.33 (br s, 1H), 3.20 (dd, J=14, 4 Hz, 1H), 2.93 (dd, J=14, 5 Hz, 1H), 2.19 (s, 1H); 13C NMR (67.5 MHz, DMSO-d6) δ 164.2, 158.7, 135.6, 134.6, 132.3, 130.0 (2C), 128.0 (2C), 127.5, 126.6, 123.4, 101.7, 55.9, 38.7, 8.9; High-resolution MS m/z 296.1261 (M+) (calcd for C16H16N4O2: 296.1273). Anal. calcd for C16H16N4O2⅕H2O; C, 64.07; H, 5.51; N, 18.68. Found: C, 64.39, H, 5.65, N, 18.29.
- Vials containing 5 g of powdered glucose are each added aseptically with 10 mg of the invention compound and sealed. After being charged with nitrogen, helium or other inert gas, the vials are stored in a cool, dark place. Before use, the contents are dissolved in ethanol and added to 100 ml of a 0.85% physiological salt water solution. The resultant solution is administered as a method of inhibiting the growth of a cancerous tumor in a human diagnosed as having such a tumor at between approximately 10 ml/day to approximately 1000 ml/day, intravenously, by drip, or via a subcutaneous or intraperitoneal injection, as deemed appropriate by those of ordinary skill in the art.
- A mixture obtained by thoroughly blending 1 g of the compound of the invention, 98 g of lactose and 1 g of hydroxypropyl cellulose is formed into granules by any conventional method. The granules are thoroughly dried and sifted to obtain a granule preparation suitable for packaging in bottles or by heat sealing. The resultant granule preparations are orally administered at between approximately 100 ml/day to approximately 1000 ml/day, depending on the symptoms, as deemed appropriate by those of ordinary skill in the are of treating cancerous tumors in humans.
- PLH is administered according to the formulation of EXAMPLE 17 to a human patient afflicted with lung cancer. PLH is administered at between approximately 10 mg per day to approximately 1000 mg per day, and in an preferred amount of 50 mg per day, until the growth of the tumor is inhibited.
- (−)-PLH is isolated according to the method of EXAMPLE 6, substantially purified, and administered according to the formulation of EXAMPLE 17 to a human patient, afflicted with ovarian cancer, at between approximately 10 mg per day to approximately 100 mg per day, and in a preferred amount of 50 mg per day, until the growth of the tumor is
- 2-isopropyl-(−)-phenylahistin, i.e.,
compound 3 of EXAMPLE 7, is synthesized according to the method of EXAMPLE 7, substantially purified, and administered according to the formulation of EXAMPLE 17 to a human patient afflicted with breast cancer at between approximately 10 mg per day to approximately 100 mg per day, and in a preferred amount of 50 mg per day, until the growth of the tumor is inhibited. - 2-dichloroisopropyl-(−)-phenylahistin is synthesized in the following manner: (−)-Phenylahistin,
compound 1 of EXAMPLE 7, is placed in the presence of Cl2 and in the presence of water and heat to yield 2 dichloroisopropyl-(−)-phenylahistin. - 2-dichloroisopropyl-(−)-phenylahistin, as synthesized in EXAMPLE 22, is substantially purified and administered according to the formulation of EXAMPLE 17 to a human patient afflicted with Lewis Lung Carcinoma at between approximately 10 mg per day to approximately 100 mg per day, and in a preferred amount of 50 mg per day, until the growth of the tumor is inhibited.
- Synthetic studies of PLH are conducted to obtain more potent and less toxic agents. According to the method described by Gordon and Steele, J. Bioorg. Med. Chem. Letters (1995)., 5, 47-50, phenylahistin are its derivatives are screened using an efficient solid phase combinatorial synthesis for a typical diketopiperazine library. By using such technique, phenylahistin is utilized as a prototype for the development of promising new antitumor agents.
- 1) Formulations Administered Intravenously by Drip, Injection Infusion or The Like
- Vials containing 5 g of powdered glucose are each added aseptically with 10 mg of compound synthesized by the method and sealed. After being charged with nitrogen, helium or other inert gas, the vials are stored in a cool, dark place. Before use, the contents are dissolved in ethanol and added to 100 ml of a 0.85% physiological salt water solution. The resultant solution is administered as a method of inhibiting the growth of a cancerous tumor in a human diagnosed as having such a tumor at between approximately 10 ml/day to approximately 1000 ml/day, intravenously, by drip, or via a subcutaneous or intraperitoneal injection, as deemed appropriate by those of ordinary skill in the art.
- 2) Formulation to be Administered Orally or the Like
- A mixture obtained by thoroughly blending 1 g of a compound synthesized by the method, 98 g of lactose and 1 g of hydroxypropyl cellulose is formed into granules by any conventional method. The granules are thoroughly dried and sifted to obtain a granule preparation suitable for packaging in bottles or by heat sealing. The resultant granule preparations are orally administered at between approximately 100 ml/day to approximately 1000 ml/day, depending on the symptoms, as deemed appropriate by those of ordinary skill in the art of treating cancerous tumors in humans.
- 3) Formulation to be Administered Topically
- Administration to an individual of an effective amount of the compound can also be accomplished topically by administering the compound(s) directly to the affected area of the skin of the individual. For this purpose, the compound administered or applied is in the form of a composition including a pharmacologically acceptable topical carrier, such as a gel, an ointment, a lotion, or a cream, which includes, without limitation, such carriers as water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other topical carriers include liquid petroleum, isopropyl palmitate, polyethylene glycol, ethanol (95%), polyoxyethylene monolaurate (5%) in water, or sodium lauryl sulfate (5%) in water. Other materials such as anti-oxidants, humectants, viscosity stabilizers, and similar agents may be added as necessary. Percutaneous penetration enhancers such as Azone may also be included. In addition, in certain instances, it is expected that the compound may be disposed within devices placed upon, in, or under the skin. Such devices include patches, implants, and injections which release the compound into the skin, by either passive or active release mechanisms.
- The in vitro efficacy studies performed with t-butyl phenylahistin included: A) a panel of six tumor cell lines, B) studies in multidrug-resistant tumor cells, and C) studies to determine the mechanism of action.
- The following cell lines (source in parentheses) were used: HT29 (human colon tumor; ATCC; HTB-38), PC3 (human prostate tumor; ATCC; CRL-1435), MDA-MB-231 (human breast tumor; ATCC; HTB-26), NCI-H292 (human non-small cell lung tumor; ATCC; CRL-1848), OVCAR-3 (human ovarian tumor; ATCC; HTB-161), B16-F10 (murine melanoma; ATCC; CRL-6475) and CCD-27sk (normal human fibroblast; ATCC; CRL-1475). Cells were maintained at subconfluent densities in their respective culture media.
- Cytotoxicity assays were performed as described above in Example 4, using Resazurin fluorescence as an indicator of cell viability.
- The disclosed compounds are effective agents against a variety of different and distinct tumor cell lines. Specifically, for example, t-butyl-phenylahistin exhibited its greatest potency against the PC-3 tumor cell line, although the greatest efficacy was displayed against the HT-29 cell line. t-butyl-phenylahistin displayed a marked differential between normal fibroblasts and the tumor cell lines, with a ratio ranging from >20->100, except for the OVCAR-3 cell line.
TABLE 10 Activity of t-butyl phenylahistin in the Tumor Panel Screen t-butyl-phenylahistin Cell Line Mean SD n HT-29 Colon IC50 nM 420 473 3 % Cytotoxicity 88 0.2 3 PC-3 Prostate IC50 nM 174 — 2 % Cytotoxicity 59.5 — 2 MDA-MB-231 Breast IC50 nM 387 — 2 % Cytotoxicity 65.5 — 2 NCI-H292 Lung IC50 nM 384 194 3 % Cytotoxicity 65 5 3 OVCAR-3 Ovary IC50 nM >20,000 — 2 % Cytotoxicity 37 — 2 B16-F10 Melanoma IC50 nM 736 650 3 % Cytotoxicity 74 2 3 CCD-27sk Fibroblast IC50 nM >20,000 — 2 % Cytotoxicity 45 — 2 - One of the major challenges in the use of chemotherapeutic agents in clinical oncology is the development of resistance to the drug effect by the tumor cells. There are several mechanisms for the development of resistance, each of which will have differential effects on chemotherapeutic drugs. These mechanisms include increased expression of ATP-dependent efflux pumps such as the P-glycoprotein encoded by MDR1 or the multidrug-resistance associated
protein 1 encoded by MRP1. Reduced drug uptake, alteration of the drug's target, increasing repair of drug-induced DNA damage, alteration of the apoptotic pathway and the activation of cytochrome P450 enzymes are other examples of mechanisms by which cancer cells become resistant to anticancer drugs. The selected compounds were studied in three different cell lines that exhibit two different mechanisms of resistance; the overexpression of the P-glycoprotein and altered topoisomerase II activity. - 1) Human Uterine Sarcoma Tumor Cell Line Pair: MES-SA (Taxol Sensitive) and MES-SA DX (Taxol Resistant).
- This cell line expresses elevated mdr-1 mRNA and P-glycoprotein (an extrusion pump mechanism). Pretreatment with cyclosporin-A (CsA) blocks P-glycoprotein and reinstates activity in the resistant cell line for those compounds for which the resistance is due to elevated P-glycoprotein.
- As can be seen from Table 11, the potency of t-butyl-phenylahistin was only slightly reduced. Cyclosporin A (CsA) pretreatment did not alter the potency of the selected compounds. In contrast, taxol was virtually inactive in the MES-SA DX resistant cell line, whereas this compound was very potent in the sensitive cell line. CsA treatment restored the sensitivity to taxol of the MES-SA DX cell line. The MES-SA DX cell line also showed reduced susceptibility to etoposide (60 fold), doxorubicin (34 fold) and mitoxantrone (20 fold).
- These data indicate that the effects of t-butyl-phenylahistin are not susceptible to the taxol-related resistance mechanism (p-glycoprotein) in this cell line, and that cross-resistance from taxol does not occur to this compound in this model.
TABLE 11 Activity of t-butyl-phenylahistin and Taxol in MES-SA Taxol Sensitive and MES-SA DX Taxol Resistant Human Uterine Sarcoma Tumor Cell Lines MES-SA Sensitive MES-SA DX Resistant No CsA Pretreat No CsA CsA Ratio CsA Pretreat Compound IC50 IC50 No IC50 Ratio IC50 Ratio Study nM nM CsA nM MES-SA nM No CsA t-butyl- phenylahistin Study I 144 — — 825 5.7 — — Study III 122 162 1.3 694 4.3 622 0.9 Taxol Study I 4.4 — — >20,000 >455 — — Study II 13.3 7.6 0.6 >>100 >>8 40 <<0.25 Study III 7.3 2.8 0.4 >24,000 >3000 2.0 <<0.001
2) Human Acute Promyelocytic Leukemia Cell Line Pair: HL-60 (Mitoxantrone-Sensitive) and HL-60/MX-2 (Mitoxantrone-Resistant) - This cell line is considered to have atypical drug resistance properties with altered topoisomerase II catalytic activity without overexpression of P-glycoprotein.
- As can be seen in Table 12, these results indicate that the potency of the novel compound in the sensitive and resistant HL-60 cell lines. In contrast, Mitoxantrone loses efficacy by a factor of 24-fold in the resistant HL-60/MX-2 cell line.
- Thus, t-butyl-phenylahistin is not susceptible to the same resistance mechanisms as Mitoxantrone in this cell line, and there is no cross-resistance from Mitoxantrone to t-butyl phenylahistin in this model.
TABLE 12 Activity of t-butyl-phenylahistin and Mitoxantrone in the HL-60 Human Acute Promyelocytic Leukemia Tumor Sensitive and Resistant Cell Line Pair HL-60 Resistant HL-60 Sensitive Ratio Compound IC50 nM IC50 nM to Sensitive t-butyl-phenylahistin 255 175 0.69 Mitoxantrone 202 4870 24.1 - 1). Action on Microtubule Function
- Human umbilical vein endothelial cells (HuVEC from Cambrex) were used in this study, for evaluating the effects of t-butyl-phenylahistin in comparison to colchicine and taxol on tubulin by staining for α-tubulin.
- Thirty minutes exposure to t-butyl-phenylahistin or colchicine (all at 2 μM) induced microtubule depolymerization as was indicated by the lack of intact microtubule structure in contrast to that observed in the DMSO Control and cell membrane blebbing (a clear indication of apoptosis) in the HuVEC cells, whereas taxol did not induce microtubule depolymerization under these conditions. Colchicine is a known microtubule depolymerizing agent whereas taxol is a tubulin stabilizing agent.
- 2). Activation of the Caspase Cascade
- Several enzymes in the caspase cascade are activated during apoptosis, including Caspase-3, -8 and -9. The activity of Caspase-3 was monitored in Jurkat cells following treatment with t-butyl-phenylahistin.
- The results indicate that caspase-3 was activated in a dose-dependent manner by treatment with t-butyl-phenylahistin in a manner similar to halimide. The caspase-3 activation occurred over a similar concentration range as for the IC50s for cytotoxicity in the Jurkat cell line (Table 13).
TABLE 13 Cytotoxicity of t-butyl-phenylahistin in Jurkat Cells Cytotoxicity Potency Efficacy NPI Compound IC50 nM % Cell Death t-butyl-phenylahistin 165 93 Mitoxantrone 41 99
3). Cleavage of Poly(ADP-ribose) Polymerase (PARP) in Jurkat Cells - In order to assess the ability of t-butyl-phenylahistin to induce apoptosis in Jurkat cells, cleavage of poly(ADP-ribose) polymerase (PARP) was monitored. PARP is a 116 kDa nuclear protein that is one of the main intracellular targets of Caspase-3. The cleavage of PARP generates a stable 89 kDa product, and this process can be easily monitored by western blotting. Cleavage of PARP by caspases is one of the hallmarks of apoptosis, and as such serves as an excellent marker for this process. Halimide was active at inducing cleavage of PARP in
Jurkat cells 10 hours after exposure of the cells to the compound. - 4). Enhanced Vascular Permeability in HuVEC Cells
- Compounds that depolymerize microtubules (e.g. combretastatin A-4-phosphate, ZD6126) have been shown to induce vascular collapse in tumors in vivo. This vascular collapse is preceded by a rapid induction of vascular cell permeability initially to electrolytes and soon after to large molecules. The enhanced permeability of HuVEC cells to a fluorescent-labeled dextran is used as a proxy assay for vascular collapse. t-butyl-phenylahistin rapidly (within 1 hour) induced significant HuVEC monolayer permeability, to an extent similar to colchicine. The microtubule stabilizing agent taxol was inactive in this assay (
FIG. 12 ). - Studies with t-butyl-phenylahistin were performed. The novel compound was studied as monotherapy and in combination with a clinically-used chemotherapeutic agent. The doses of the selected novel compound were determined from the acute tolerability testing (Maximally Tolerated Dose, MTD) and were adjusted if necessary during each study. The doses of the clinically-used chemotherapeutic agents were selected on the basis of historical studies.
- t-butyl-phenylahistin was were compared in the HT-29 human colon tumor, the DU-145 human prostate and the MCF-7 human breast tumor xenograft models.
- The above models all use the subcutaneous xenograft implantation technique and are potentially subject to selective effects of a compound on the subcutaneous vasculature producing a magnified (or apparent) antitumor activity. In order to circumvent this possibility, two other tumor models have been incorporated in the research. One of these is the observation of lung metastases following the intravenous injection of B16-F10 mouse melanoma tumor cells. The other model is the implantation of MDA-231 human breast tumor cells in the mouse mammary fat pad. While this latter model is a xenograft model, the subcutaneous vasculature does not play a role.
- Methods
- 1). Xenograft Models
- Animals used were (exceptions are indicated for individual studies): female nude mice (nu/nu) between 5 and 6 weeks of age (˜20 g, Harlan); group size was 9-10 mice per group unless otherwise indicated.
- Cell lines used for tumor implantation were: HT-29 human colon tumor; MCF-7 human breast tumor; A549 human non small cell lung tumor; MiaPaCa-2 human pancreas tumor; DU-145 human prostate tumor.
- The selected novel compound was administered as monotherapy via the intraperitoneal (i.p.) route at the doses indicated for the individual study; for the combination studies the selected reference chemotherapy agents were injected 15-30 min prior to the compound.
- Vehicles used in these studies were: 12.5% DMSO, 5% Cremaphor and 82.5% peanut oil for the selected novel compounds; (1:3) Polysorbate 80:13% ethanol for taxotere; (1:1) Cremaphor:ethanol for paclitaxel; for CPT-11 each mL of solution contained 20 mg of irinotecan hydrochloride, 45 mg of sorbitol NF powder, and 0.9 mg of lactic acid, the pH being adjusted to 7.4 with NaOH or HCl. Saline dilutions are used to achieve the injection concentrations used for the reference compounds.
- HT-29 Human Colon Tumor Model
- Animals were implanted subcutaneously (s.c.) by trocar with fragments of HT-29 tumors harvested from s.c. growing tumors in nude mice hosts. When the tumor size reached 5 mm×5 mm (about 10-17 days) the animals were matched into treatment and control groups. Mice were weighed twice weekly and tumor measurements were obtained using calipers twice weekly, starting on
Day 1. The tumor measurements were converted to estimated mg tumor weight using the formula (W2×L)/2. When the estimated tumor weight of the control group reached an average of 1000 mg the mice were weighed, sacrificed and the tumor removed. The tumors were weighed and the mean tumor weight per group was calculated and the tumor growth inhibition (TGI) was determined for each group (100% minus the change in the mean treated tumor weight/the change in the mean control tumor weight×100. - In this model unless otherwise noted for the individual study, the selected novel compound was injected intraperitoneally every third day for 15 days [1, 4, 8, 11 and 15 (q3dx5)]; CPT-11 was administered intraperitoneally on
days - MCF-7 Human Breast Tumor Model
- Female nude mice (˜20 g) were implanted s.c. with 21-day release estrogen (0.25 mg)
pellets 24 hours prior to the s.c. implantation with MCF-7 tumor fragments (harvested from s.c. tumors in nude mice hosts). The study then proceeded as described for the HT-29 model, using taxotere as the standard chemotherapy agent. - In this model unless otherwise noted for the individual study, the novel compound was injected via the intraperitoneal route daily on Days 1-5, inclusive (qdx5); taxotere was administered intravenously on
Days - A549 Human Lung Tumor Model
- Animals were implanted s.c. by trocar with fragments of A549 tumors harvested from s.c. growing tumors in nude mice hosts. When the tumor size reached 5 mm×5 mm (about 10-17 days) the animals were matched into treatment and control groups. The rest of the study proceeded as described for the HT-29 model, using taxotere and CPT-11 as the standard chemotherapy agents.
- In this model unless otherwise noted for the individual study, the tested compound was administered via the intraperitoneal route on a q3dx5 dose schedule for the CPT-11 combination or on a qdx5 dose regimen for the combination with taxotere; CPT-11 was administered via the intraperitoneal route on a qwx3 schedule; taxotere was administered intravenously on a qodx3 dose regimen.
- MiaPaCa-2 Human Pancreas Tumor Model
- Animals were implanted s.c. by trocar with fragments of MiaPaCa-2 tumors harvested from s.c. growing tumors in nude mice hosts. When the tumor size reached 5 mm×5 mm (about 10-17 days) the animals were matched into treatment and control groups. The rest of the study proceeded as described for the HT-29 model, using gemcitabine as the standard chemotherapy agent.
- In this model unless otherwise noted for the individual study, test compound was administered every third day via the intraperitoneal route on
Days Days - DU-145 Human Prostate Tumor Model
- Male mice were implanted s.c. by trocar with fragments of DU-145 tumors harvested from s.c. growing tumors in nude male mice hosts. When the tumors reached ˜5 mm×5 mm (at about 13-17 days) the animals were matched into treatment and control groups. The remainder of the study proceeded as for the HT-29 model, using taxotere as the standard chemotherapy agent.
- In this model unless otherwise noted for the individual study, test compound was administered via the intraperitoneal route on
Days Days - Non Subcutaneous Implantation Tumor Models
- The animals used were: female nude mice (nu/nu) (MDA-231 study) or B6D2F1 (B16-F10 studies) mice between 5 and 6 weeks of age (˜20 g, Harlan); group size was 10 mice per group unless otherwise indicated.
- The cell lines used were: MDA-MB-231 human breast tumor and B16-F10 murine melanoma cells.
- Compound was administered as monotherapy via the intraperitoneal route at the does indicated for the individual study; for the combination studies the selected reference chemotherapy agents were injected 15-30 min prior to the NPI compound.
- MDA-231 Human Breast Tumor
- Female nude mice were injected in the mammary fat pad with 2×106 MDA-231 cells harvested from in vitro cell culture. When the tumor size reached 5 mm×5 mm (about 14-28 days) the animals were matched into treatment and control groups. The study then proceeded as described for the HT-29 model, using paclitaxel as the standard chemotherapy agent.
- In this model unless otherwise noted for the individual study, the test compound was administered via the intraperitoneal route on
Days - B16-F10 Metastatic Murine Melanoma Model
- Mice received B16-F10 cells (prepared from an in vitro cell culture of B16-
F 10 cells) by the iv route onDay 0. OnDay 1 mice were randomized into treatment and control groups and treatment commenced. Mice were weighed twice weekly, starting onDay 1. All mice are sacrificed onDay 16, the lungs removed, weighed and the surface colonies counted. Results are expressed as mean colonies of treated mice/mean colonies of control mice (T/C)×100%). The metastasis growth inhibition (MGI) is this number subtracted from 100%. Paclitaxel was the standard chemotherapy agent used in this study. - In this model unless otherwise noted for the individual study, the test compounds were administered via the intraperitoneal route on Days 1-5 (qdx5); paclitaxel was administered intravenously on Days 1-5(qdx5).
- When appropriate (n≧3), results are presented as means±SEM. Statistical analysis of studies with several groups was performed using ANOVA with Neuman-Keuls post test, unless otherwise indicated. A one-tailed t-test was also used based on the hypothesis that the compound or drug, or the combination, would reduce tumor growth.
- Studies in the HT-29 Human Colon Tumor Xenograft Model
- 1. Study of Activity of t-Butyl-Phenyalhistin in the HT-29 Human Colon Tumor Xenograft Study
- The results of this study are presented in
FIG. 17 and Table 14. The combination therapy group indicated a marked synergy between the novel compound and CPT-11. The individual tumor weights demonstrate the effectiveness of the cotherapy treatment (FIG. 18 ). The TGI for the combination group surpasses the NCI criterion for a positive effect, whereas the TGI for CPT-11 monotherapy did not reach this level.TABLE 14 Summary of Studies Performed in the HT-29 Human Colon Tumor Model Chemotherapeutic Combination Study Description NPI-Compound Agent Exceed NCI Number Number, Result Name, Result Results Criterion Status Endpoint mg/kg ip TGI % Dose TGI % TGI % (TGI ≧ 58%) Comments 2139 TGI t-butyl- No Effect CPT-11 32.7 77.7*,# Combination Synergy phenylahistin 100 ip 30 qwx3 q3dx5
*p < 0.05 vs Control;
** p < 0.01 vs Control;
#p < 0.05 vs CPT-11 Alone;
## p < 0.01 vs CPT-11 Alone;
+ = Number of Deaths
2. Summary of the Effects of t-butyl-phenylahistin in Combination with CPT-11 in the HT-29 Human Colon Tumor Xenograft Model - When combined with CPT-11, t-butyl-phenylahistin enhanced the effect of CPT-11, the standard chemotherapeutic agent, to a level well in excess of the NCI criterion of a TGI≧58% for a positive effect. The results generated in the study are very comparable for both the in-life observations and for the weights of the tumors excised at autopsy.
- The study involved an assessment of t-butyl-phenyalhistin alone and in combination with taxotere.
- 1. Activity of t-butyl-phenylahistin Alone or in Combination with Taxotere in the DU-145 Human Prostate Xenograft Model
- A study comparing t-butyl-phenylahistin alone and in combination with taxotere was initiated. The results are shown in
FIG. 9 . - The excised tumor weights at autopsy confirmed the observations made during the in-life segment of the study. The tumor growth inhibition indices indicated a marked inhibition of tumor growth. Taxotere alone did not reach the NCI established criterion for a positive effect (TGA≧58%).
- 2. Studies in the MCF-7 Human Breast Tumor Xenograft Model
- This study considered the effects of t-butyl-phenylahistin in the MCF-7 human breast tumor xenograft model. The doses of the compound were administered on
Days Days - The selected novel compound has early onset, statistically significant effects when used in combination with taxotere in this model, apparently almost completely blocking estimated tumor growth (
FIG. 10 ). t-butyl-phenylahistin exhibited a significant potentiation of taxotere. - 3. Studies in the Murine Melanoma B16 F10 Metastatic Tumor Model
- This study examined the effect of t-butyl-phenylahistin alone and in combination with paclitaxel on the number of metastases appearing on the surface of the
lung 16 days after the intravenous injection of B16 F10 melanoma cells to the mouse. This model is not a xenograft model; however, it does not involve a high degree of vascularization into the tumor mass. - This study does not itself establish that combination therapy is more effective than monotherapy, it does indicate that t-butyl-phenylahistin is most effective in highly vascularized tumors (
FIG. 12 ). - Comparative activity of a phenylahistin or its analog against a pathogenic fungus, relative to known antifungal compounds recited above, for use in determining the phenylahistin or its analog's AF/IS value is measured directly against the fungal organism, e.g. by microtiter plate adaptation of the NCCLS broth macrodilution method described in Diagn Micro and Infect Diseases 21:129-133 (1995). Antifungal activity can also be determined in whole-animal models of fungal infection. For instance, one may employ the steroid-treated mouse model of pulmonary mucormycosis (Goldaill, L. Z. & Sugar, A. M. 1994 J Antimicrob Chemother 33:369-372). By way of illustration, in such studies, a number of animals are given no phenylahistin or its analog, various doses of phenylahistin or its analog (and/or combinations with one or more other antifungal agents), or a positive control (e.g. Amphotericin B), respectively, beginning before, at the time of, or subsequent to infection with the fungus. Animals may be treated once every 24 hours with the selected dose of phenylahistin or its analog, positive control, or vehicle only. Treatment is continued for a predetermined number of days, e.g. up to ten days. Animals are observed for some time after the treatment period, e.g. for a total of three weeks, with mortality being assessed daily. Models can involve systemic, pulmonary, vaginal and other models of infection with or without other treatments (e.g. treatment with steroids) designed to mimic a human subject susceptible to infection.
- To further illustrate, one method for determining the in vivo therapeutic efficacies (ED50, e.g. expressed in mg phenylahistin or its analog/kg subject), is a rodent model system. For example, a mouse is infected with the fungal pathogen such as by intravenous infection with approximately 10 times the 50% lethal dose of the pathogen (106 C. albicans cells/mouse). Immediately after the fungal infection, phenylahistin compounds are given to the mouse at a predetermined dosed volume. The ED50 is calculated by the method of Van der Waerden (Arch Exp Pathol Pharmakol 195:389-412, 1940) from the survival rate recorded on 20th day post-infection. Generally, untreated control animals die 7 to 1 3 days post-infection.
- In another illustrative embodimemt, C. albicans Wisconsin (C43) and C. tropicalis (C112), grown on Sabouraud dextrose agar (SDA) slants for 48 h at 28° C., are suspended in saline and adjusted to 46% transmission at 550 nm on a spectrophotometer. The inoculum is further adjusted by hemacytometer and confirmed by plate counts to be approximately 1 or 5×107 CFU/ml. CF-1 mice are infected by
injection - Benzimidazoles and griseofulvin are anti-tubulin agents capable of binding to fungal microtubules. Once bound, these compounds interfere with cell division and intracellular transport in sensitive organisms, resulting in cell death. Commercially, benzimidazoles are used as fungicidal agents in veterinary medicine and plant disease control. A wide variety of fungal species, including Botrytis cinerea, Beauveria bassiana, Helminthosporium solani, Saccharomyces cerevisiae and Aspergillus are susceptible to these molecules. Toxicity concerns and increasing drug resistance, however, have negatively impacted their usage. Griseofulvin is used clinically to treat ringworm infections of the skin, hair and nails, caused by Trichophyton sp., Microsporum sp., and Epidermophyton floccosum. Its antifungal spectrum, however, is restricted to this class of fungal organisms. Genotoxicity is also a significant side effect. Terbinafine, while an alternative first-line treatment, is more costly. Further, clinical resistance recently has been observed in Trichophyton rubrum (the major causative agent for all dermatophyte infections).
- In Candida albicans, microtubule/microfilament formation is affected where cells are exposed to the microtubule inhibitors nocodazole and chloropropham. These results further validate the exploration of cytoskeleton inhibitors as effective antimycotic agents. Accordingly, several of the compounds disclosed herein were evaluated for antimycotic activity.
- Specifically, disclosed compounds were evaluated alongside commercially available microtubulin inhibitors as well as recognized antifungal agents. The test compounds and controls used in this study: (−)-Phenylahistin and t-butyl phenylahistin, Colchicine (commercial microtubulin inhibitor tested versus 3 Candida isolates), Benomyl (commercial microtubulin inhibitor tested versus 3 Candida isolates), Griseofulvin (commercial microtubulin inhibitor and antibiotic control for testing versus 6 dermatophyte isolates), Amphotericin B (antibiotic control for testing versus 3 Candida isolates), Itraconazole (antibiotic control for testing versus 2 Aspergillus isolates).
- Microorganisms against which these compounds were tested included: Candida albicans, Candida glabrala, Aspergillus fumigatus, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophylon floccosum. With the exception of Candida glabrata (one isolate), two isolates of each species were tested.
- Antifungal susceptibility testing was accomplished according to the methods outlined in the National Committee for Clinical Laboratory Standards, M38-A “Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi; Approved Standard.” This includes testing in RPMI-1640 with glutamine and without bicarbonate, an inoculum size of 0.4-5×104, and incubation at 30 or 35° C. for 48 hours. The minimum inhibitory concentration (MIC) was defined as the lowest concentration that resulted in an 80% reduction in turbidity as compared to a drug-free control tube. Drug concentrations were 0.03-16 μg/ml for the investigational compounds, 0.015-8 μg/ml for itraconazole and griseofulvin.
- The minimum inhibitory concentration (MIC) at which a compound prevented the growth of the target microorganism was assessed according to the modified version of the NCCLS protocol. Minimum inhibitory concentrations (MIC) were determined at the first 24-hour interval where growth could be determined in the drug-free control tube. The defined MIC was the lowest concentration that exhibited an 80% reduction in turbidity as compared to the growth control. The minimum lethal concentration (MLC) was determined by plating 0.1 μl from the MIC concentration and each concentration above the MIC. The MLC was called at the first concentration that exhibited five or fewer colonies of fungal growth representing a 99.95% kill. When a MIC was obtained, a minimum fungicidal concentration (MFC) was determined to assess the fungistatic/fungicidal nature of the compound. This procedure entails diluting drug-treated cell samples (removed from test wells containing compound at and above the MIC) to compound concentrations significantly below the inhibitory concentration and depositing them on agar plates. The compound is scored as fungistatic if the cells are able to resume growth and fungicidal if no regrowth is possible because the compound had killed the organisms.
- Compounds disclosed herein were shown to be effective against two Trichophyton species. T. rubrum is the principal causative agent for human dermatophytic infections, and would be the key organism to target in the development of a clinical agent.
- Compound t-butylphenylahistin at least was equivalent in potency compared to griseofulvin, a current, standard pharmaceutical agent used for treating dermatophytic infections.
- Compound (−)-Phenylahistin also was potent when tested versus T. rubrum and even more potent versus the sensitive T mentagrophytes isolate.
- In those instances when an MFC could be determined, the results indicate that these compounds are fungistatic in nature (see Tables 19 and 20).
TABLE 17 Antifungal Activity of Phenylahistins MICs and MFCs, μg/ml A. fumigatus A. fumigatus C. albicans 90028 C. albicans 10231 C. glabrata isolate #1 isolate #2 Compound MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC (−)-Phenylahistin >70 ND** >70* ND >70 ND >16 ND >16 ND t-butyl phenylahistin >32 ND >32 ND >32 ND >16 ND <0.03 0.125 amphotericin B 0.5 0.5 0.5 0.5 1 1 ND ND ND ND griseofulvin ND ND ND ND ND ND ND ND 0.5 ND itraconazole ND ND ND ND ND ND 1 ND ND ND colchicine >128 ND >128 ND >128 ND ND ND ND ND benomyl 64 >512 64 >512 64 >512 ND ND ND ND -
TABLE 18 Antifungal Activity of Phenylahistins MICs and MFCs, μg/ml T. rubrum T. rubrum T. mentagrophytes T. mentagrophytes E. floccosum E. floccosum isolate #1 isolate #2 isolate #1 isolate #2 isolate #1 isolate #2 Compound MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MFC NPI2350 >16 ND 0.16 >16 16 >16 >16 ND >16 ND >16 ND NPI2460 <0.03 0.125 <0.03 <0.03 4 >16 >16 ND >16 ND >16 ND amphotericin B ND ND ND ND ND ND ND ND ND ND ND ND griseofulvin 0.5 ND <0.015 ND 1 ND 2 ND 2 ND 4 ND itraconazole ND ND ND ND ND ND ND ND ND ND ND ND colchicine ND ND ND ND ND ND ND ND ND ND ND ND benomyl ND ND ND ND ND ND ND ND ND ND ND ND - The examples described above are set forth solely to assist in the understanding of the invention. Thus, those skilled in the art will appreciate that the disclosed methods and compounds encompass and may otherwise provide further derivatives of phenylahistins.
- One skilled in the art would readily appreciate that the present invention is well adapted to obtain, for example, the ends and advantages mentioned, as well as others inherent. The methods and procedures described herein are presently representative of preferred embodiments and are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention.
- It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.
- As noted above, all patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are hereby incorporated by reference herein to the extent allowable by law, such that each individual patent and publication may be treated as specifically and individually indicated to be incorporated by reference.
- The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions indicates the exclusion of equivalents of the features shown and described or portions thereof. It is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be falling within the scope of the invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/335,198 US20060167010A1 (en) | 1998-11-12 | 2006-01-18 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10821198P | 1998-11-12 | 1998-11-12 | |
US10873698P | 1998-11-17 | 1998-11-17 | |
US09/440,316 US6358957B1 (en) | 1998-11-12 | 1999-11-12 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
US09/995,851 US6713480B2 (en) | 1998-11-12 | 2001-11-27 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
US10/632,688 US7026322B2 (en) | 1998-11-12 | 2003-08-01 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
US11/335,198 US20060167010A1 (en) | 1998-11-12 | 2006-01-18 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/632,688 Continuation US7026322B2 (en) | 1998-11-12 | 2003-08-01 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060167010A1 true US20060167010A1 (en) | 2006-07-27 |
Family
ID=34115790
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/632,688 Expired - Lifetime US7026322B2 (en) | 1998-11-12 | 2003-08-01 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
US11/335,198 Abandoned US20060167010A1 (en) | 1998-11-12 | 2006-01-18 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/632,688 Expired - Lifetime US7026322B2 (en) | 1998-11-12 | 2003-08-01 | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
Country Status (2)
Country | Link |
---|---|
US (2) | US7026322B2 (en) |
WO (1) | WO2005011699A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050197344A1 (en) * | 2003-08-01 | 2005-09-08 | Palladino Michael A. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US20060223823A1 (en) * | 2002-08-02 | 2006-10-05 | Yoshio Hayashi | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US20060235226A1 (en) * | 2005-03-29 | 2006-10-19 | Yoshio Hayashi | Synthesis of diketopiperazines |
US20070078138A1 (en) * | 2002-08-02 | 2007-04-05 | Michael Palladino | Analogs of dehydrophenylahistins and their therapeutic use |
US20080221122A1 (en) * | 2006-11-03 | 2008-09-11 | Palladino Michael A | Analogs of dehydrophenylahistins and their theapeutic use |
US10076518B2 (en) | 2015-03-06 | 2018-09-18 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
US10238650B2 (en) | 2015-03-06 | 2019-03-26 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
US11229642B2 (en) | 2016-06-06 | 2022-01-25 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
US11786523B2 (en) | 2018-01-24 | 2023-10-17 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2417960C (en) | 2000-08-04 | 2012-07-10 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
DK1571970T3 (en) * | 2002-10-02 | 2011-11-28 | Dmi Biosciences Inc | Diagnosis and monitoring of diseases |
CN104095851A (en) * | 2003-05-15 | 2014-10-15 | 安皮奥制药股份有限公司 | Treatment of T-cell mediated diseases |
JP2007506767A (en) * | 2003-09-25 | 2007-03-22 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | Method and product using N-acyl-L-aspartic acid |
DE102004043463A1 (en) * | 2004-06-09 | 2006-02-09 | Heinz Voigt | Differentiation of proteins, for use in diagnosis of cancer, comprises separating antigens from specimen electrophoretically and reacting with antibody composition |
AR058408A1 (en) | 2006-01-02 | 2008-01-30 | Basf Ag | PIPERAZINE COMPOUNDS WITH HERBICITY ACTION |
WO2008014613A1 (en) * | 2006-08-04 | 2008-02-07 | Manus Pharmaceuticals (Canada) Ltd. | Multifunctional bioactive compounds |
EP2300011A4 (en) | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | Therapeutic methods and compounds |
EP2318379A1 (en) * | 2008-08-13 | 2011-05-11 | Basf Se | Method for preparation of piperazindione derivates |
US8507496B2 (en) | 2010-09-07 | 2013-08-13 | Dmi Acquisition Corp. | Treatment of diseases |
PL2766029T3 (en) | 2011-10-10 | 2020-08-24 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
KR20140075772A (en) | 2011-10-10 | 2014-06-19 | 앰피오 파마슈티컬스 인코퍼레이티드 | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
CN103841974A (en) | 2011-10-28 | 2014-06-04 | 安皮奥制药股份有限公司 | Treatment of rhinitis |
MX2015010937A (en) | 2013-03-15 | 2015-10-29 | Ampio Pharmaceuticals Inc | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same. |
CA2958080A1 (en) | 2014-08-18 | 2016-02-25 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
EP3310375A4 (en) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
CN109580801B (en) * | 2018-06-26 | 2021-09-07 | 深圳海王医药科技研究院有限公司 | High performance liquid chromatography for detecting tubulin inhibitor and related impurities |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6069146A (en) * | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
US6358957B1 (en) * | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
JPH059164A (en) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | Production of optically active mandelonitrile derivative |
JP3131574B2 (en) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | Novel antitumor substance, microorganism and method for producing the substance, and cell cycle inhibitor and antitumor agent containing the substance as active ingredient |
BR0017067A (en) | 2000-01-18 | 2002-10-22 | Nereus Pharmaceuticals Inc | Cell division inhibitor, dehydrogenase, method for producing a cell division and compound inhibitor |
CA2494049C (en) | 2002-08-02 | 2011-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
-
2003
- 2003-08-01 US US10/632,688 patent/US7026322B2/en not_active Expired - Lifetime
-
2004
- 2004-07-29 WO PCT/US2004/024940 patent/WO2005011699A1/en active Application Filing
-
2006
- 2006-01-18 US US11/335,198 patent/US20060167010A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6069146A (en) * | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
US6358957B1 (en) * | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223823A1 (en) * | 2002-08-02 | 2006-10-05 | Yoshio Hayashi | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US20070078138A1 (en) * | 2002-08-02 | 2007-04-05 | Michael Palladino | Analogs of dehydrophenylahistins and their therapeutic use |
US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US7956058B2 (en) | 2002-08-02 | 2011-06-07 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US8247552B2 (en) | 2002-08-02 | 2012-08-21 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US8618292B2 (en) | 2002-08-02 | 2013-12-31 | Beyondspring Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US20050197344A1 (en) * | 2003-08-01 | 2005-09-08 | Palladino Michael A. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
US20060235226A1 (en) * | 2005-03-29 | 2006-10-19 | Yoshio Hayashi | Synthesis of diketopiperazines |
US7732605B2 (en) | 2005-03-29 | 2010-06-08 | Nereus Pharmaceuticals, Inc. | Synthesis of diketopiperazines |
US20080221122A1 (en) * | 2006-11-03 | 2008-09-11 | Palladino Michael A | Analogs of dehydrophenylahistins and their theapeutic use |
US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
US10076518B2 (en) | 2015-03-06 | 2018-09-18 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
US11045467B2 (en) | 2015-03-06 | 2021-06-29 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
US10238650B2 (en) | 2015-03-06 | 2019-03-26 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
US10357491B2 (en) | 2015-03-06 | 2019-07-23 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
US11918574B2 (en) | 2015-03-06 | 2024-03-05 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
US10668063B2 (en) | 2015-03-06 | 2020-06-02 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
US10550104B2 (en) | 2015-07-13 | 2020-02-04 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
US11254657B2 (en) | 2015-07-13 | 2022-02-22 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
US11857522B2 (en) | 2016-02-08 | 2024-01-02 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
US11229642B2 (en) | 2016-06-06 | 2022-01-25 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
US11786523B2 (en) | 2018-01-24 | 2023-10-17 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia |
Also Published As
Publication number | Publication date |
---|---|
US20040102454A1 (en) | 2004-05-27 |
WO2005011699A1 (en) | 2005-02-10 |
US7026322B2 (en) | 2006-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7026322B2 (en) | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds | |
US7674903B2 (en) | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | |
US6358957B1 (en) | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds | |
US7935704B2 (en) | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | |
JP2007520565A (en) | Synthesis of dehydrophenylahistine and their analogs, and dehydrophenylahistine and their analogs | |
US7625885B2 (en) | Cytotoxin compound and method of isolation | |
US8633154B2 (en) | Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth | |
KR20010001237A (en) | Antifungal agent containing obovatol or redobovatol | |
JP5548876B2 (en) | Antifungal | |
US20100279861A1 (en) | Antifungal Agents | |
AU2002249520A1 (en) | A novel antifungal molecule 2-(3,4-dimethyl-2,5-dihydro-1h-pyrrol-2-yl)-1 methylethyl pentanoate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: DALIAN WANCHUN BIOTECHNOLOGY CO. LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEREUS PHARMACEUTICALS, INC.;REEL/FRAME:030715/0457 Effective date: 20130130 |
|
AS | Assignment |
Owner name: BEYONDSPRING PHARMACEUTICALS, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DALIAN WANCHUN BIOTECHNOLOGY CO. LTD.;REEL/FRAME:030723/0712 Effective date: 20130701 |